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Preamble
This document has been developed as an expert consensus
document by the American College of Cardiology Founda-
tion (ACCF) and the Society for Cardiovascular Angiog-
raphy and Interventions (SCAI), in collaboration with the
Society of Thoracic Surgeons (STS) and Society for Vas-
cular Medicine (SVM). Expert consensus documents are
intended to inform practitioners, payers, and other inter-
ested parties of the opinion of ACCF and document
cosponsors concerning evolving areas of clinical practice
and/or technologies that are widely available or new to the
practice community. Topics chosen for coverage by this
ECD are so designed because the evidence base, the
experience with technology, and/or clinical practice are not
considered sufficiently well developed to be evaluated by the
formal ACCF/American Heart Association (AHA) Prac-
tice Guidelines process. Often the topic is the subject of
considerable ongoing investigation. Thus, the reader should
view the ECD as the best attempt of the ACCF and
document cosponsors to inform and guide clinical practice
in areas where rigorous evidence may not yet be available or
evidence to date is not widely applied to clinical practice.
When feasible, ECDs include indications or contraindica-
tions. Some topics covered by ECDs will be addressed
subsequently by the ACCF/AHA Practice Guidelines
Committee.
The ACCF Task Force on Clinical Expert Consensus
Documents (TF CECD) makes every effort to avoid any
actual or potential conflicts of interest that might arise as a
result of an outside relationship or personal interest of a
member of the writing panel. Specifically, all members of
the writing panel are asked to provide disclosure statements
of all such relationships that might be perceived as relevant
o the writing effort. This information is documented in a
able, reviewed by the parent task force before final writing
ommittee selections are made, reviewed by the writing
ommittee in conjunction with each conference call and/or
eeting of the group, updated as changes occur throughout
he document development process, and ultimately pub-
ished as an appendix to the document. External peer
eviewers of the document are asked to provide this infor-
ation as well. The disclosure tables for writing committee
embers and peer reviewers are listed in Appendices 1 and
, respectively, of this document. Additionally, in the spirit
f complete transparency, writing committee members’
omprehensive disclosure information—including relationships
ith industry and other entities that do not pertain to thisdocument—is available online. Disclosure information for
members of the ACCF TF CECD—as the oversight group
for this document development process—is also available
online.
The work of the writing committee was supported exclu-
sively by the ACCF without commercial support. Writing
committee members volunteered their time to this effort.
Meetings and/or conference calls of the writing committee
were confidential and attended only by committee members.
Executive Summary
The last expert consensus document on cardiac catheteriza-
tion laboratory standards was published in 2001 (1). Since
then, many changes have occurred as the setting has evolved
from being primarily diagnostic based into a therapeutic
environment. Technology has changed both the imaging
and reporting systems. The lower risk of invasive procedures
has seen the expansion of cardiac catheterization laborato-
ries to sites without onsite cardiovascular surgery backup
and even to community hospitals where primary percutane-
ous coronary intervention (PCI) is now being performed.
This has increased the importance of quality assurance (QA)
and quality improvement (QI) initiatives. At the same time,
the laboratory has become a multipurpose suite with both
diagnostic procedures to investigate pulmonary hyperten-
sion and coronary flow and with therapeutic procedures that
now include intervention into the cerebral and peripheral
vascular systems as well as in structural heart disease. These
new procedures have impacted both the adult and pediatric
catheterization laboratories. The approaches now available
allow for the treatment of even very complex heart disease
and have led to the development of hybrid cardiac cathe-
terization laboratories where a team of physicians (including
invasive cardiologists, cardiovascular surgeons, noninvasive
cardiologists, and anesthesiologists) is required.
The Cardiac Catheterization
Laboratory Environments
Despite a growth in procedural sites and in procedural
capabilities in the cardiac catheterization laboratory, the
total number of coronary interventional procedures has
steadily declined over the last few years.
Cardiac Catheterization at a Hospital With
Cardiovascular Surgery
Full-service hospitals should provide, not only cardiovascu-
lar surgery, but also cardiovascular anesthesia and consulting
services in vascular, nephrology, neurology, and hematology.
Advanced imaging and mechanical support services should
also be available. Not every hospital with onsite cardiovas-
cular surgery should be offering all services unless the
expertise is available to evaluate, treat, and handle any
potential complications that occur. Patients requiring highly
specialized procedures or pediatric procedures should have
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equipment to perform these procedures at the highest level.
Cardiac Catheterization at a Facility Without
Cardiovascular Surgery
Despite prior guidelines that suggest limitations to the
expansion of cardiac catheterization without onsite surgical
backup, the number of these sites has increased dramatically
over the last decade. The Certificate of Need (CON)
regulatory programs have had little impact on this expan-
sion. Whether quality and outcomes are similar to hospitals
with onsite cardiovascular surgery remains uncertain. The
actual number of laboratories without surgical backup is
difficult to confirm, but most estimates suggest it is around
25% to 35% of all laboratories in the United States. Because
of fixed costs to maintain these facilities, costs and charges
per patient at these sites may actually be higher than in
facilities with onsite surgery.
The remarkably low risk now associated with diagnostic
cardiac catheterization suggests that only a few cardiovascular
patients cannot safely undergo procedures in these labora-
tories. The 2001 ACC/SCAI consensus document suggests
limiting diagnostic procedures in laboratories without car-
diovascular surgical backup to the very lowest-risk patients;
the current document lifts almost all these restrictions.
Limitations related to age, congestive heart failure (CHF)
status, the severity in stress test abnormalities, left ventric-
ular (LV) function, and the presence of valve disease have all
been removed. It is still recommended that patients with
pulmonary edema due to ischemia, patients with complex
congenital heart disease, and pediatric patients still be
treated only in full-service facilities.
Certain therapeutic procedures should still be done only in
acilities with cardiovascular surgical backup. These include
herapeutic procedures in adult congenital heart disease and
ediatrics. It is generally believed that elective and primary
CI are permissible in sites without cardiovascular surgery,
f there is strict adherence to national guidelines. In partic-
lar, there must be a documented working relationship with
larger facility with cardiovascular surgical services and an
mergency transportation system operative. The document
utlines the current guidelines where this is acceptable. The
ommittee also believes that it is the responsibility of any
acility performing coronary intervention without cardiovas-
ular surgical backup to document that all national risk
tratification and medication guidelines are being followed.
n addition, a QA/QI system must be operative and active,
nd, if an ST-elevation myocardial infarction (STEMI)
rogram is in place, the laboratory should be operational 24
ours a day, 7 days a week. Any national volume guidelines
ust also be strictly followed.
Quality Assurance Issues in the
Cardiac Catheterization Laboratory
The modern cardiac catheterization laboratory is a complex,
highly sophisticated medical and radiological facility wherepatients with both chronic-stable and life-threatening ill-
nesses are evaluated. With the expansion of laboratories and
the increase in the complexity of procedures, it is essential to
have an active QA/QI system in place regardless of the
laboratory setting. The committee strongly encourages all
laboratories to participate in national registries, such as the
ACC’s National Cardiovascular Data Registry (NCDR), to
ensure data are systematically collected and available in a
predefined format to allow for future analyses. In this
manner, all laboratories can benchmark their performance
and make appropriate corrections.
Patient Outcomes
The rate of normal or insignificant coronary artery disease
angiographically found at cardiac catheterization in any 1
laboratory obviously varies depending on the types of
patients studied, but the range is high, varying anywhere
from 20% to 39%.
Complications related to the catheterization procedure
are very low and should be 1% for diagnostic procedures
and 2% for elective PCI. The risk is obviously higher in
the setting of an acute myocardial infarction (AMI), but
even in that situation, the overall mortality should be 4%.
Complication rates 5% must be considered excessive and
a cause for concern and programmatic review.
At least 60% of PCI procedures are done ad hoc follow-
ing lesion discovery on a diagnostic angiogram. Although
there is no evidence this practice has an adverse effect on
outcomes, ad hoc procedures should be discouraged when
the patient would benefit from a multidisciplinary discus-
sion regarding options for therapy or when an interventional
procedure at a later time would reduce the risk of contrast
nephropathy. In the acute STEMI setting, when multivessel
disease is evident, only the culprit lesion should undergo
emergency intervention.
Data relating to outcomes in peripheral vascular and
cerebrovascular intervention are incomplete. The technol-
ogy continues to evolve as do the indications. Laboratories
historically dedicated to coronary disease have had to
transform themselves technically, logistically, and adminis-
tratively to provide optimal care for this population. Large
image detectors are often required and are not optimal for
coronary angiography. This area is further complicated by
the fact that noncardiologists (i.e., vascular surgeons and
interventional radiologists) may also be participating, so
guidelines, as well as credentialing issues, may vary among
the groups. Because no clear benchmarks yet exist, partici-
pation in an ongoing national database for these procedures
is particularly important.
Peer Review Continuous QA/QI Programs
Most major QA problems are unrelated to equipment but
are due to operational factors. These tend to include
inadequate laboratory space, lack of a physician director or
advocate, lack of specific operating rules, and a poor
feedback mechanism. More than ever, a continuous QA/QI
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cardiac catheterization laboratory. It should be dedicated to
the lab but not be independent of the other hospital
programs. It must be adequately staffed and appropriately
funded. The basic components must include a committee
with a chair and staff coordinator, a database, and a means
of data collection. There should be goals to eliminate
outliers, reduce variation, and enhance performance. Feed-
back mechanisms should be clearly in place. The committee
should also be committed to educational opportunities for
the staff and incorporating practice standards and guidelines
into the laboratory operation. Some composite “scorecard”
methods should be included that address cognitive knowl-
edge, procedural skill, clinical judgment, and procedural
outcomes. These data need to be collected in a systematic
manner and analyzed appropriately. Often a simple com-
parison of outcomes among physicians in the laboratory is
effective in modifying behavior.
To help facilitate organization of a QA/QI process, the
current document outlines the major organizational indica-
tors, provides a representative case review form, and outlines
the minimum components that should be included in a
standard cardiac catheterization form.
Quality indicators should include structural, patient care,
system-specific, guideline-driven, and cost-related items.
Structural indicators include factors such as training, con-
tinuing medical education (CME), procedural volume,
awards, presentations, publications, and credentialing. Pa-
tient care indicators include issues such as quality of proce-
dures, report generation, timeliness, and appropriateness.
System-specific indicators incorporate items such as lab
turnover, preprocedural processes, emergency response
time, and staff performance. Guideline-driven indicators
should focus on infection control, radiation safety, medica-
tion and contrast use, procedural indications, and new
device usage. Cost-related issues include such things as
length of stay, disposables, types and adequacy of supplies,
staffing, and use of off-label devices.
In addition to the above, there should be defined
outcomes-related indicators collected. These include indi-
vidual physician complications, service outcomes (e.g., ac-
cess, door-to-intervention times, and satisfaction surveys),
and financial outcomes.
To do this properly requires a serious commitment from
the facility administration to ensure that a robust QA/QI
program is in place and the program committee is active and
aggressive regarding its responsibilities.
Minimum Caseload Volumes
Using minimum case volumes as a surrogate for quality
presumes that a high procedural volume equates to a high
skill level and that low-volume operators are less skilled. In
fact, there is limited statistical power to make judgments in
the low-volume instance, and the relationship between
procedural volume and outcome remains controversial. This
applies to the laboratory facility as well as the physician toperator. The particular issue of minimum case volumes is
currently being addressed by a forthcoming update to the
“ACCF/AHA/SCAI Clinical Competence Statement on
Cardiac Interventional Procedures.” This document simply
outlines the currently available data; the final recommenda-
tion awaits the decisions of the competence statement
writing committee.
Establishing an appropriate oversight QA/QI process is
more important than focusing on minimum volumes. All
major complications should be reviewed by the QA com-
mittee at least every 6 months, and any individual operator
with complication rates above benchmarks for 2 consecutive
6-month intervals should have the issue directly addressed
by the QA director and followed up with written conse-
quences. Ideally, some subset of all operators should be
randomly reviewed at least annually. All operators should be
required to attend regularly cardiac catheterization confer-
ences and obtain a minimum of 12 CME hours per year.
Stimulation training may assist in improving skills.
The very low complication rate for diagnostic catheter-
ization makes suggestions for a minimum volume threshold
particularly difficult. The prior catheterization standards
document suggested 150 cases per year as a minimum, but
that committee acknowledged this was arbitrary and had no
data to support the recommendation (1). This committee
feels that there is no clear minimum volume for diagnostic
catheterization that can be supported and prefers to emphasize the
QA process to ensure the procedures are of the highest quality.
The annual minimum operator interventional procedural
volume of 75 cases per year has become an accepted
standard. Numerous publications and editorials have ad-
dressed this issue in detail. Although some relationships
between operator and/or institutional volumes and out-
comes have been described in certain reports, many publi-
cations have struggled to confirm these data. Obviously the
relationship between volume and outcomes is complex, and
many confounding issues are evident. Low-volume opera-
tors in high-volume laboratories tend to fare better. Com-
plicating the issue further, however, is the fact that many
competent interventional cardiologists do not perform 75
rocedures each year. Some cardiologists perform PCI primar-
ly when on-call, and some are at the beginning or the end of
areers and are either ramping up or winding down a practice.
ome perform procedures at multiple facilities, and the data for
uch individuals are often incomplete.
The data for primary PCI are particularly difficult to
ategorize because of the low volumes being performed.
his committee believes that it is appropriate for all primary
CIs to be evaluated by the institutional QA committee,
egardless of operator volume. Operators wishing to participate in
rimary PCI should be required to attend these review sessions.
The guidelines for the performance of both elective
nd primary PCI in a facility without cardiovascular
urgical backup are also evolving. Recent prospective
tudies and meta-analyses of available data both suggest
hese procedures can be done safely under restrictions.
Aa
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focus of the ACCF/AHA/SCAI Writing Committee to
Update the 2007 Clinical Competence Statement on
Cardiac Interventional Procedures. Because these pa-
tients are at highest risk for complications, national
guidelines for the proper PCI, particularly in the setting
of an AMI, must be strictly followed. The facility must
have a robust QA program, clear and documented sys-
tems for the urgent transfer of patients to a facility with
cardiovascular surgical support, documentation that all
medication and indication guidelines are being observed,
and 24/7 availability.
Training in Interventional Procedures
The use of minimum volumes and rotation duration for
training in interventional cardiology procedures has been
established by the ACCF Core Cardiology Training Sym-
posium (COCATS). These are still the established require-
ments for Level 1, Level 2, and Level 3 training. These are
summarized in this report, but the committee recognizes
that even here, there is a gradual shift away from minimum
numbers and toward a competence standard. The formal
training to achieve credentials in peripheral vascular inter-
vention is highlighted for cardiology fellows, and compared
with that of interventional radiologists and vascular sur-
geons; little difference actually exists.
Training in structural heart disease intervention is clearly
an area where volume numbers should not supplant evi-
dence for competence by a QA review of outcomes. By
definition, most of these procedures require a multidisci-
plinary approach and should not be attempted by casual
operators. It is recommended that both the training and
practice activity associated with structural heart disease inter-
vention be concentrated among a limited number of laborato-
ries and operators with a particular interest in these procedures.
Often a close working relationship between adult and pediatric
operators provides the optimal environment.
Procedural Issues in the Cardiac
Catheterization Laboratory
Patient Preparation
A number of procedural issues are addressed. Heightened
awareness of protective care from communicable diseases,
such as human immunodeficiency virus (HIV) or hepatitis,
is important. Each laboratory should have a written protocol
for increased sterile technique for highly infectious cases.
The protocol should include caps, masks, double gloving,
and protective eyewear. Disposal methods and disinfectant
techniques are also important.
Patient preparation should include a checklist of items to
be reviewed when the patient first arrives at the laboratory.
Appropriate consent should include risks, benefits, alterna-
tive therapies, and the potential need for ad hoc procedures.
All PCI consent forms should outline the potential for
emergency surgery. A “time-out” should be a required part rof each procedure and should include the name, the proce-
dure, the signed consent, allergies, antibiotic administration,
the correct site, confirmation of the pre-wash, the need for any
special equipment or imaging, and any pertinent clinical factors
(including labs such as the creatinine level). If the radial artery
is to be used, the Allen test results should be noted.
The committee reviewed the minimum laboratory data in
preparation for cardiac catheterization and found a wide
variability in practice patterns. The following recommenda-
tions were made: 1) routine laboratory data should include
the hemoglobin, platelet count, electrolytes, and creatinine
obtained within 2 to 4 weeks of the procedure. These should
be repeated if there has been a clinical or medication change
within that period or recent contrast exposure; 2) unless
there is known liver disease, a hematologic condition of
concern, or the ongoing use of warfarin, a protime is not
deemed necessary prior to the procedure; 3) for overnight
tests, a nothing by mouth (NPO) order is not always in the
best interest of the patient; fasting should be no more than
2 hours after clear liquids or 6 hours after a light meal.
Hydration should be considered an important component
prior to contrast administration; and 4) women of child-
bearing age should have a urine or serum beta-HCG test
within 2 weeks of the procedure. There is little fetal risk
during the first 2 weeks of gestation. In addition, the
committee could find no data to suggest a concern regarding
nitinol device use in patients with nickel allergies.
For patients on warfarin, the drug is usually stopped 3
days prior to the procedure. An acceptable international
normalized ratio (INR) of 1.8 for femoral or 2.2 for
radial cases is suggested. Vitamin K reversal is discouraged.
Patients on aspirin, unfractionated heparin, low-molecular-
weight heparin, or glycoprotein IIb/IIIa inhibitors need not
have the drugs stopped before catheterization. Dabigatran
should be stopped 24 hours prior if the estimated glomerular
filtration rate (eGFR) is 50 mL/min and 48 hours before
if the eGFR is between 30 mL/min to 50 mL/min.
For patients with chronic kidney disease (CKD), there is
a risk of contrast nephropathy following the procedure. The
highest-risk patients are those with eGFR 60 mL/min
and diabetes mellitus. It is recommended that patients with
CKD have nephrotoxic drugs, such as nonsteroidal anti-
inflammatory drugs (NSAIDs), held on the day of the
procedure and that adequate hydration with either intrave-
nous (IV) saline or sodium bicarbonate at 1.0 mL/kg/min to
1.5 mL/kg/min for 3 to 12 hours prior and 6 to 12 hours
postprocedure should be completed as well. Contrast media
should be minimized, and either low-osmolar or iso-
osmolar contrast should be used. A contrast volume/
creatinine clearance ratio of 3.7 has been suggested as a
ceiling for contrast use to reduce nephrotoxicity risk. A
follow-up creatinine level should be obtained in 48 hours.
cetylcysteine is no longer recommended.
Patients with a strong atopic history or prior contrast
llergy should be considered for pre-medication with ste-
oids and/or H1 and H2 blockers. Shellfish allergies are not
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tients usually have the insulin dose reduced by half the night
prior and then held the morning of the procedure. Diabetic
patients should have procedures early in the schedule, if
possible, to avoid hypoglycemia. Metformin should be held
regardless of the creatinine clearance and not restarted until
there is postprocedural documentation that the creatinine
has returned to baseline. An awareness of the treatment of
anaphylactoid reactions to contrast is important. Delayed
hypersensitivity rashes should not be confused with reac-
tions to new drugs initiated after the procedure.
Procedural Issues
Radial artery use for access has increased over the last few
years. Though the procedure may take slightly longer and
radiation exposure is slightly higher, the radial access site
has less vascular complications than the femoral approach.
In addition, it allows for earlier ambulation and is particu-
larly efficacious in the obese. Medications during the procedure
and sterile techniques have not changed over the last decade.
Technical and Hemodynamic Issues
Except for the equipment advances, the actual performance
of coronary angiography has changed little over the last
decade. Facilities with biplane capabilities are less common
now. Biplane coronary angiography may reduce total con-
trast load in patient with CKD and is important in
structural heart intervention. Hemodynamics are less
stressed in most laboratories despite accurate hemodynamic
measurements being critical in certain disease states (such as
constrictive pericarditis). Intracoronary hemodynamics have
most recently focused on the use of the pressure wire. The
cardiac catheterization procedure can provide information
regarding ventricular performance, cardiac output, vascular
resistance, and shunt magnitude. The hemodynamics before
and after pulmonary vasodilators are also critical to the
decision algorithm on therapy for patients with pulmonary
hypertension. Vasodilator or inotropic stress testing in
patients with low-gradient, low-valve area aortic stenosis,
likewise, provides vital information on the best therapeutic
option in these patients. Transseptal catheterization has had
resurgence with the success of such procedures as balloon
mitral valvuloplasty and atrial fibrillation ablation. Entry
into the left atrium (LA) provides percutaneous therapeutic
options for pulmonary vein stenosis and, for some cases,
with mitral regurgitation. Myocardial biopsies are useful in
restrictive heart disease and in heart transplant patients.
Within the hybrid laboratory environment, LV puncture
allows for percutaneous aortic valve replacement via an
apical approach. Intracardiac ultrasound and Doppler imaging
methods have proven their value in a number of situations,
including atrial septal visualization during percutaneous patent
foramen ovale (PFO) or atrial septal defect (ASD) closure,
left-sided electrophysiological ablation studies, mitral valvulo-
plasty, and LA appendage occluder deployment.In addition, there are now therapeutic options to aug-
ment cardiac output using placement of an intra-aortic
balloon pump or the use of catheters, either connected to a
rotary pump or that have a rotary micropump within the
catheter itself. The percutaneous application of extracorpo-
real membrane oxygenation (ECMO) can now be per-
formed in the cardiac catheterization laboratory as well.
The known vagaries of contrast angiography in defining
vascular lesion severity and composition has led to the
development of a range of intravascular imaging devices,
including intravascular ultrasound (IVUS) and other devices
that provide plaque imaging with virtual histology and tissue
ingrowth assessment using optical coherence technology.
Although many are still investigational, they all carry some
inherent risk of vessel injury that should be appreciated.
Postprocedural Issues
Vascular Hemostasis
In cases of femoral access where no vascular closure device
is being used, if heparin has been used during the procedure,
the activated clotting time (ACT) should return to near
normal (180 s) before sheaths are removed and manual
compression applied. Common practice is to confine the
patient to bed after sheath removal. Bed rest for 1 to 2 hours
after either 4- or 5-F sheaths and 2 to 4 hours after 6- to
8-F sheaths is suggested. The radial approach obviates
prolonged bed rest. All patients should have the access site
auscultated prior to discharge. Should a pseudoaneurysm
occur, most can be closed with compression and percutane-
ous thrombin.
A bleeding risk score for PCI has been developed from
the NCDR database. It provides an opportunity to identify
those at highest risk for a vascular complication.
The use of vascular occlusion devices has grown rapidly
despite evidence their application does not reduce overall
vascular complications. An AHA Scientific Statement re-
garding these devices recommends a femoral arteriogram
with identification of sheath site and vascular features be
done before their use. The use of any vascular device is
considered a Class IIa (Level of Evidence: B) indication.
Medication Use
Little has changed in the use of sedative and pain control
medications after the procedure. Hypertension should be
aggressively managed with agents such as labetalol, hydral-
azine, metoprolol, or nicardipine. Vagal reactions can be
quite serious, and pre-medication with narcotics prior to
sheath removal may help reduce their occurrence. Hypoten-
sion after cardiac catheterization is potentially multifactorial
and includes diuresis, ischemia, retroperitoneal bleeding, as
well as vagal reactions. If a retroperitoneal bleed is sus-
pected, the most effective rapid response is to return to the
laboratory for contralateral access and identification of the
bleeding site.
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Little has changed over the last decade in regard to
personnel issues. A cardiac catheterization procedure re-
quires a critical mass of interdisciplinary personnel to allow
safe and optimal performance of the procedure. Technical
staff should be certified. The staff should be provided
opportunities for ongoing continuing education.
Defined physician personnel in the cardiac catheteriza-
tion include the attending or operating physician (the
individual in charge), the teaching attending physician (often
supervising cardiology fellows), and secondary operators.
A laboratory director is a prerequisite for all laboratories
and should be an experienced (generally5 years) interven-
tionalist, board-certified, and familiar, if not proficient, with
the various procedures and technical equipment being used
in the laboratory. In small or new laboratories, a physician
director may be just starting his practice. If the director does
not have 500 PCI procedures performed, his or her cases
should be randomly reviewed by the QA process until that
minimum number is achieved and competence established.
The laboratory director may or may not be the interven-
tional fellowship director. However, he or she should work
closely with the fellowship training program. The director is
responsible for monitoring physician and staff behavior and
ensuring their competence. The director should be the labo-
ratory’s advocate for adequate resources. He or she should
collaborate with hospital personnel to ensure safety and com-
pliance with all regulations and possess strong management skills
as well.
Cardiovascular trainees may perform all aspects of the
procedure as their skill level matures, but they cannot be
primary operators and must function under the direct
supervision of the attending physician. Physician extenders
(nurse practitioners and physician assistants) are primarily
used for the pre- and postprocedural evaluations and follow-
up, but in monitored situations, they can directly assist the
primary operator in the actual procedure.
The number and type of nursing personnel varies widely,
but a supervising nurse’s role is to manage nonphysician
nursing and technical personnel to ensure patient care is
optimal and that the staff is properly trained and respected.
The committee notes there is currently no formal certifica-
tion for this position (despite its complexity) and endorses a
movement toward such a certification option on a national
level.
With the movement away from cine film to digital
storage and archival systems, it is important to have access
to computer technical support. Because of the increased
importance of patient and staff radiation safety, laboratories
should have routine access to qualified medical and health
physicists. Support is needed beyond meeting the minimum
regulatory safety regulations.
All members of the cardiac catheterization team must
have Basic Life Support certification in cardiopulmonaryresuscitation (CPR) techniques, and the committee strongly
urges certification in advanced cardiac life support as well.
The Hybrid Cardiac Catheterization Laboratory
The hybrid cardiac catheterization laboratory/operating
room is an integrated procedural suite that combines the
tools and equipment available in a cardiac catheterization
laboratory with anesthesia and surgical facilities and pos-
sesses the sterility of an operating room. It must meet all of
the standard features of both an operating room and a
cardiac catheterization facility. Procedures suited for a
hybrid room include those that require surgical access (i.e.,
percutaneous valve replacement, thoracic or abdominal
stented grafts, and large-bore percutaneous ventricular assist
devices), those where conversion to an open surgical proce-
dure may be required (i.e., bailout or apical approach to
percutaneous aortic valve replacement, vascular plug deploy-
ment in paravalvular prosthetic valve regurgitation, and
percutaneous ventricular septal defect closure), hybrid treat-
ments (i.e., combined PCI or other vascular stenting with
surgical approaches and epicardial atrial fibrillation abla-
tion), electrophysiology (EP) device implantation or re-
moval, and certain emergency procedures such as ECMO
insertion or emergent thoracotomy.
The staff must be comfortable with both the surgical suite
and the cardiac catheterization laboratory environment.
This is generally done by using a specific team to allow for
the necessary training. As the room is neither a standard
operating room nor catheterization laboratory, physician
training on its use is also a requirement.
The laboratory location can be either in proximity to the
operating rooms or to the catheterization suite. It must be
located on a clean core or semirestricted corridor where
scrubs, hats, and masks are required. Scrub alcoves are a
necessity along with a separate control room with wide
windows. These rooms are larger than the standard cardiac
catheterization laboratory room, though radiation shielding
and video equipment are similar. A wide range of lighting is
required (dim for viewing images and bright for surgical
procedures). The mounting of the x-ray gantry is important
so as not to interfere with laminar airflow or the anesthe-
siologist. The table also differs from the routine laboratory
as surgeons need a fully motorized table and tabletop, yet it
must be compatible with the production of high-quality
x-ray images.
In short, the hybrid laboratory requires considerable
planning and a firm understanding of how the room is to be
used before its construction. Its dual function provides an
opportunity to expand the procedures in the catheterization
laboratory. Its stringent requirements demand a cooperative
working relationship with a variety of disciplines to be a safe
and successful endeavor.
Ethical Concerns
A detailed discussion of ethical issues is beyond the scope of
this document. The physician’s primary obligation is always
i2
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regulatory, or social pressures otherwise. Physician respon-
sibilities have increased dramatically with mandates from
payers and the government for an ever-increasing amount of
documentation. Much of this is time-consuming and creates
unnecessary redundancy with little direct impact on the
primary obligation. The changing healthcare reimburse-
ment landscape has driven many physicians to align with
larger health systems where there may be a further increase
in the pressure for increased productivity in the face of
declining reimbursement. With the decline in the fee-for-
service system and the approaching shift toward reimburse-
ment bundling, the physician must never leverage patient
interests to produce a better profit margin.
A few of the major ethical concerns are addressed in this
section. They include the inappropriateness of the sharing
of fees, fee splitting, and fee fixing. Unnecessary procedures
performed, especially those justified as malpractice protec-
tion, are improper and not in the patient’s interest. Guide-
lines for appropriate use in many areas are now emerging to
address this. Physician self-referral concerns led to the
introduction of the Stark laws in 1989, and these regulations
are designed to limit procedures being done to simply
augment profit. Informed consent continues to get more
and more complex, but a clear and understandable descrip-
tion of the procedure, the alternatives, the benefits, and the
risks is simply a mainstay of good patient care. Teaching
hospitals have a particular obligation to inform the patient
of the skill level of all personnel involved. Cardiology has
been the leader in developing evidence-based medicine, and
clinical research involving patients requires strict adherence
to safety guidelines and the protocol being employed. The
opportunity for monetary rewards or self-promotion should
never override patient safety and respect. Physicians and
industry must work together to advance medical knowledge
and avoid bias. Physicians should not accept industry gifts.
Conflict of interest committees are designed to oversee any
potential conflict and are in place to protect both the
physician and the institution.
X-Ray Imaging and Radiation Safety
Substantial changes in the x-ray equipment have occurred
over the last decade. The movement from cine film to a
digital medium has been completed, and the transition from
the standard image intensifier to the flat-panel image
detector is in progress. Flat-panel detectors enhance image
uniformity and brightness and have a much greater dynamic
range compared to the standard image intensifier. Radiol-
ogists routinely receive formal training in understanding
how x-ray images are created, but this learning process is
much more informal in cardiology. This section provides an
overview of how x-ray images are made and discusses the
role of each of the pieces of equipment. The major changes
over the last decade include changes in the generator, x-ray
tube, image detector, image processing, and image display.
The dose-area product (DAP) is a measure of the total iradiation exposure and is derived from an ionizing chamber
on the output of the x-ray tube. It does not address the
amount of radiation to specific organs. The use of the
interventional reference point (IRP) is recommended to
estimate the amount of skin dose the patient receives.
The biological risk from x-rays is due to disruption to
the cellular DNA backbone either by direct or indirect
(free-radical) injury. A deterministic injury results in
enough individual cellular death to create organ dysfunc-
tion. These types of injury are dose-dependent (such as
skin burns). A stochastic injury to the DNA results in
mutations or cancers, and a single x-ray can be at fault.
Although the likelihood of this happening increases with
the dose, it is not dose dependent. The effective dose
encompasses the stochastic risk and is used to provide a
metric of radiation safety. It is the weighted sum of the
estimates of dose to each individual organ. The breast,
bone marrow, and lungs are among the most sensitive
organs in this model. The effective dose correlates with
the DAP.
The IRP dose at the isocenter of the gantry (usually the
midportion of the patient) is derived by estimating the dose
in the midportion of the patient and then dropping back 15
cm (assuming that is where the skin on the patient’s back is
located). It provides an estimate of the deterministic injury
dose.
Recommended guidelines for patient and operator dose
limits to reduce deterministic and stochastic injury are
provided in the document and reflect current National
Council on Radiation Protection and Measurements
(NCRP) reports. The NCRP now accepts as a minimum
the wearing of a single monitoring device on the thyroid
collar; however, the recommended 2-monitor technique
provides the best estimate of risk. A pregnant worker must
also wear a monitor at waist level under the lead apron.
Maximum allowable radiation for medical workers is 50
millisieverts (mSv) per year whole body and a lifetime
cumulative dose of 10 mSv  age.
An understanding of x-ray image formation and basic
radiation safety principles allows for the understanding of
means to limit exposure to both the patient and operator.
Exposure to the patient can be reduced by minimizing the
framing rate, reducing imaging time, use of retrospectively
stored fluoroscopy instead of acquisition, use of pulse
fluoroscopy, and limiting use of “high-dose” fluoroscopy,
avoiding magnification when possible, using collimation
and other filters at the output of the x-ray tube, keeping the
image detector close to the patient, and avoiding angulation
that increases the source-to-image distance. For the opera-
tor, the same rules apply. Plus it is important to remember
time, distance, and barriers. The impact of x-rays decreases
in proportion to the inverse-square law (1/d2). Lead shield-
ng is effective if use properly.
All cardiac catheterization laboratories manufactured since
005 are required to provide real-time exposure information,
ncluding reference point air kerma. Most fluoroscopes also
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incorporated in the patient record and part of the QA/QI
process.
Special Concerns for the Pediatric
Catheterization Laboratory
There are 120 specialized children’s hospitals in the United
States, and all have cardiac catheterization facilities. All
facilities that perform cardiac catheterization on pediatric-
aged patients must have the full complement of resources
available, including cardiovascular surgery. Pediatric labora-
tories may be dedicated facilities or shared with an adult
program.
Differences in Goals Between the Pediatric Laboratory
and the Adult Laboratory
Diagnostic catheterizations in children are essentially always
focused on structural heart abnormalities. Hemodynamic
measures plus chamber and vessel angiography are much
more commonly done than in adult laboratories. Because
of the variability in patient size, most data are indexed to
body surface area. Often the procedure requires signifi-
cant sedation or general anesthesia. Due to improvements
in noninvasive imaging, three fourths of all pediatric
catheterizations are therapeutic and not simply diagnos-
tic. A substantial number of unique procedures are
performed in congenital heart disease (such as atrial
septostomy) and are not applicable to adults. Therapeutic
procedures that might also be performed in certain adult
congenital patients include PFO and ASD closure, val-
vuloplasty, angioplasty, stent implantation in pulmonary
and arterial vessels, vascular closure (patent ductus arte-
riosus, fistulae, anomalous vessels), devise closure of a
ventricular septal defect, transcatheter pulmonary or aor-
tic valve replacement, foreign body retrieval, pericardio-
centesis, endomyocardial biopsy, and a range of electro-
physiological procedures. Hybrid procedures are becoming
more important where novel access may be provided (i.e.,
palliation of the hypoplastic left heart patient with access
provided directly through the anterior right ventricle).
Who Should Perform Pediatric Catheterizations?
All pediatric catheterizations should have a director respon-
sible for all aspects of the laboratory operation, similar to the
adult laboratory. Attending physicians should be board-
certified in pediatrics and at least board eligible in pediatric
cardiology. There may be exceptional cases where a com-
petent operator can be granted privileges, but this should
not be common practice.
The pediatric age range is from 0 to 18 years. It is
recommended that catheterizations in patients within this
age range be done by a pediatric cardiologist. Adult con-
genital heart disease patients may have procedures per-
formed by a pediatric cardiologist or with an adult and
pediatric cardiologist together. The only exception is theadult cardiologist with a special interest and expertise in
adult congenital heart disease.
Quality Assurance Issues in the Pediatric Cardiac
Catheterization Laboratory
Complication rates differ substantially from the adult labo-
ratory and are much higher due to the serious nature for
many of the disease processes and the critical hemodynamic
state at the times encountered. In 1 registry, adverse events
in the pediatric laboratory were found to be 16% overall,
with 10% related to diagnostic catheterization and 19%
related to interventional procedures. Death occurred in
0.9%. The latest addition of pediatric data to the ACC-
NCDR via the IMPACT (Improving Pediatric and Adult
Congenital Treatment) registry should provide ongoing
monitoring of these procedures. By necessity, informed
consent is usually provided by the patient’s parents. Similar
concerns regarding informed consent in the adult laboratory
still apply.
Inpatient Versus Outpatient Settings for Procedures
For most children, an overnight stay following the proce-
dure is medically prudent. This is especially the case with
young children where it is difficult for them to remain still
after the procedure. Any blood loss may be significant in
small children. Often families have traveled long distances,
and local medical attention to a problem may not exist.
Despite the small size, the sheaths used during pediatric
catheterizations are similar to those in adults (5-F to 8-F).
Each laboratory should establish a written policy on who
might be expected to be discharged immediately following
the procedure.
Operator and Laboratory Volumes
Similar to the discussion regarding adult laboratories, the
heterogeneity of the patient population and the low volume
of procedures make specific minimum volumes problematic.
The American Academy of Pediatrics Guidelines suggests
the use of specific outcome benchmarks rather than mini-
mum operator or laboratory volumes as a guide to compe-
tence. The committee consensus, however, suggests a min-
imum operator volume of 50 per year and a minimum
laboratory volume of 100 per year seems reasonable.
Having a robust QA/QI program in pediatric laboratories
is of great importance. There should essentially be no
“normal” cardiac catheterization procedures. The same rules
outlined for an adult QA/QI program apply to the pediatric
laboratory otherwise.
Procedural Differences Compared With the
Adult Cardiac Catheterization Laboratory
The need for specific baseline laboratory data greatly differs
in the pediatric catheterization laboratory. Many patients do
not have noncardiac disease and are not on any medications.
There is no standard laboratory data required before the
procedure, and no standard pre-medication regiment. Se-
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Vascular access is also individualized depending on whether
the patient is a neonate, young or older child, or is of adult
size. Most procedures are performed via the femoral artery
and vein. Transseptal procedures are common. Newborn
procedures are performed generally via the umbilical vein.
Venous access can also be accomplished via the internal
jugular, subclavian, basilica, and transhepatic approaches. In
very young children, balloon aortic valvuloplasty or stenting
open the patent ducts may require a carotid artery cut-down.
Heparin is variably used during the procedure, whereas
vascular occluders are not used in children. As more invasive
percutaneous methods are being developed, the potential for
catastrophic events increases. There should be access to
ECMO in addition to routine resuscitation equipment.
Biplane x-ray capabilities should be standard, though
certain procedures can be done with single-plane systems
satisfactorily.
Hemodynamics and Angiography
Right and left heart hemodynamics and angiography are
routine procedures and require high-resolution equipment
to ensure the diagnosis. The framing rates depend on the
patient’s heart rate and 30 frames per second (fps) is often
required to capture all the necessary information. Due to the
high heart rates, contrast must be injected at a higher rate
(i.e., over 1 to 2 s).
Laboratory Personnel
There is essentially no difference in the types of personnel
needed to run an efficient pediatric catheterization labora-
tory dedicated to the highest standards compared with an
adult laboratory.
Radiation Protection and Pregnant Patients
The same principles apply in this age group as with adults.
Children are more susceptible than adults to the stochastic
effects from ionizing radiation (they live longer and that
increases the risk of a cancer developing). A urine or serum
beta-HCG level should be obtained within 2 weeks of the
procedure in menstruating women. If a pregnant patient
must be studied, all of the previously described means to
reduce radiation exposure should be followed, and the
abdominal and groin area should be shielded from direct
x-ray exposure. Scattered radiation still occurs, however.
Summary
The cardiac catheterization laboratory has undergone major
changes in the last decade. It is a much more sophisticated
environment where a gradual shift in emphasis from a
diagnostic laboratory to a therapeutic environment is occur-
ring. As the risk of both diagnostic and interventional
procedures has declined, there has been liberalization in the
types of patients who may safely have procedures performed
in both outpatient settings and in laboratories without
cardiovascular surgical backup. The influence of peripheralvascular and structural heart intervention has also required a
change in focus for many laboratories and has given rise to
the hybrid cardiac catheterization facility. The advances in
percutaneous therapies for structural heart disease are just
now beginning to impact both the adult and pediatric
catheterization laboratory.
Some of the routine practices in many laboratories are
being questioned. For instance, the committee no longer
suggests a protime be obtained before a procedure, unless an
abnormality is anticipated. Overnight NPO orders should
be replaced with shorter-term fasting as hydration is impor-
tant. Acetylcysteine is no longer recommended to reduce
contrast nephropathy.
QA is a focus of this report, and its importance is
mounting as it becomes harder to justify minimum volume
requirements for both the operator and the laboratory. The
importance of national databases to provide benchmarks is
emphasized.
Radiation safety has also entered into the discussion more
prominently as patients and regulators have expressed con-
cern regarding the amount of medical radiation the public
receives. Measures of the amount of radiation exposure
should be a routine part of the cardiac catheterization
report.
The cardiac catheterization laboratory and its functions
will continue to evolve and grow over the next decade as
newer devices and treatment options emerge. The cardiac
catheterization laboratory of today differs significantly from
that of a decade ago. It is anticipated that the cardiac
catheterization laboratory 10 years from now will undergo a
similar evolution.
1. Introduction
The last expert consensus document on cardiac catheteriza-
tion laboratory standards from the ACCF and SCAI was
published in 2001 (1). Although the fundamentals of
invasive cardiovascular procedures remain unchanged, many
changes have occurred related to the catheterization labo-
ratory and its operational environment. Modifications and
evolution have occurred with the imaging equipment tech-
nology, the range of diagnostic modalities, the spectrum of
pharmacological therapies and mechanical interventions,
and the local delivery of cardiovascular health care. Com-
munity hospitals without surgical backup have begun per-
forming diagnostic catheterizations on higher-risk patients
as well as elective interventional procedures on lower-risk
patients, and community programs have been developed
that permit onsite primary angioplasty on patients with
AMI. At the same time, the cardiac catheterization labora-
tory has become a multipurpose interventional suite undertak-
ing many therapeutic procedures for the coronary, cerebral, and
peripheral vessels, providing corrective intervention for con-
genital and structural heart disease, sometimes merging with
surgical suites into hybrid procedure rooms for valvular and
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signed to update the latest information regarding the
catheterization laboratory environment and its operation.
1.1. Document Development Process
and Methodology
The development of consensus documents involves multiple
healthcare professionals and often 2 or more medical soci-
eties. Given the importance of practice guidelines and
expert consensus documents, governing principles have been
established to ensure the accuracy, balance, and integrity of
the content, as well as the composition of committees
responsible for these documents. The ACCF has created a
methodology manual for expert consensus document writing
committees that can be accessed at www.cardiosource.org (2).
.1.1. Writing Committee Organization
his writing committee was commissioned by the ACCF
F CECD in conjunction with SCAI. Coordination and
taff support were provided by the ACCF. Nominations for
riting group membership were made to the TF CECD
ith representatives and liaisons solicited from the TF
ECD, SCAI, STS, and SVM. Care was taken to select
cknowledged experts in cardiovascular catheterizations and
nterventions with members from both the academic and
rivate practice sectors and representing a diverse geogra-
hy. The committee consisted of 16 members: 12 from
CCF, 3 from SCAI, 1 from STS, 1 from SVM, and 1
nvited radiation physicist content expert.
.1.2. Relationships With Industry and Other Entities
s part of the nomination and application process, all
riting committee candidates were required to provide an
p-to-date disclosure of their relationships with industry
nd other entities (RWI). Both the ACCF and SCAI
elieve that including experts on writing committees who
ave relationships with industry strengthens the writing
ffort, though a stringent approach to keeping all relation-
hips transparent and appropriately managed is necessary.
s such, it was required that the majority (50%) of writing
ommittee members had no RWI relevant to the entire
ocument. All relevant relationships occurring in the prior
2 months were required to be disclosed (Appendix 1),
ncluding the nature and extent of the relationship, as well
s the establishment of new industry relationships at any
ime during the document writing process. Members with
elevant RWI were not allowed to draft or vote on docu-
ent sections where a conflict may have been perceived
resent.
The writing committee chair was selected by the TF
ECD chair, and it was required that this individual have
o relevant RWI. The writing committee chair along with
upport staff created and reviewed a tentative outline of
ections for the consensus document. Companies, vendors,
nd other entities that had products or services related to the
atheterization laboratory document were identified and aategorized according to which sections of the document a
elationship might exist. Writing committee members were
hen selected and assigned to specific sections. Each section
ad a primary author who could have no relevant RWI for
hat section or topic area. Each section also had 1 primary
internal) reviewer from the writing committee.
.1.3. Consensus Development
he writing committee convened by conference call and
-mail to finalize the document outline, develop the initial
raft, revise the draft per committee feedback, and ulti-
ately sign off on the document for external peer review. All
articipating organizations participated in peer review, re-
ulting in reviewers representing 371 comments. A group of
0 experts, separate from the writing committee, was
elected for official review: 3 were nominated by ACCF, 3
y SCAI, 2 by STS, and 2 by SVM. In addition, 21 content
eviewers from 3 ACCF Councils provided comments.
here were no restrictions regarding the reviewers’ RWI,
hough all reviewers were required to provide full disclosure
egarding relevant relationships. This information was made
vailable to the writing committee and is included in
ppendix 2.
Comments were reviewed and addressed by the writing
ommittee. A member of the ACCF TF CECD served as
ead reviewer to ensure that all comments were addressed
dequately. Both the writing committee and TF CECD
pproved the final document to be sent for board review.
he ACCF Board of Trustees and SCAI Board of Direc-
ors reviewed the document, including all peer review
omments and writing committee responses, and approved
he document in February 2012.
The STS and SVM endorsed the document in February
012. This document is considered current until the TF
ECD revises or withdraws it from publication.
.1.4. Document Methodology
he writing committee for this expert consensus document
n cardiac catheterization laboratory standards began by
eviewing the 2001 “ACC/SCAI Clinical Expert Consen-
us Document on Cardiac Catheterization Laboratory Stan-
ards” (1). At the same time, the group conducted a brief review
f the literature and clinical practice evolution relative to the
atheterization laboratory environment. With this insight, it
as agreed that there was enough important information to
arrant a new consensus document. A formal review of the
iterature was performed and clinical data were reviewed
onsidering a range of cardiovascular topics including, but
ot limited to, the following: hospitals and clinical environ-
ents with and without surgical back-up for complex
iagnostic and interventional procedures; QA, proficiencies,
nd patient safety; procedural and postprocedural manage-
ent issues including unique patient groups; new pharma-
ological and mechanical therapies; laboratory designs, im-
ging equipment, and technologies.
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The workplace and function of the cardiac catheterization
laboratory has steadily evolved over the last 70 years.
Although numerous historic events have occurred during
this time, and the developmental phases of the catheteriza-
tion laboratory are not strictly delineated, 4 broadly defined
intervals can be considered. In the earliest phase, roughly
from 1940 to 1960, procedures were primarily focused on
hemodynamic assessments and structural heart disease.
With the development of radiographic techniques and
subsequently surgical revascularization, anatomy-focused
diagnostic studies became the mainstay of laboratory activity
in the interval from 1960 to 1980. The advent of PCI and
multiple percutaneous revascularization devices were the
hallmarks requiring changes in the catheterization labora-
tory in the era from 1980 to 2000. Most recently, interven-
tions on peripheral and cerebrovascular disease, structural
cardiac abnormalities, and percutaneous valve therapies are
influencing the needs and resources of the catheterization
laboratory.
2. The Cardiac Catheterization
Laboratory Environments
2.1. The Current Landscape
Over the 10 years since the publication of the “ACC/SCAI
Clinical Expert Consensus Document on Cardiac Cathe-
terization Laboratory Standards” (1), much has changed in
the cardiac catheterization laboratory. The importance of
invasive hemodynamic assessment has been supplanted by
major improvements in noninvasive imaging technologies.
With this change, there has been an unfortunate loss in the
capability of many laboratories to provide complex hemo-
dynamic information, even when it might be of value
clinically. The focus has now shifted primarily to coronary
anatomy assessment, where sophisticated tools now allow
for low-risk coronary interventions that were completely
unavailable just a decade ago. Improved techniques have
also reduced the overall risk for cardiac catheterization and
transformed diagnostic catheterization into an outpatient
procedure. Similar advances in interventional methods have
nearly eliminated the need for immediate surgical standby
for low-risk procedures, and a substantial amount of inter-
ventional procedures are now being performed in settings
without an in-house coronary surgical team even available—
something the prior consensus document condemned.
Of the 5,099 hospitals in the United States, the 2007
National Healthcare Cost and Utilization Project statistics
note that a remarkable number of hospitals, a total of 4,345
(85.2% of all), now provide cardiac catheterization services,
and 1,061 (20.8%) provide cardiac surgical services (3). As
reported in the 2009 Update on Heart Disease and Stroke
statistics from the AHA (4), the total number of inpatient
cardiac catheterizations, however, actually declined slightly
from 1996 to 2006, despite the incidence of inpatient PCI orates increasing from 264 to 267 per 100,000 population.
During the same period, the incidence of coronary artery
bypass grafting (CABG) declined from 121 to 94 per
100,000 patients (5). It is clearly a very dynamic time in the
cardiac catheterization laboratory.
2.2. General Complications From
Cardiac Catheterization Procedures
With the increase in the widespread use of cardiac cathe-
terization, there has been a general decline in the risk of the
procedure. Complication rates from diagnostic catheteriza-
tion are quite low. As suggested by the “ACCF/AHA/
SCAI Clinical Competence Statement on Cardiac Inter-
ventional Procedures” in 2007 (6), complications can generally
e divided into 3 major categories: coronary vascular injury,
ther vascular events, and systemic nonvascular events. Major
dverse cardiac and cerebrovascular events (MACCE) include
eath, stroke, myocardial infarction (MI), and ischemia requir-
ng emergency CABG. MACCE for diagnostic procedures
ccurs in 0.1% of diagnostic procedures (6). Additional
omplications include vascular access site complications, con-
rast nephropathy, excessive bleeding, and other miscellaneous
omplications such as arrhythmias, hypotension, coronary
erforation, and cardiac tamponade. The specific defini-
ions of cardiac catheterization complications have been
tandardized to a great extent and outlined by the
CC-NCDR (7).
In a single-center review of diagnostic cardiac catheter-
zation for 7,412 patients over a 10-year period (8), only 23
0.3%) had major complications, and there were no deaths
elated to the diagnostic procedure. Complications were
east common after procedures done by more experienced
hysicians, when smaller catheter sizes were used and when
nly left heart (and not left and right heart) procedures were
erformed. Obese patients had more vascular complications.
ata from the ACC-NCDR database regarding PCI for
oth elective procedures and for acute coronary syndromes
ACS) are shown in Table 1 (9). These data reveal a trend
oward fewer complications from PCI and a low risk-
djusted in-hospital mortality of 2.0% for ACS patients
ho had undergone PCI and 0.5% for elective PCI
atients.
In 2009, the Mayo Clinic published 25-year trend data
egarding their experience with 24,410 PCI procedures (10)
Fig. 1). The authors analyzed the first 10 years (1979 to
989), the period from 1990 to 1996, the period from 1996
o 2003, and then finally the period from 2003 to 2004.
hey found that despite an older and sicker population with
ore comorbid conditions, the success rate from PCI had
mproved from initially 78% to 94%, hospital mortality had
allen from 3.0% to 1.8%, and the need for emergency
ABG had dropped from 5% to 0.4%. In their latest
ssessment, major adverse complications following PCI
ccurred in only 4.0% of in-hospital patients.
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Hospital With Cardiovascular Surgical Capability
Table 2 outlines the optimal onsite support services that allow
for cardiac catheterization to be performed safely in any patient
with heart disease. A hospital with all of these services is
considered a “full-service” facility. Although cardiac surgical
capability is the defining service, the other important support
services listed are critical for optimal patient care and manage-
ment. The catheterization laboratory in this setting is fully
equipped for the most complex studies. Although direct
surgical intervention is infrequently needed during percutane-
ous interventional procedures, the associated depth of expertise
Table 1. Complication Rates for PCI Reported From the ACC-N
ACS
Variable
Q1 to Q2 (2005)
(n92,534)
esion information, %
Previously treated 7.5
Bypass graft lesion 7.7
High-risk (Type C) lesion 43.3
Lesion length 25 mm 20.4
Bifurcation lesion 11.4
rocedural information, %
Radial access 1.2
Multivessel PCI 13.9
Stents used during PCI
DES 83.6
BMS 9.6
Angioplasty only 6.8
rocedural complications and results, %
Dissection 2.4
Acute closure 0.7
Perforation 0.3
Procedural success 93.0
ascular complications, %
Access site occlusion 0.07
Peripheral embolization 0.08
Access vessel dissection 0.20
Pseudoaneurysm 0.42
Arteriovenous fistula 0.07
leeding complications, %
Access site bleeding 1.20
Retroperitoneal bleeding 0.33
Gastrointestinal bleeding 0.54
Genitourinary bleeding 0.20
Other bleeding 0.60
n-hospital outcomes, %
Transfusion after PCI 5.1
Stroke 0.3
Emergency bypass 0.4
Note: all outcomes are self-reported with only a small portion validated. Modified with permissi
ACS  acute coronary syndrome (includes unstable angina); BMS  bare-metal stent; DES 
intervention.within the facility (technology, equipment, personnel, andspecialized physicians such as anesthesiologists, perfusionists,
and surgeons) have experience with the most complex cases
and greater experience with emergent and critically ill patients.
Often associated higher volumes translate into improved pa-
tient care and outcomes for high-risk patients. Therefore,
although surgical service may not be directly required, the
associated local expertise is available should the need arise.
Essentially all laboratories that have full support services are
located in a hospital setting. There may be special situations
where a mobile laboratory is temporarily attached to or in an
adjacent facility beside the hospital. In this latter setting, the
situation should be considered similar to the inpatient labora-
Database
Percutaneous Coronary Intervention
Non-ACS
1 to Q2 (2009) Q1 to Q2 (2005) Q1 to Q2 (2009)
(n144,989) (n50,532) (n79,892)
7.3 8.2 7.5
6.4 6.9 5.9
46.9 33.7 38.7
21.3 17.9 18.5
12.3 11.2 12.1
2.0 1.6 2.3
12.9 15.5 15.3
65.5 85.7 73.0
27.3 7.6 20.4
7.2 6.7 6.6
2.1 2.2 2.0
0.7 0.5 0.5
0.3 0.3 0.3
94.3 94.0 94.8
0.03 0.03 0.02
0.04 0.02 0.02
0.17 0.24 0.19
0.46 0.38 0.84
0.05 0.27 0.27
0.78 0.67 0.49
0.42 0.25 0.17
0.67 0.27 0.15
0.13 0.07 0.05
0.97 0.27 0.27
4.7 2.6 2.3
0.3 0.1 0.1
0.4 0.2 0.2
Roe et al. (9). Source of new data: ACC-NCDR Cath PCI Registry.
uting stent; Non-ACS  those without any acute ischemic criteria; PCI  percutaneous coronaryCDR
Q
on fromtory with full support services in the hospital.
majo
2236 Bashore et al. JACC Vol. 59, No. 24, 2012
Cardiac Catheterization Laboratory Standards June 12, 2012:2221–3052.3.1. Patients Eligible for Invasive Cardiovascular
Procedures at a Hospital With Full Support Services
(Including Cardiovascular Surgery)
In this environment, all patients and all procedures can, in
general, be safely undertaken, provided the operators are
sufficiently experienced and competent in the procedures
being performed. Even though a hospital may have the
appropriate support services as outlined above, some pa-
tients should still be referred to an even more highly
specialized center if the technical expertise and experience
required (e.g., transseptal puncture, valvuloplasty, assess-
ment of complex congenital disease, and percutaneous ASD
occlusion) are not available. To this end, there is a growing
number of centers focused on structural heart disease. This
is particularly true for the pediatric patient population. The
laboratory setting appropriate for the pediatric population is
outlined in Section 10.7 of this document.
Figure 1. Trends in In-Hospital Outcomes Following PCI: The Mayo
Modified with permission from Singh et al. (61). In-hospital MI  Q-wave MI; MACE 
Table 2. Optimal (Recommended) Onsite Support Services for
Invasive Cardiac Procedures
Cardiovascular surgery
Cardiovascular anesthesia
Intensive care unit
Vascular services
Nephrology consultative services and dialysis
Neurology consultative services
Hematologic consultative and blood bank services
Advanced imaging services (echocardiography/Doppler, MRI, CT)
Mechanical circulatory support services
Endovascular surgery/interventions
If a pediatric catheterization laboratory, similar services for
pediatric-aged patientsCT  computed tomography; MRI  magnetic resonance imaging.2.4. The Cardiac Catheterization Laboratory at a
Hospital Without Cardiovascular Surgical Capability
With the increase in the number of cardiovascular laboratories
over the last couple decades, the performance of both diagnos-
tic and interventional coronary procedures is now becoming
more commonplace in settings without cardiovascular surgery,
despite guideline recommendations limiting PCI in these
settings. Perhaps surprisingly to many, evidence exists that
having a strict CON regulatory program is only modestly
associated with lower rates of cardiac catheterization. In fact, in
1 review, only minimally reduced rates of equivocally or weakly
indicated procedures for AMI were found in CON states,
whereas the presence of a CON requirement had no effect on
strongly indicated procedure rates (11).
The actual number of laboratories without onsite surgical
backup providing either elective or primary PCI is difficult to
confirm. Data from the ACC-NCDR database suggests that
about one third of the laboratories performing cardiac cathe-
terization do not have cardiovascular surgery backup, with at
least elective PCI being performed without surgical backup in
around one fourth (ACC-NCDR database information).
These data are similar to other databases. For instance, from
July 2000 through December 2006, according to the National
Registry of Myocardial Infarction (NRMI), 35.1% of partici-
pating hospitals providing primary PCI reportedly did not have
onsite surgery. Of note, only a little more than half (53.6%)
were in rural settings (12), suggesting the possibility of multiple
primary PCI sites in an urban environment.
There are limited data on comparative costs, but 1 report
suggests that the costs and charges of elective PCI at a hospital
without cardiovascular surgery might be considerably more
than those at a full-service hospital ($3,024 more in costs and
$6,084 more in charges) (13). Based on the available informa-
ic Experience
r adverse cardiovascular events.Clintion, therefore, anywhere from about one fourth to one third of
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not have onsite cardiovascular surgery. This is quite a large
number considering that most national organizational guide-
lines have discouraged the practice over the last decade.
Some insight into which patient groups might benefit from
undergoing PCI can be gained by considering risk factors for
periprocedural death. The latest data from the New York State
Cardiac Advisory Committee (2005 to 2007) is of interest and
summarized in Table 3. It seems appropriate to be cognizant of
the patients at greatest risk for developing an adverse outcome
Table 3. Multivariate Risk Factors for Deaths Within 30 Days
Following PCI, 2005–2007
Risk Factor Prevalence Odds Ratio
Non-emergent PCI risk factors
Demographic
Body surface area squared 3.0
Ventricular function
LVEF 40% to 49% 13.3% 1.9
LVEF 30% to 39% 6.1% 2.8
LVEF 20% to 29% 3.2% 2.1
LVEF 20% 0.8% 3.9
Preprocedural MI
MI; 1 to 7 days prior 12.9% 3.4
MI; 8 to 14 days prior 1.3% 3.4
Comorbidities
Cerebrovascular disease 8.0% 2.0
CHF, current 5.4% 2.6
COPD 6.4% 2.6
Malignant ventricular arrhythmias 0.4% 4.1
Peripheral vascular disease 7.3% 1.8
Renal failure, creatinine 1.6 to 2.5 (mg/dL) 5.9% 1.9
Renal failure, creatinine 2.5 (mg/dL) 1.4% 2.4
Renal failure, dialysis 2.1% 4.2
Vessels diseased
Three-vessel disease 13.7% 1.8
Left main disease 3.9% 1.9
Emergency PCI risk factors
Demographic
Female gender 27.1% 1.8
Hemodynamic state
Unstable 4.1% 4.4
Ventricular function
LVEF 20% to 29% 6.2% 2.2
LVEF 20% 1.2% 3.7
Comorbidities
CHF, current 5.1% 2.3
Malignant ventricular arrhythmias 1.6% 3.3
Renal failure, creatinine 1.1 to 1.5 (mg/dL) 38.2% 1.7
Renal failure, creatinine 1.6 to 2.0 (mg/dL) 4.7% 3.2
Renal failure, creatinine 2.0 (mg/dL) 1.8% 6.0
Renal failure, requiring dialysis 0.7% 7.0
Severity of CAD (1-, 2-, or 3-vessel disease):
no severity with odds ratio 1.5
Only those with odds ratio of 1.5 listed. Modified with permission from King et al. (58).
CAD  coronary artery disease; CHF  congestive heart failure; COPD  chronic obstructivepulmonary disease; LVEF  left ventricular ejection fraction; MI  myocardial infarction; PCI 
percutaneous coronary intervention.when considering whether PCI can be safely done in low-volume
settings or in those institutions without cardiovascular surgical
programs.
2.4.1. Patients Acceptable for Diagnostic Cardiac
Catheterization at a Facility Without Cardiovascular
Surgical Capability
Diagnostic cardiac catheterization is increasingly being per-
formed in facilities without onsite surgical backup. These
facilities include hospital settings (often rural), freestanding
laboratories, and mobile cardiac catheterization units (either
parked at a hospital or occasionally at a cardiovascular clinic).
With diagnostic cardiac catheterization now principally an
outpatient procedure, these types of laboratories have become
more accepted and widespread. To ensure these sites are
properly monitored, and that contingencies are in place for
urgent transfer if a complication occurs that may require
surgical intervention, SCAI has proposed a list of requirements
for offsite surgical backup of PCI procedures (14). Before
performing elective procedures, the cardiothoracic surgeon must
be available and the receiving hospital must be capable of accept-
ing patients before the procedure is initiated. These requirements
are outlined in Table 4 and have been modified by this committee.
Although primarily designed for programmatic backup of inter-
ventional procedures, similar requirements should be in place even
for diagnostic procedures in a setting without onsite cardiovascular
surgery. The focus of these requirements is to ensure that a written
and monitored program is in place before any invasive cardiovas-
cular procedures are considered acceptable in a facility without
onsite cardiovascular surgery.
Given the low risk of complications outlined above and the
favorable reports regarding both safety and the quality, the
committee feels that the prior relatively stringent restrictions
regarding eligibility for undergoing diagnostic cardiac cathe-
terization suggested in the 2001 cardiac catheterization stan-
dards document may now be relaxed. The highest-risk patients
are still better served clinically in a laboratory with onsite
cardiovascular surgical backup. For the most part, however, the
vast majority of stable patients can safely undergo diagnostic
cardiac catheterization in this setting. Table 5 outlines the
current recommendations regarding the specific types of pa-
tients who should be excluded from laboratories without
cardiovascular surgical backup and contrasts them with the
previous document (1). The committee feels these newer
recommendations better reflect the reality of the clinical care
currently being provided in the cardiology community. The
data to support this change are based on available literature for
identifying the high-risk patient and a general consensus of the
committee.
2.4.2. Patients Acceptable for Elective Coronary
Intervention in a Facility Without Cardiovascular
Surgical Capability
There are now multiple reports that the performance of
elective PCI in hospitals without onsite cardiovascular
surgery has acceptable outcomes and risk, if proper patient
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are in place. Data from the ACC-NCDR reveal an increase
in the number of such facilities from 8.7% to 16% during the
Table 4. Minimum Requirements for the Perf
in a Setting Without Onsite Cardiovascular S
1. A working relationship between the interventional ca
hospital must be established.
2. The cardiothoracic surgeon must have privileges at th
3. Surgical backup must be available for urgent cases a
4. Ideally, face-to-face meetings between cardiothoracic
regular basis.
5. Before performing elective procedures, the cardiotho
must be capable of accepting the patient before the
6. The interventional cardiologist must review with the s
an urgent transfer be required.
7. The interventionalist should be familiar with and have
intra-aortic balloon pump.
8. The interventionalist should be qualified to deal with
(pericardiocentesis) and embolization, should either e
9. Hospital administrations from both facilities must en
10. Both the referring and the receiving hospital must ha
patients, including a listing of the proper personnel.
11. A transport provider must be available to begin trans
life-sustaining equipment.
12. The transferring physician should obtain surgical con
13. The initial diagnostic and PCI consent should inform
surgical backup.
Modified with permission from Dehmer et al. (14).
PCI  percutaneous coronary intervention.
Table 5. General Exclusion Criteria for Invasi
Cardiothoracic Surgery
Exclusions: Catheterization Laborator
2001 Document
Diagnostic procedures
Age 75 years No
NYHA functional class 3 or 4 No
Pulmonary edema due to ischemia Pul
Markedly abnormal stress test with high No
likelihood of LM or 3-vessel disease
Known LM coronary disease No
Severe valvular dysfunction with reduced No
(
LV function
Patients at risk for vascular complications Per
Complex congenital heart disease Com
Acute or intermediate coronary syndromes ACS
All pediatric procedures All
Therapeutic procedures
Diagnostic or therapeutic pericardiocentesis Per
All therapeutic procedures in adult congenital All
All pediatric therapeutic procedures All
Elective PCI Elec
Primary PCI (not available at time) Prim
The current recommendations are compared to the prior consensus
ACS  acute coronary syndrome; LM  left main; LV  left ventricular; N
intervention.period from 2004 to 2005 (15), despite national guidelines
to the contrary. As suggested by the NRMI database, the
number may be as high as 25% to 35% in 2010.
nce of Invasive Cardiovascular Procedures
al Services
ists and cardiothoracic surgeons at the receiving
rring facility to allow review of treatment options.
ours and for elective cases at mutually agreed times.
ons and cardiologists involved should occur on a
urgeon must be available and the receiving hospital
stic or PCI procedure is started.
n the immediate needs and status of the patient should
able appropriate life support devices, such as an
encies such as pericardial tamponade
ccur.
a transfer agreement.
igorous and detailed protocol for rapid transfer of
hin 20 minutes of a request and must have appropriate
rior to transfer.
tient that the procedure is being done without onsite
ardiac Procedures in a Setting Without
hout Cardiothoracic Surgical Backup
Current Document
itation
ion
y edema due to ischemia
test result limitation
ry anatomic restriction
r or LV function limit unless severe
4) symptoms
le only if vascular services are available
congenital heart disease
pt where PCI procedures are approved
ric procedures
centesis allowed if operator competent
eutic procedures in adult congenital
ric therapeutic procedures
CI permissible under specified guidelines (55)
CI permissible under specified guidelines (55)
ent (1).orma
urgic
rdiolog
e refe
t all h
surge
racic s
diagno
urgeo
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emerg
vent o
dorse
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docum
YHA  New York Heart Association; PCI  percutaneous coronary
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the case when other active PCI programs are located within
the same geographic area. It behooves the cardiology com-
munity to foster these programs only when such programs
improve access to a higher level of cardiovascular care than
would otherwise be available. This has become a particular
hot button issue since the publication of certain politically
provocative articles such as COURAGE (Clinical Out-
comes Utilizing Revascularization and Aggressive Drug
Evaluation) (16), which suggests PCI did not improve the
rates of death or MI in patients with stable angina, or
SYNTAX (Synergy Between Percutaneous Coronary Inter-
vention with Taxus and Cardiac Surgery) (17), which asserts
that PCI with drug-eluting stents is inferior to CABG for
left main and multivessel disease. There is a declining
volume of PCI despite the improvement in outcomes from
stent technology and consistent with a better appreciation of
which procedures provide optimal benefit to patients. These
types of studies suggest maturation of the technology so that
further expansion may be limited despite concerns regarding
a need for more procedures in an aging population. To this
end, some have called for a moratorium on allowing any
further expansion of PCI services, especially to low-volume
facilities without cardiovascular surgical backup (18).
If the financial and marketing incentives are ignored,
however, when patients are appropriately selected, most
published studies regarding the risks of elective PCI at
facilities without onsite cardiovascular surgical backup have
shown the procedure to be relatively safe. The Swedish
Coronary Angiography and Angioplasty Registry (19) of
34,383 patients found no difference in outcomes of elective
PCI between hospitals with or without surgical backup.
Similarly community sites in the United States (10,13,20–22),
Germany (23), Japan (24), the Netherlands (25), the United
Kingdom (26), and Australia (27) all confirm there is little
or no difference in the outcomes among patients undergoing
elective PCI in hospitals with or without onsite surgery. A
similar finding was suggested by an analysis of 4 controlled
trials (28–31) involving 6,817 patients (32). A meta-analysis
of nonprimary PCI (elective and urgent; n914,288) also
found no difference in outcomes in PCI performed at sites
with onsite cardiovascular surgery compared with those
without (33).
The issue is further complicated due to the fact the
published literature to date is limited by its methodology
(registries, cohort studies, self-reported, and unmonitored
data) and lack of long-term follow up. In addition, the
exceeding low event rate in the elective setting makes it
difficult to demonstrate differences in smaller studies (type
II error). Finally, there is simply a lack of large, randomized
studies with independent monitoring of events in this arena.
In 2007, SCAI addressed the issue and concluded that
although they were unable to support the widespread use of
PCI without onsite surgery, they acknowledged that many
of these programs are now in existence and suggests that
criteria be met in order to ensure patient safety. Theyproposed that certain patient characteristics and lesion
characteristics should be considered “high risk,” and these
features should be taken into account before deciding
whether a patient is a candidate for PCI in this setting. It is
the consensus of this committee that high-risk patients or
those with high-risk lesions should not undergo elective
PCI in a facility without onsite surgery (Table 6).
In the 2007 “ACCF/AHA/SCAI Update of the Clinical
Competence Statement on Cardiac Interventional Proce-
dures” (6), similar patient and lesion characteristics were
found to be associated with higher short-term mortality
after PCI and would thus be considered high risk. That
statement also included the following groups as high risk:
the advanced in age, females, and those with ACS, a
peripheral vascular disease, or impaired renal function (es-
pecially in diabetic patients with regard to contrast nephrop-
athy). High-risk target-lesion anatomic features included
the modified 1990 classification scheme proposed by the
ACC/AHA Clinical Task Force on Clinical Privileges in
Cardiology (34). In that scheme, lesions were classified as
Type A, Type B1, Type B2, or Type C. Type C lesions were
considered the highest risk and had an angioplasty success
rate of 61%, in those days, and a complication rate of 21%.
The characteristics of a high-risk Type C lesion included
Table 6. Elective PCI Patient and Lesion Characteristics That
Identify High-Risk Patients Who May Be Unsuitable for PCI in
a Facility Without Cardiothoracic Surgical Backup
High-risk patient
1. Decompensated CHF (Killip Class 3 to 4)
2. Recent (8 weeks) cerebrovascular accident
3. Known clotting disorder
4. Left ventricular ejection fraction 30%
5. Chronic kidney disease (creatinine 2.0 mg/dL or
creatinine clearance 60 mL/min)
6. Serious ongoing ventricular arrhythmias
High-risk lesion
1. Left main stenosis 50% or 3-vessel disease (70% proximal or
mid lesions) unprotected by prior bypass surgery
2. Target lesion that jeopardizes an extensive amount of myocardium.
Jeopardy scoring systems, such as SYNTAX, may be useful in
defining the extent.
3. Diffuse disease (20 mm length)
4. Greater than moderate lesion calcification
5. Extremely angulated segment or excessive proximal or in-lesion
tortuosity
6. Inability to protect side branches
7. Older SVG grafts with friable lesion
8. Thrombus in vessel or at lesion site
9. Vessel characteristics that, in the operator’s judgment,
would impede stent deployment
10. Chronic total occlusions
11. Anticipated probable need for rotational or other atherectomy device,
cutting balloon, or laser
Modified with permission from Dehmer et al. (14) and high-risk features from the New York State
Percutaneous PCI Registry 2006–2007 (58).
CHF  congestive heart failure; PCI  percutaneous coronary intervention; SVG  saphenous
vein grafts; SYNTAX  Synergy Between Percutaneous Coronary Intervention with Taxus and
Cardiac Surgery.
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stenosis), stenosis bend of 60 degrees, and excessive
tortuosity. The data from these resources suggest that
high-risk patients and target lesions can be defined prior to
the performance of an elective PCI procedure and that it is
appropriate to avoid these patients when there is no onsite
cardiovascular surgery available.
In 2011, the initial results from the randomized Atlantic
Cardiovascular Patient Outcomes Research Team (Atlantic
C-Port-E) trial was reported (35). Only those sites with
200 PCIs per year and performing 24/7 PCIs were eligible
for enrollment. Individual operators were required to meet
the standard of 75 PCI cases per year. Sixty sites partic-
ipated, and 13,981 patients were enrolled at sites without
cardiovascular surgery whereas 4,515 patients were enrolled
at sites with surgery. The authors concluded that PCI
success was 90% in both situations, but this was lower in
hospitals without onsite surgery (a success rate difference of
1.1% on per-patient basis and 0.7% on lesion basis). In
addition, slightly more unplanned catheterization and PCI
procedures occurred in patients undergoing PCI at a non-
surgical site. Emergency CABG was rare, but it was slightly
higher in sites without surgery (0.2% versus 0.1%). Overall
mortality and catheterization complications were similar
between the 2 groups. Their conclusion was that PCI was
safe within the bounds established by the trial.
Finally, further support for the safety of PCI in facilities
without cardiovascular surgery comes from the ACC-
NCDR data registry (36). These data revealed that centers
without onsite cardiovascular surgery were predominantly in
nonurban areas, had lower PCI volumes, treated a higher
percentage of patients who presented with subsets of MI,
and had better reperfusion times in primary PCI than
centers with onsite facilities. There was also no difference in
procedure success, morbidity, emergency cardiac surgery
rates, or mortality (regardless if elective PCI or primary
PCI). Although the data are observational, voluntarily
submitted, and included from only 60 sites without cardio-
vascular surgery, it does suggest the current usage of these
facilities may be safe and emphasizes the importance of
reporting outcomes to a national data registry.
2.4.3. Patients Acceptable for PCI in ACS in a
Facility Without Cardiovascular Surgical Capability
Primary PCI has now been shown to be more effective than
fibrinolytic therapy in obtaining coronary reperfusion in
patients with STEMI (37). Based on GRACE (Global
Registry of Acute Coronary Events) data from 1999 to
2005, the use of primary PCI increased worldwide from
16% to 53%, whereas fibrinolytic therapy decreased from
50% to 28% (38). The improvement in patient outcomes as
a result of this shift has led to a growing interest in offering
primary PCI to as many patients as possible. Due mostly to
access issues, however, only about 33% of patients with
STEMI in the United States receive primary PCI, whereas
56% still receive fibrinolytics, and the remainder receives pneither (39). This has provided the impetus to consider
regionalization of STEMI care in the United States and a
relook at the potential advantage of primary PCI particularly at
rural hospitals without onsite cardiovascular surgery (40).
A standard treatment protocol using rapid interhospital
transfer of STEMI patients between 6 referral centers and 2
STEMI accepting hospitals (41) revealed that 87.7% of
patients received primary PCI. Door 1-to-departure time
averaged 46 minutes, and Door 1-to-balloon time at the
accepting hospital averaged 117 minutes. The authors
suggested that, in a coordinated healthcare system, primary
PCI can be centralized.
An NRMI report compared 58,821 STEMI patients
from 214 hospitals with onsite cardiovascular surgery to 52
hospitals without. The authors found no difference in
mortality among patients undergoing primary PCI at the
different sites. They did report, however, that the overall
STEMI mortality was higher, and the patients were less
likely to receive guideline-recommended medications at the
hospitals without surgical backup (42). In an NRMI data-
base follow-up report (42) involving 100,071 patients from
2004 to 2006, the in-hospital mortality was found to be
lower at hospitals with cardiovascular surgical support com-
pared with those without (5.0% versus 8.8%). Hospitals
with surgical services had higher use of guideline-
recommended medical therapies, which may have contrib-
uted to better outcomes.
Support for the concept of performing primary PCI at the
local facility also comes from a small randomized trial (43)
and 2 registries (44,45) with favorable outcomes, though a
study from Michigan also suggests that expanding a primary
PCI program to hospitals without onsite cardiovascular
surgery only improves access to a modest degree (46). A
recent meta-analysis of primary PCI for STEMI of 124,074
patients demonstrated no increase in in-hospital mortality
or emergency bypass at centers without onsite surgery
compared with those that had cardiovascular surgery avail-
able (33). Despite the mixed data, there remains much
enthusiasm from rural and hospitals without cardiovascular
surgery to offer this service. Some of this is driven by the
importance of providing timely access to early reperfusion
strategies for STEMI patients in the local community. It is
also driven by fear of loss of profitable cardiac patients and
the concern that without the service, the hospital will be
perceived as less than a full-service facility.
Some of these programs are also only providing primary
PCI during working hours and not during off-hours. A
review from the NRMI database has pointed out that there
is a 70% less likelihood of patients with STEMI undergoing
primary PCI if the presentation is off-hours (12). Since no
clinical characteristics explain the reason a smaller percent-
age of these patients undergo primary PCI, the conclusion
is that the procedure is just not available when the patient
arrives in the emergency department. In fact, the authors
note that 47% of the hospitals in the study perform 10rimary PCIs per year, suggesting that the volume of such
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primary PCI is only performed during normal daytime
laboratory hours and not 24/7.
The 2009 Focused Update of the ACC/AHA Guidelines
for the Management of Patients With STEMI also focused
on the strategy to be followed, depending on whether the
patient initially presents to a PCI-capable facility or to a
non–PCI-capable facility (47). It does not specifically ad-
dress whether the hospital has onsite cardiovascular surgery.
A consensus document from the SCAI notes that there is
no justification for providing elective PCI procedures with-
out onsite surgery and without providing primary PCI 24
hours a day (14). AHA has also endorsed the principle that
a facility providing primary PCI care should be operating
around the clock (48). There are few data in this regard, but
in 1 small study, the results of primary PCI done during
off-hours appears similar to those done during regular
working hours (49).
The ACC/AHA guidelines for the management of acute
STEMI patients focus on the development of a community-
wide system. Table 7 outlines their current recommenda-
tions for triage and transfer of STEMI patients for PCI.
Included in the table are definitions for the “high-risk”
STEMI patient. Although it is tempting to recommend
that patients with these high-risk features be excluded from
primary PCI at a hospital without cardiovascular surgery
services, there are no data to confidently support that
recommendation. In addition, coronary anatomic features
are only discovered after angiography has been performed,
so it is difficult to include such features as contraindications
for intervention.
In an attempt to gather data on the wisdom of the use of
primary PCI in the community at large, several ongoing
Table 7. Recommendations From the 2009 Joint STEMI/PCI F
Settings Without Onsite Cardiovascular Surgery
Class I: Each community should develop a STEMI system of care that follows st
national initiative, Mission: Lifeline, to include the following:
● Ongoing multidisciplinary team meetings that include emergency medical se
hospitals/STEMI receiving hospitals to evaluate outcomes and quality impro
● A process for prehospital identification and activation;
● Destination protocols for STEMI receiving centers; and
● Transfer protocols for patients who arrive at STEMI referral centers who are
shock. (Level of Evidence: C)
Class IIa: It is reasonable for “high-risk” patients who receive fibrinolytic therap
soon as possible to a PCI-capable facility where PCI can be performed eith
Consideration should be given to initiating a preparatory antithrombotic (antipla
catheterization laboratory. (Level of Evidence: B)
Class IIb: Patients not at high risk under the same conditions as listed in Class
High risk is defined in CARESS-in-AMI (59) as STEMI patient with 1 high-risk fe
previous MI, Killip Class 2, LV ejection fraction 35% for inferior MI; any
High risk is defined in TRANSFER-AMI (60) as STEMI patient with 2 mm ST-seg
along with at least 1 of the following: systolic BP 100 mm Hg, heart rate
1 mm ST elevation in right-sided V4 lead, indicative of RV involvement.
Reprinted from Kushner et al. (47).
BP  blood pressure; bpm  beats per minute; CARESS  Combined Abciximab Reteplase SLV  left ventricular; MI myocardial infarction; ST ST segment of the ECG; STEMI  ST-elevation myoca
of Routine Angioplasty and Stenting After Fibrinolysis to Enhance Reperfusion in Acute Myocardial Infarctionprograms have been undertaken including regionalization of
care across the United States (50): the AHA’s Mission:
Lifeline program (48), the Reperfusion of Acute Myocardial
Infarction in Carolina Emergency Departments (RACE)
(51), and the ACCF’s D2B Alliance (www.d2balliance.org).
These programs are all working to develop community-
based approaches to providing the optimal reperfusion
strategy in STEMI patients, and they are tracking the
results. Regionalization and improvements regarding in-
field diagnosis, transfer and triage improve access times
(door to balloon [D2B], emergency medical services to
balloon [E2B], and/or S2B [symptoms to balloon]) and can
optimize the use of primary PCI while avoiding duplication
of local services. Given that fibrinolytic therapies are still in
use in about 25% of U.S. hospitals, and even at PCI-capable
hospitals (12), the choice of a reperfusion strategy is
complex.
In many geographic situations, the ability to provide
primary PCI at a hospital without surgical backup is
suggested as a necessary step if other systematic approaches are
unable to minimize the time from symptom onset to reperfu-
sion. Evidence from the TRANSFER-AMI (Trial of Routine
Angioplasty and Stenting After Fibrinolysis to Enhance Rep-
erfusion in Acute Myocardial Infarction) study and CARESS
(Combined Abciximab Reteplase Stent Study in Acute Myo-
cardial Infarction) studies suggest a pharmacoinvasive ap-
proach with immediate transfer to a PCI center improves
outcome (52–54). If the pharmacoinvasive approach is verified,
this semielective approach to PCI at a tertiary hospital may
reduce the concern over needing to offer primary PCI services
in the local community or all local hospitals.
The Atlantic Cardiovascular Patient Outcomes Research
Team (C-Port) trial randomized 451 AMI patients at
ed Update on the Appropriate Performance of Primary PCI in
ds at least as strong as those developed for the American Heart Association’s
, non–PCI-capable hospitals/STEMI referral centers, and PCI-capable
nt data;
ry PCI candidates, are ineligible for fibrinolytic drugs, and/or in cardiogenic
imary reperfusion therapy at a non–PCI-capable facility to be transferred as
n needed or as a pharmacoinvasive strategy.
lus anticoagulant) regimen before and during patient transfer to the
ommendation. (Level of Evidence: C)
s. High-risk features include extensive ST-segment elevation, new-onset LBBB,
ior MI with 2 mm ST-segment elevation in 2 ECG leads.
elevation in 2 anterior leads or 1 mm ST-segment elevation in inferior MI
bpm, Killip Class 2 to 3, 2 mm ST-segment depression in anterior leads, or
udy in Acute Myocardial Infarction; ECG  electrocardiogram; LBBB  left bundle-branch block;ocus
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months, found better composite outcome (driven primarily
by a reduction in reinfarction), in the primary PCI group
compared with the fibrinolytic cohort with no significant
difference in mortality (43). The newest PCI guidelines
have reflected the more recent data since the last Catheter-
ization Standards document and have elevated the use of
elective PCI from a Class III indication to a Class IIb (55).
Primary PCI in facilities without onsite cardiovascular
surgery is considered a Class IIa instead of Class IIb
indication in the latest revision of these guidelines.
Recommendation: Because of the current lack of defin-
tive data in this area, this committee recommends that all
acilities that perform primary PCI in a setting without
ardiovascular surgical backup comply with all current
uidelines on the establishment of such a program (as
utlined in this section and in the accompanying tables). It
s critical the facility documents that all medication and risk
tratification guidelines are being followed as well, and that
he facility has availability for STEMI patients 24 hours per
ay, 7 days per week. The committee cannot recommend any
CI programs without cardiovascular surgical backup that only
rovide primary PCI coverage during daytime and weekday hours.
To further ensure quality oversight, the facility should
lso be part of a defined registry to monitor outcomes and
rack all complications on a regular basis. D2B should be
racked closely, with goal D2B times of 90 minutes in
75% of cases. Regionalized systems of care may provide a
ore efficient system of diagnosis and triage and transfer,
nd they may or may not justify the current trend of
stablishing primary PCI capability at hospitals without
urgical backup (56).
Table 8. Assessment of Proficiency in Coronary Intervention
Type Component
Individual Cognitive ● Formal tra
● Present re
● Board cert
12 month
interventio
Procedural ● Risk-adjus
● Individual
● Peer recog
Judgment ● Appropriat
aboratory Procedural outcomes ● Risk-adjus
● Compariso
● Laboratory
Activity ● A minimum
● Director w
operator (
● QA staffin
Support ● Experience
● Regularly
complicat
● Facilities aABIM  American Board of Internal Medicine; ACC  American College of Cardiology; ACGME  Accred
CI  percutaneous coronary intervention; QA  quality assurance.Finally, pharmacoinvasive strategies (54,57), if confirmed in
other experiences, may provide superior, or at least comparable,
outcomes to primary PCI at low-volume centers, and this
should be evaluated further to determine whether increased
centralization of services may result in improved outcomes.
3. Quality Assurance Issues in the
Cardiac Catheterization Laboratory
The modern cardiac catheterization laboratory is an amal-
gamation of complex, highly sophisticated medical and
radiological instrumentation used in the diagnosis and
management of patients with both chronic stable disease
and acute life-threatening illnesses. In any complex,
procedure-oriented area, it is essential to have a QA
program that incorporates QI to provide ongoing feedback
within an established infrastructure for change. The Cardiac
Catheterization Laboratory QA/QI committee should be
considered a separate entity specific to the cardiac catheter-
ization laboratory. Interactions with other medical staff
and/or hospital QA/QI committees are critical, with per-
sonnel often assigned to work in multiple QA/QI commit-
tees and to share similar concerns, projects, and expertise.
The following discussion summarizes the key compo-
nents of a QA/QI program for the diagnostic and interven-
tional cardiac catheterization laboratory. These components
are as follows: 1) clinical proficiency; 2) equipment mainte-
nance and management; and 3) peer review. A fourth
component, radiation safety, is discussed separately in this
document. Table 8 outlines clinical proficiency based on
cognitive skills, procedural conduct, and clinical judgment.
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ent by ABIM: 3-year fellowship in ACGME-accredited program
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Catheterization Laboratory
3.1.1. Rate of “Normal Catheterizations”
The frequency of normal hemodynamic and angiographic
findings at diagnostic catheterization is a function of the
pretest likelihood of disease and the physician’s clinical
acumen. For purposes of definition, “normal” coronaries are
defined pragmatically as those without a “significant” diam-
eter reduction (50%) on visual inspection. Since the
publication of the 2001 Expert Consensus Document on
Catheterization Laboratory Standards, there has been scant
information reported on this topic in populations of patients
undergoing diagnostic coronary angiography. New data
from SCAI indicate that the frequency of normal angio-
grams is 20% to 27%, which appeared to vary little over a
reporting period of several years (62,63). Notably, in a
report from the ACC-NCDR, the proportion of patients
undergoing elective diagnostic catheterization who were
found to have minimal obstructive disease (20% stenosis)
was remarkably high at 39.2% (64).
It is recognized that many studies include patients with
“insignificant disease,” which is defined as 50% coronary
diameter narrowing by visual estimate. Clearly, ACS occurs
in patients without “significant” antecedent luminal narrow-
ing on angiography. In addition, certain clinical syndromes
may relate to coronary endothelial or microvascular dysfunc-
tion. Some laboratories may also have a high prevalence of
patients studied for noncoronary issues, such as pulmonary
hypertension, cardiomyopathy, valvular heart disease, or
adult congenital heart disease. Ultimately, the rate of normal
studies in any facility may more properly be viewed as a
system performance metric as the outcome of any given
angiographic study reflects pretest likelihood, complex de-
cision pathways, local practice, and patient preference (65).
3.1.2. Specific Complication Rates Following
Diagnostic Catheterization
There is extensive, albeit dated, literature on the major
complications of diagnostic cardiac catheterization
(62,63,66). Fortunately, the (composite) rate of MACCE is
“acceptably” low at 1% to 2%. As expected, the likelihood
of major complications increases significantly with the
severity of the underlying cardiac and noncardiac disease
(67). Patients with both valvular and coronary artery disease
are slightly more likely to sustain a complication than
patients with isolated coronary artery disease (68). Although
complications encountered in patients with valvular or
myocardial disease are more likely to reflect the patient’s
underlying clinical status, specific complication rates for
transseptal catheterization (69) and endomyocardial biopsy
(70) have been reported and fall within the previously
referenced range. Because of patient selection, the likeli-
hood of major complications during outpatient studies is
less than that found during inpatient examinations (67),
although the constantly changing definition of “outpatient” fmay blur this distinction. Current estimates from the
NCDR continue to support the validity of the above-cited
estimates for MACCE.
3.1.2.1. ACCESS SITE COMPLICATIONS
Although not considered a “major complication” of diag-
nostic procedures, access site complications remain an
important contributor to patient morbidity (71). It must be
acknowledged that over the past decade, dynamic changes
have occurred in the choice of access site for procedures, the
caliber of diagnostic catheters, anticoagulation and anti-
thrombotic protocols, and the means of achieving access site
hemostasis (72,73). Progressive changes in the practice of
invasive cardiology, in addition to advances in technology
and technical competence, have led to significant reductions
in access site complications for patients undergoing invasive
diagnostic and therapeutic procedures (72).
3.1.2.2. CEREBROVASCULAR COMPLICATIONS
Reported rates of clinically evident periprocedural cerebro-
vascular complications were generally 1 per 1,000 patients
ndergoing diagnostic cardiac catheterization and angiog-
aphy (62). More recently, reports of subclinical manifesta-
ions of cerebrovascular events during and immediately
ollowing retrograde aortic valve catheterization in the
etting of evaluation for aortic valve stenosis have appeared
74). Although admonitions against this practice have
ppeared in the literature (75), the true rate of clinical
stroke” in this setting is still unknown. However, in view of
he increasing interest in catheter-based aortic valve repair/
eplacement techniques, this salient complication will re-
ain an important focus of attention. Cerebrovascular
omplications in the setting of PCI will be discussed below.
.1.3. Diagnostic Accuracy and Adequacy
n important, although generally ignored area, is that of the
ompleteness and accuracy of diagnostic catheterization
rocedures. Incomplete procedures (aborted or technically
nadequate procedures) that fail to obtain the critical infor-
ation for diagnostic purposes and erroneous interpretation
f the acquired information are markers of quality no less
mportant than outcome data. Failure to selectively engage
ative coronary arteries or coronary bypass grafts often
esults in insufficient opacification of the lumen to accu-
ately assess coronary anatomy or stenosis presence and/or
everity. Inability to recognize the presence of anomalous
oronary arteries contributes to this problem. The implica-
ions of inadequate or incomplete studies are significant and
ange from the need to repeat procedures to the perfor-
ance of unnecessary and more invasive procedures. Inad-
quate opacification of the ventricle due to hand injections
s inappropriate. In the coronary interventional era, the need
or high-quality diagnostic angiography is great, as life-
ltering decisions are generally made on the basis of this
nformation. This includes failure to opacify vessels fully due
o inappropriate injection, incorrect catheter sizing, or
ailure to obtain adequate views that best characterize the
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hemodynamic recordings in patients with valvular heart
disease and the failure to accurately demonstrate coronary
anatomy must be viewed as critical measures of outcome.
For all the above reasons, it is reasonable to expect a rate of
either inadequate or incomplete procedures to be 1%.
3.2. Patient Outcomes After Coronary
Interventional Procedures
3.2.1. Major Adverse Cardiac or
Cerebrovascular Events
Although patient outcomes are often considered the most
important indicators of proficiency and competence in
interventional cardiology (76), they are arguably the most
difficult to accurately quantify. Moreover, the importance of
risk adjustment for even crude event frequencies cannot be
overstated (77). Therefore, it is essential that careful and
complete preprocedural and intraprocedural information is
accurately and reliably collected, sorted, and analyzed.
Given that operator and institutional outcomes depend on
many demographic, clinical, anatomic, and administrative
variables, an adequate information system within the labo-
ratory is mandatory, and the emphasis on both individual
and institutional outcomes is appropriate (78–80). This is
particularly so when attempting to risk-adjust outcomes for
low-volume operators (81). The ability to estimate the
likelihood of a significant complication (82,83), choose
devices, and conduct procedures appropriately (84),
promptly recognize and treat ischemic and other complica-
tions (85), and ultimately select (or refuse) cases appropri-
ately are the hallmarks of an experienced, competent
operator.
It is the responsibility of the director of the cardiac
catheterization laboratory to establish a method of QA to
track major events, (e.g., death and serious hemodynamic
and/or arrhythmic events). Ongoing peer review of ran-
domly selected cases from all operators is highly desirable
and strongly encouraged. It should include the assessment
Table 9. In-Hospital or Short-Term MACCE Following Elective P
Study Population Year Reference
Death
(%)
CC-NCDR (registry) 2002 Anderson et al. (130) 1.4
IRIUS (RCT) 2003 Moses et al. (131) 0.09
ESEARCH (registry) 2004 Lemos et al. (132) 1.6
YNERGY (RCT) 2004 SYNERGY (133) 0.47
CUITY (RCT) 2006 Stone et al. (134) 1.4
HLBI DR (registry)† 2007 Yatskar et al. (71) . . .
HLBI DR (registry) 2009 Venkitachalam et al. (93) 0.2
CC-NCDR (registry) 2009 Aggarwal et al. (135) . . .
ACC-NCDR (registry)‡ 2009 Mehta et al. (136) . . .
VENT (registry) 2009 Novack et al. (137) 0.1
30 days; †access site bleeding requiring transfusion; ‡transfusion requiring; §non-CABG bleed
. . .  not reported; ACC  American College of Cardiology; CABG  coronary artery bypassoronary Arteries; MACCE  major adverse cardiac or cerebrovascular events; MI  myocardial infarc
nstitute; PCI  percutaneous coronary intervention; RCT  randomized controlled trial; TIMI  Thrombof angiographic quality, technique, and thresholds being
used for intervention. In addition, periodic review of less
severe complications (e.g., hematoma or other vascular entry
site injury) should be part of any ongoing QI program.
Admittedly, some outcomes may be hard to standardize
(e.g., periprocedural MI), but there is little ambiguity when
outcomes for PCI are either consistently superior (e.g.,2%
ajor complication rate) or consistently suboptimal (e.g.,
5% major complication rate). At present, with overall
n-hospital mortality averaging 1% and rates of emergent
ABG averaging 1%, a composite major complication
ate of 3% to 4% (95% confidence interval: 1.9% to 4.1%)
or non-emergent PCI is to be expected (Tables 1 and 8, Fig. 1).
Since the 2001 “ACC/SCAI Clinical Expert Consensus
Document on Cardiac Catheterization Laboratory Stan-
dards” (1), much information has been added to the litera-
ture on PCI outcomes and complication rates in increas-
ingly high-risk populations (e.g., advanced age, patients
with CKD or ACS). Table 9 provides specific complication
rates following PCI from large-scale clinical trials and
“real-world” registries; Table 1 outlines data from a volun-
tary registry, the ACC-NCDR database. Each series in-
cludes patients undergoing PCI for a variety of indications
under widely varying clinical conditions. The definitions of
elective, urgent, and emergent vary among studies. Compli-
cation rates (especially bleeding and access site complica-
tions) in the GP IIb/IIIa inhibitor era vary, not only
according to the definition applied, but in the rigor with
which these outcomes are ascertained. For this reason,
in-hospital complication rates in nonclinical trial, “real-
world” settings remain a challenge in interpretation, given
the unverified (nonadjudicated) and likely biased nature of
such reporting. These results, however, can provide approx-
imate boundaries for expected complication rates (“perfor-
mance benchmarks”) in “all-comers” undergoing PCI. The
use of 30-day event rates to more completely assess PCI
outcomes (86,87) and, by inference, benchmark operator
performance (88) has also been proposed.
the “Stent” Era
MI
(%)
In-Hospital
CABG (%)
Neurologic
(%)
Major
Vascular (%)
Significant
Bleeding (%)
0.4 1.9 . . . . . . . . .
1.9 0 . . . . . . . . .
0.8 1.0 . . . . . . . . .
5.7 0.3 0.9 . . . 2.06§/2.46
5.0 . . . 0.1 0.5 5.5
. . . . . . . . . 1.8 . . .
2.0 0.3 . . . 6.0 . . .
. . . . . . 0.22 . . . . . .
. . . . . . . . . . . . 2.4
6.5 . . . . . . . . . . . .
I risk score; non-CABG bleeding, GUSTO risk score.
; GUSTO  Global Utilization of Streptokinase and tissue Plasminogen Activator for OccludedCI in
ing, TIM
graftingtion; NCDR  National Cardiovascular Data Registry; NHLBI  National Heart Lung and Blood
olysis In Myocardial Infarction.
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outcome within the composite MACCE outcomes follow-
ing PCI, has been the subject of intense interest since the
early days of PCI (89). Efforts to predict its occurrence have
been limited by its infrequency, resulting in studies of low
statistical power and poor predictive ability. Accordingly,
composite outcome variables, all of which included death,
have been constructed and allow for improved precision in
the estimate of an overall frequency of major complications
following PCI (82,90,91). However, there are numerous
limitations to the use of such composite variable constructs,
particularly when inferences regarding an element (e.g.,
mortality) may be misinterpreted (92). As in-hospital mor-
tality rates following PCI have declined in parallel with the
many positive advances in interventional cardiology (93),
larger sample sizes are necessary to estimate its frequency
and to meaningfully predict its occurrence. The most
robust estimate of the overall risk of in-hospital mortal-
ity, culled from large-scale, nonclinical trial registries
published after 2001, ranges from 0.7% to 1.8% (94 –96).
These same studies are also in general agreement regard-
ing the risk factors predictive of in-hospital mortality:
age, gender, CKD, left ventricular ejection fraction
(LVEF), antecedent MI, shock, prevalent heart failure,
and peripheral vascular disease. Anatomic features (i.e.,
left main disease), procedural indication (i.e., urgent
versus emergent), and intraprocedural variables (i.e., the
number of lesions attempted and total occlusion at-
tempted) are less agreed upon as predictors of mortality
in these models.
3.2.1.1. PCI IN THE SETTING OF ST-ELEVATION MYOCARDIAL INFARCTION
Table 10 summarizes outcomes from the latest published
literature on PCI for STEMI—decidedly the highest-risk
group of patients undergoing PCI. Event rates are unad-
justed, and rates of access site and bleeding complications
reflect a complex mix of systemic anticoagulation, systemic
lytic activity, adjunctive use of platelet antagonists, and
varying definitions and rigor of ascertainment. Nevertheless,
some themes are evident across these diverse studies (e.g.,
the relative constancy of the risks of in-hospital death,
stroke, and significant bleeding).
Table 10. In-Hospital or 30-Day MACCE Following PCI for STEM
Study Population Year Reference
CADILLAC* 2002 Stone et al. (138)
NHLBI-DR (registry) 2007 Abbott et al. (139)
HORIZONS-AMI (RCT) 2008 Stone et al. (140)
NRMI (registry) 2009 Pride et al. (42)
GRACE (registry) 2009 Steg et al. (141)
Medicare (database) 2010 Chen et al. (142)
*Outcomes at 30 days for the stent-plus abciximab arm; †PCI with bare-metal stent: ‡PCI with
. . . not reported; MACCE  major adverse cardiac or cerebrovascular events; MI  myocardial infar
Infarction; PCI  percutaneous coronary intervention; STEMI  ST-elevation myocardial infarction; RCT3.2.2. Ad Hoc PCI Issues
The performance of a coronary interventional procedure at
the same laboratory visit as the diagnostic procedure is a
strategy referred to as “ad hoc” PCI (97). If this is to be
used, then it is important the discussion occurs with the
interventionalist prior to entering the catheterization labo-
ratory room. Ad hoc PCI should be discouraged in cases
where the patient would benefit from a multidisciplinary
discussion. Patients presenting with a STEMI or ACS,
where the culprit vessel is readily identifiable, generally
require an interventional procedure in conjunction with the
diagnostic procedure for expeditious patient care and to
reduce recurrent in-hospital ischemic events. However,
when “routine” diagnostic procedures are immediately fol-
lowed by “routine” coronary intervention, the considerations
are more complex from a risk–benefit perspective. Consid-
erations for when ad hoc procedures are encouraged include
patient and physician convenience, the potential for a
decrease in vascular access complications, a desire to avoid
higher contrast load in patients with chronic kidney disease,
and cost reduction.
Using the ACC-NCDR database, Krone et al. (98)
published the outcomes of 68,528 patients undergoing PCI
with the diagnosis of stable angina from 2001 to 2003, 60%
of whom underwent ad hoc PCI. A multivariate analysis
was performed to determine whether the performance of an
ad hoc PCI had an independent association with procedure
success or an adverse event. Patients categorized as high risk
and those with significant renal disease were less likely to
undergo PCI at the time of the diagnostic procedure. There
was no difference in mortality, renal failure, or vascular
complications when ad hoc patients were compared with
patients undergoing staged procedures at a separate setting
from the diagnostic case, so there appears to be no evidence
that patient outcomes are affected.
When tracking outcomes for ad hoc versus separate
setting PCI, important issues for the assessment of quality
must be addressed. Complications encountered during the
diagnostic catheterization and angiography (e.g., coronary
dissection or abrupt occlusion) may be treated with prompt
intervention but should not be considered ad hoc interven-
tions. This leads to coding issues, as does the success of the
the “Stent” Era
ath
)
(Recurrent)
MI (%)
Neurological
(%)
Significant
Bleeding (%)
.7 0.8 0.2 2.5
.0 1.7 0.4 3.3
.58 1.75 0.5 6.6
.56 1.0 0.5 7.19
2.1‡ 2.0/2.5 0.6/0.5 3.2/2.1
.3 . . . . . . . . .
uting stent.I in
De
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2
4
2
3
3.7†/
10
drug-el
ction; NHLBI  National Heart Lung and Blood Institute; NRMI  National Registry for Myocardial
 randomized controlled trial.
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composite procedure was “successful,” how is the original
complication recorded? Complications encountered during
the interventional portion of the procedure should be
attributed to the interventional procedure and not to the
antecedent diagnostic study. Given the increasing use of the
ad hoc approach, it will be important to continually and
carefully define the indications, clinical outcomes, and
overall cost effectiveness of this practice pattern (99).
3.3. Peripheral Vascular Intervention
The development of vascular medicine as a specialized
discipline, which overlaps “traditional” medical, cardiologi-
cal, radiological, and surgical disciplines, has led to the
expansion of the types of angiographic procedures per-
formed in cardiac catheterization laboratories. Laboratories
historically dedicated to coronary angiography and cardiac
diseases have had to transform themselves technically,
logistically, and administratively in order to provide optimal
care for a patient with cardiac and vascular disease. Large
image intensifiers for vascular rooms are not optimal for
coronary angiography. Performance criteria for training and
credentialing in vascular medicine have been adopted by key
stakeholders (100), and guidelines for maintenance of com-
petence and technical proficiency have also been developed
(101). Although minimum caseload volumes have been
suggested, there currently is insufficient literature regarding
performance metrics and outcomes analogous to coronary
intervention (e.g., procedure-specific complication rates,
patient-specific complication rates, and target organ or
vascular bed versus overall clinical outcomes). From a
catheterization laboratory standards standpoint, compara-
tive outcome data are presently absent but are much needed
in order to establish performance benchmarks and appro-
priate use criteria. The issue is further complicated by the
fact that noncardiologists (e.g., vascular surgeons or inter-
ventional radiologists) are now participating in some of
these studies, and guidelines regarding training and ongoing
credentialing for these groups often differ from those of the
invasive cardiologist. Laboratory participation in a central-
ized data repository is currently being developed by the
NCDR. Data from resources as these will help define the
ongoing changes in how the traditional cardiac catheteriza-
tion laboratory is being used.
3.4. Peer Review Continuous QA/QI Program
A continuous QA/QI program is an essential component to
the cardiac catheterization laboratory and must be in place
for all laboratories. This should be a dedicated program to
address the specific issues of the catheterization labora-
tory, but it need not be independent from other hospital
QI programs. The peer review component for this process
is designed to promote clinical proficiency under the
broad rubric of system-level performance analyses, which
should connote a more constructive (rather than punitive)
context (102).The core components of the Continuous Quality Im-
provement (CQI) program are data collection, feedback,
and intervention (103). Table 11 outlines the essential
components of the process. The CQI committee should be
adequately staffed and resourced by the facility. It should be
chaired by the medical director of the cardiac catheterization
laboratory because he/she should be the individual primarily
responsible for quality within the facility. The administra-
tive co-chair should be a required staff position for this
committee with specific job description assignments to
QA/QI. Additional membership should include invasive/
interventional physicians with nonpartisan representation
from all physician groups. Finally, noninvasive cardiolo-
gists, noncardiology physicians, and support personnel
from hospital administration may or may not be included,
based on what the committee chairman deems appropri-
ate for committee effectiveness. Though individual phy-
sician performance is being reviewed, the results of the
entire process apply to the performance of the laboratory
as a whole.
The peer review component of the QA program includes
the challenge of assessing clinical proficiency of the opera-
tors in the cardiac catheterization laboratory and should not
be limited to a simple “scorecard” analysis (102). Issues of
cognitive knowledge, procedural skill, clinical judgment,
and procedural outcomes are best assessed by a composite of
a series of variables that reflect the overall quality of care (6).
This information must be collected in a systematic manner
and analyzed appropriately. Finally, an approach must be
developed for quality improvement that involves not only a
process for change but also a measure for feedback on the
effectiveness of the solutions as well as educational oppor-
tunities for all involved (103).
Table 11. Basic Components of the Continuous Quality
Improvement Program for the Cardiac Catheterization Laboratory
Committee with chairman and staff coordinator
Database and data collection
Data analysis, interpretation, and feedback
QA/QI implementation
Goals outlined to eliminate outliers, reduce variation, and enhance
performance
Tools available to accomplish data collection and analysis
Feedback mechanisms in place
Educational provisions for staff and operators
Incorporation of practice standardization/guidelines
Professional interaction and expectation
Incentives for high-quality metrics
Adequate financial support for QI personnel
Administrative oversight and action plans
Thresholds for intervention
Appropriate use assessmentQA  quality assurance; QI  quality improvement.
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Quality Indicators, Data Collection and Analysis,
and QA/QI Interventions
A review of cardiac catheterization laboratory settings has
outlined certain practical lessons learned by the Laboratory
Survey Committee of the SCAI (104). This committee
noted that the major QA problems were not usually related to
equipment but rather to inadequate laboratory space, lack of a
physician medical director, lack of specific operating rules for
the laboratory space, and lack of a functioning QA program
(104). Not only must a QA program provide procedural compli-
cation information, but the committee emphasized that a feed-
back mechanism to modify behavior must be in place.
A QA program is only as effective as the commitment of
all involved in the process of healthcare delivery, with the
most conspicuous components being the assessment of
procedural outcomes and individual operator proficiency
(6). It is the responsibility of each individual operator to
actively participate in the QA process along with other team
members as well as actively participate in both CME and
maintenance of competence activities on a regular basis.
Each interventionalist should be aware of his/her own
volume, complications, and outcomes. These data should
be used to direct personal improvement. However, a pro-
cedure must be in place to assure this information is both
accurate and complete. Utilizing “indicators” to help quan-
tify the quality of the physician’s performance may be
beneficial. The indicators for organizational purposes in-
clude structural, process, and outcomes (105).
Structural indicators are those often considered by the
hospital credentials committee and include staff credentialing/
re-credentialing. This committee must assess medical training,
licensure, board certification, procedure volume, and CME.
Additionally, the committee/hospital may require, or consider
appropriate, specific training courses/CME for a given proce-
dure, society membership/offices held, awards/honors, and
publications/presentations. Establishing a transparent stan-
dard for a given facility limits confrontation when physi-
cians are either inadequately trained or fail to maintain
required qualifications. The committee must be empowered
to withdraw credentials when individuals fail to meet
written minimum standards.
Process indicators refer to patient management regarding
evaluation and treatment. Table 12 lists examples of proce-
dural or process indicators. Since these are less objective and
potentially amenable to observer bias as opposed to “hard”
clinical outcomes, they are more difficult to measure and
validate. These indicators are, however, helpful in working
through the entire process from protocols and staffing to the
rapidity of room turnover and patient length of stay. By
tracking these indicators, analysis of outcomes issues an
assessment of cost containment can be addressed within the
QA process (106).
PCI appropriate use indicators are also important. Thelatest suggestions from the ACCF/SCAI/STS/AATS/AHA/ASNC/HFSA/SCCT should be valuable in ensuring
that only appropriate patients are undergoing interventional
procedures, and these guidelines can be used to help
monitor appropriate use activity (107).
Outcome indicators are outlined in Table 13. These are
now often publicly available, and they are the most recog-
nizable. Risk adjustment is the essential component to
outcomes reporting and, therefore, dictates the need for
detailed databases (7). Benchmarking individual physician
and laboratory performance against national standards (e.g.,
the ACC-NCDR database) is an important component to
this process (108). Though risk adjustment is essential to
this process, awareness of the potential public health haz-
ards with public reporting of inadequately risk-adjusted
outcomes is of great concern (109). Although individual
physician and hospital scorecards provide information on
performance, they are not sufficient when used alone.
Outcome data should not be used to punish an outlying
practitioner but rather to search for causes that can be
remedied and processes that can be improved (102,103).
Effective data collection requires a data repository and
dedicated personnel for data acquisition. Information tech-
nology systems for the cardiac catheterization laboratory
and the hospital should be integrated to allow for informa-
tion transfer regarding patient demographics, catheteriza-
tion data, and hospital laboratory data, thereby decreasing
personnel data entry time. Hospital administration must be
actively involved in this process to provide the needed staff
support. Though identification of the most appropriate data
Table 12. Examples of Patient Management/
Process Indicators
Direct patient care–related indicators
Quality of angiographic studies
Radiation utilization (e.g., dose per procedure)
Report generation/quality of interpretation
Appropriateness
System-specific indicators
Patient transport/lab turnover/bed availability
Preprocedure assessment process and adequacy
Emergency response time
Cardiovascular surgery/anesthesia/respiratory care/perfusion performance
Guidelines-driven indicators
Infection control
Patient radiation dose (use of all available dose indicators, not only
fluoroscopy time)
Treatment protocols (radiographic contrast issues, drugs usage)
Procedure indications
New device use
Cost-related indicators
Length of stay pre-/post-procedure
Disposables needed
Quality and adequacy of supplies
Number and qualification of personnel/staffing
Modified with permission from Heupler et al. (102).collection instrument is still not standardized, an under-
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essential for accurate and complete data acquisition with
data entry verified for accuracy.
Data analysis requires a review of specific adverse events,
as well as risk-adjusted event rates, for the facility/operator.
Specific adverse events should be identified, and an individ-
ual case review should be performed. A potential list of case
examples that should be reviewed might include those listed
under clinical outcomes in Table 13 (102). Table 14
represents an example of an adverse event case report form.
Such case reports should be completed by a “neutral”
observer whenever possible to avoid confrontation. Results
should be reviewed and discussed as indicated at regularly
scheduled CQI meetings. In the case of possible litigation,
the cardiac catheterization laboratory CQI process should
work with the hospital risk management department and
not be driven by the latter.
Interventions to improve performance should be the goal
of the peer review process. The CQI process should focus
on improving the performance of the “low-end physician”
and not the elimination of this person, unless the perfor-
mance is repeatedly below minimum standards and the
individual is recalcitrant to positive suggestions. Once per-
formance variance has been identified, programs should be
established to correct these variances and address specifics
issues to improve the total laboratory performance (102).
Continuing employment of physicians not performing ap-
Table 13. Outcomes-Related Indicators
I. Physical outcomes
Individual physician MACCE
Death
Stroke/nerve injury
MI
Respiratory arrest
Perforation of vessel of heart with sequelae
Nerve injury
Radiation injuries
Emergent cardiovascular surgery
Access site complications
Access site complications requiring surgery
Rate-based outcomes (outcomes related to volume)
Diagnostic cardiac catheterization completion rates
PCI success rates
Normal cardiac catheterization rates
II. Service outcomes
Access to facility information
Door-to-balloon times
Satisfaction surveys
III. Financial outcomes
Procedural costs (as laboratory and as individual physician)
Risk management/litigation costs
Modified with permission from Heupler et al. (102).
MACCE  major adverse cardiac and cerebrovascular events; MI  myocardial infarction.propriately, despite efforts from the CQI process, should bethe responsibility of hospital oversight committees, group
practices, or departmental leadership.
The tools available for the CQI process are many.
Establishing practice protocols and order sets helps stan-
dardize practice and reduce variation in individual perfor-
mance. Appropriately used in a nonpunitive forum, score-
card benchmark performance can provide feedback that may
allow outliers to see where potential areas of improvement
are required. Identifying the need for an intervention is a
clear component of this process. Counseling may be re-
quired with confidential but swift correction of unprofes-
sionalism. Education, either with in-lab proctoring or ex-
ternal CME, can allow for any potential knowledge gap to
be narrowed. Laboratory surveys provide feedback for both
individuals as well as overall laboratory process performance.
Working with hospital administration to consider incentives
to improve performance and enhance educational opportu-
nities may prove beneficial. Finally, administrative policy for
intervention must be established to address the potentially
“uncorrectable” outlier. SCAI has provided an outline of the
components of an ideal quality control and inspection
program and a Quality Improvement Toolkit (QIT) that is
now available on their Web site (http://www.scai/QIT).
Subspecialty “boards” in adult interventional cardiology are
properly focused on proficiency, both cognitive and techni-
cal (6). For coronary interventional procedures, proficiency
is most easily related to procedural volume, although profi-
ciency and volume are only loosely associated. Some quan-
titative evidence now exists for selected volumetric cut
points for interventional procedures (55) though controversy
remains and enforcement is basically nonexistent, except at
the credentialing committee level at each facility. The recent
PCI guidelines acknowledge the controversial relationship
between quality and volume. Risk-adjusted outcomes re-
main preferable to institutional and individual operator
volumes as a quality measure (55). This issue is currently
being addressed by the ACCF/AHA/SCAI Writing Com-
mittee to Update the 2007 Clinical Competence Statement
on Cardiac Interventional Procedures. The situation is even
less clear with respect to diagnostic catheterization. Given
the absence of similar quantitative data for diagnostic
procedures, as well as the significantly decreased associated
morbidity and mortality associated with diagnostic cathe-
terization, operator proficiency may be better assessed in a
larger overall context. Rates of normal studies, peer review
of the diagnostic quality of studies, rates of referral for
intervention, and perhaps development of criteria for the
appropriateness of these studies have all been suggested as
methods of incorporating physician practice into the QI
process for diagnostic procedures. The quality and the
timeliness of catheterization reports should also be part of
the QI process. A preliminary report should be immediately
available and a final report completed within 24 hours.
However, processes for credentialing and the assessment of
proficiency must be developed in accordance with both local
governance policies, as well as professionally developed
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care systems should fall within the legal purview of these
institutions. It is hoped that these systems use criteria similar
to those outlined in this document in association with the
major cardiovascular societies to support the decision to cre-
dential physicians and monitor system performance.
Over a 10-year period, improvements in instrumentation,
imaging, data recording, and procedural outcomes have
proceeded rapidly. Consequently, continuing education for
practitioners beyond the standard level of training programs
has become the norm for the acquisition of many of these
advanced skills. Training programs themselves are also
changing from the traditional 1-year program in interven-
tional cardiology to 2-year programs in some institutions.
Subspecialty certification “boards” in interventional cardiol-
ogy reflects this burgeoning knowledge base (6,110). All of
this translates into the need to provide continuing education
to all members of the team. The implementation of new
technology requires a critical evaluation of both the experi-
ence in the literature as well as the experience within
individual institutions. An organized didactic program cou-
Table 14. Data Quality Event Review Form (R
Patient Data
Patient Name:________________________ Age:______ ID
Procedure:________________ Physician:_______________
Reason for Review:
Potential for Patient Safety:______________; Sentinel Eve
Mortality: In Lab_________; In Hospital___________ 30 D
Morbidity: Neuro:________; Vascular:___________; Corona
Arrhythmia:________; Renal:___________; Radiation:__
Other:____________________________________________
Case Summary:
_________________________________________________
_________________________________________________
Risk Group: Average/Low High Salvage
Clinical __________ _______ _______
Cath __________ _______ _______
Process Review:
Appropriate Uncertain Inappropriate
Indication :________________________________________
Technique :_______________________________________
Management :_____________________________________
Related to: Disease:______; Provider:_____; System:____
Preventable:_________; Not Preventable:________; Comm
Recommendation by
Reviewer:_________________________________________
_________________________________________________
Reviewer:______________________________________
Recommendation by
Committee:_______________________________________
_________________________________________________
_________________________________________________
Patient Safety/Risk Management Review: Y N; Hospital/D
Corrective Action: Y N; Education_____; Proctor_______; O
Date:______________ Signature:_____________________pled with cautious early clinical experience is an idealmechanism for the introduction of new therapies. These
types of programs, in conjunction with attendance at re-
gional or national scientific meetings devoted to the unbi-
ased presentation of new data, provide a solid infrastructure
for credentialing purposes. Attention to this aspect of
laboratory QI is critical to maintaining expertise.
3.4.2. Noncardiologists Performing
Cardiac Catheterization
An independent operator in the cardiac catheterization
laboratory must be proficient, not only in the technical
aspects of the invasive procedure, but also in the cognitive
aspects, including preprocedural evaluation, indications,
cardiac physiology and pathophysiology, emergency cardiac
care, radiation safety, and interpretation and clinical appli-
cation of the cardiac catheterization data. ACCF has
developed recommendations for training in diagnostic car-
diac catheterization, as well as specific technical skills,
including both education and case volume (111). Cardiol-
ogy fellowship training requires completion of a 3-year
program in order for the operator to be considered
sentative Data Collection Form)
__________________
e:________________
____________
__________
_______;
__
_________________
_________________________________________________
_________________________________________________
______________________
______________________
_______________________
________________
_______________________________
_________________________________________________
_______________________________
_________________________________________________
_________________________________________________
ment Review: Y N;
______________
_________________epre
#:____
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nt:___
ay___
ry:___
_____
_____
_____
_____
_____
______
_____
_;
ents:
_____
_____
_____
_____
_____
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ther:_
______competent to perform diagnostic angiography and an
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ventions (76).
The spectrum of participation in cardiac catheterization is
broad and includes physician-supervised assistance by non-
physicians, independent nonphysician performance, and
noncardiologist performance of cardiac catheterization.
Nonphysicians serving in an assistant role during the cath-
eterization with a cardiologist present are standard practices
in most training and teaching programs and not the issue
here. There is limited literature regarding safety/outcomes
of nonphysicians independently performing cardiac cathe-
terization. This topic was reviewed by SCAI in a statement
regarding nonphysicians performing cardiac catheterization
as independent operators (112). No relevant data are cur-
rently available establishing either the safety or the health-
care manpower requirement for nonphysicians performing
as independent operators in the cardiac catheterization
laboratory, and this practice is not appropriate. Some
exceptions to this policy include right-heart catheterization
procedures performed by competent operators from inten-
sive care units or electrophysiologists utilizing the cardiac
catheterization facility.
Medical and surgical subspecialties create training re-
quirements to establish and maintain patient safety and
quality of care (76,100,111). Hospital privileges for specific
procedures are based upon training requirements. It is an
ethical obligation to honestly disclose relevant information
to the patient (e.g., the training credentials of the primary
operator for any procedure, including cardiac catheter pro-
cedures). Beneficence is the ethical obligation to act in the
patient’s best interest (112). Patients, the public, and the
government are rightly seeking greater assurance that phy-
sicians hold the interests of their patients above their own.
Diagnostic cardiac catheterization and percutaneous coro-
nary intervention should be performed by trained cardiolo-
gists, or comparably trained noncardiology physicians, who
have been trained specifically for this procedure (110,111).
It is not appropriate for noncardiologists to perform percu-
taneous coronary interventions.
3.4.3. National Database Use
In assessing quality, adverse outcomes are often equated to
a lack of quality which, in turn, is related to performance.
However, it is obvious that adverse events will occur, even in
the best hands and at the best centers (113). The frequency
of these events is, in large part, related to the condition of the
patient and experience of the operator and center. Volume
alone may not be the best barometer of quality (114).
The SCAI Registry was developed to offer individual
centers an opportunity to assess their results relative to the
national reporting network of catheterization laboratories
on a voluntary basis. This registry tracked both diagnostic
and interventional procedures and was the standard for
assessing quality in the 1980s and 1990s, though the
information was not risk adjusted and the number of
variables was limited. This database is no longer beingsupported. With the termination of this database, no effort,
to date, has been attempted to track and risk adjust
diagnostic adverse outcomes on a national basis. State
Health Departments require low-volume diagnostic labora-
tories to complete a data form on all patients. However,
comparative national data for diagnostic catheterization
have not been available since the 1990s.
ACC-NCDR is a voluntary national registry that cur-
rently receives data from approximately 1,300 participating
hospitals. The purpose of this registry is to provide risk-
adjusted outcomes to individual institutions and their phy-
sicians. Such risk-adjusted outcomes are considered the
most appropriate measure of quality (108). The data collec-
tion processes as well as the details regarding the dataset
have been described in detail (7). Each data element is
predefined, linked to ACCF/AHA PCI Guidelines, and
available at www.cardiosource.org. Data at each participat-
ing facility are entered locally into ACC-NCDR–certified
software. Compatibility with individual laboratory reporting
systems and ACC-NCDR, or any regional/national data-
base such as the Northern New England Cardiovascular
Disease Study Group or the New York State Department of
Health Database, is essential to allow for complete data
entry and minimize duplication. Many local QA programs
are based on these data, and the sites themselves are
responsible for auditing the data for completeness and
accuracy. In addition, the ACC-NCDR has a limited
national audit system of approximately 5% of the data. This
registry has developed and validated a number risk adjust-
ment models for specific adverse outcomes (7,108,113,115).
An example of the output from the ACC-NCDR Cath PCI
dashboard is shown in Figure 2.
This writing committee strongly encourages all laborato-
ries to participate in a national or regional registry to
benchmark their results and provide an ongoing system for
tracking complications. Benchmark data are important, and
because the validity of these data are dependent on a high
number of participating laboratories, this committee
strongly recommends that all cardiac catheterization labo-
ratories actively participate in such a data registry.
3.4.4. Catheterization Laboratory
Reporting Requirements
The catheterization report should be individualized to a
particular institution depending upon the recommendations
of the medical director and participating physicians, the
administrative and informational infrastructure of the insti-
tution, and the requests of the referring physicians. Table 15
presents standard information required in such a report
(116). A complete procedural report, finalized within 24
hours of a procedure and inclusive of content in Table 15, is
a requisite and standard of care. Furthermore, structured
reporting using standardized data elements captured as
discrete data is highly preferred to verbose (i.e., handwritten
or dictated) reporting. An initiative to define best practice
workflows for data acquisition, processing, and reporting is
Figure 2. Example of the NCDR CathPCI Executive Summary Quality Dashboard
NCDR  National Cardiovascular Data Registry; PCI  percutaneous coronary intervention.
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mat for diagnostic and therapeutic cardiac catheterization
procedures. Prior to this, institutional preference for the use
of a vendor-based versus a “home-grown” standardized
reporting system should be viewed in the context of ensur-
Table 15. Minimum Components of the Standard
Catheterization Report
1. Indications for the procedure
a. Patient demographics
b. Pertinent patient history including risk factors
c. Specific indication for each component of the procedure (e.g., right-heart
and renal angiography)
2. Procedure information
a. Primary operator and additional staff present
b. Procedures performed
c. Access site information
d. Equipment utilized
3. Procedure documentation
a. Medications, including dose and duration of antiplatelet therapies
b. Radiographic contrast used and dose
c. Fluoroscopic time
d. Radiation dose (mGy and Gy  cm2)
. Diagnostic findings
a. Coronary anatomy (diagram optional but ideal)
b. Ventricular functional assessment (EF, LVEDP)
c. Other hemodynamic information (HR, BP)
d. Other angiography
i. Aortography (thoracic, abdominal)
ii. Renal angiography
e. Relevant hemodynamics
i. Right and left heart
ii. Response to medications or maneuvers
iii. Oxygen saturations
iv. Cardiac output-result and method
v. Valvular assessment (gradients; valve areas when appropriate;
estimation of regurgitation severity; summary of mild, moderate, and
severe disease assessment)
. Interventional procedure(s)
a. Separate listing for each procedure including site and procedure
performed
. Documentation of equipment and medications in catheterization laboratory
results (i.e., ACTs)
. Complications encountered in lab
. Conclusion (a diagram provides visual information and is much preferred
over textual alone reporting)
a. Summary of appropriate of findings
i. Coronary anatomy
ii. Ventricular function
iii. Hemodynamics
iv. Valvular pathology
v. Interventional procedures
b. Recommendations or patient disposition (optional) based upon physician
and laboratory preference
It is suggested that a preliminary report of the findings be made available immediately and the
complete report made available within 24 hours. A catheterization report should focus on the
coronary tree diagram as the preliminary report. Procedural details can be reserved for a second
and more complete report.ACT activated clotting time; BP blood pressure; EF ejection fraction; HR hemodynamic
response; LVEDP  left ventricular end-diastolic pressure.ing compatibility with a national database for complete data
entry while minimizing duplicated effort. Appropriate im-
mediate post procedure chart documentation is required for
inpatient procedures if the completed catheterization report
is not immediately available. Notification of findings to the
patient, family, and referring physician/primary care physi-
cian should be expected standard practice.
3.4.4.1. STORAGE OF INFORMATION (LENGTH AND TYPE)
There are several essential components to an information
storage system for the cardiac catheterization laboratory,
regarding both written word and recorded images. Impor-
tant considerations for an individual institution are price,
performance, capacity, and function. In choosing a system,
users must first be considered so as to select a system that is
operator- and institution-friendly. Linking the catheteriza-
tion laboratory reporting system with the hospital informa-
tion system improves information availability and patient
care. In-laboratory and postprocedural complications and
hospital outcomes should be tracked and reported regularly
by the CQI committee. If possible, 1-month and
intermediate-term outcomes and readmissions should also
be monitored. Staff efficiency is improved when demograph-
ics are entered once into a system that “talks” throughout
the hospital and/or health system. Additionally, inventory
and billing can be linked to this system. This seamless
interface between report generation and the information
management system, not only provides an accessible report
for patient care, but also enhances inventory maintenance
and verifies billing (117).
As with all information systems, compliance with the
1996 Health Insurance Portability and Accountability Act
(HIPAA) must be assured. Though physician access for
patient care is important, all patient information interac-
tions must be verified as HIPAA compliant, whether that
be accessing lab values or signing reports (118).
Information storage strategies may take several forms.
Varying redundant array of independent disks (RAID)
schemes provide different levels of data access performance
and system failure protection (119). The RAID schemes
divide and replicate data among multiple hard drives,
writing identical data as well as splitting data on more than
1 disk. Error correction is accomplished through redun-
dancy, allowing read/write problems to be detected and
corrected. This technology is particularly useful when large
files (i.e., cine images) require storage.
The more advanced the data storage system, the more
data replication mechanisms and storage servers are likely
to be available. Long-term archiving provides for ex-
panded storage, data protection, or both, when the
primary space capacity is reached. Disaster recovery is
essential to any storage system to prevent permanent data
loss. Having a disaster recovery system in a nondirect
access format prevents a computer virus, for example,
from infecting and erasing data. Data duplication via a
mirror image server, often at a remote facility, may be
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replacement (120).
The Integrating Health Care Enterprise (IHE) was
originally developed with support of the Radiological Soci-
ety of North America and the Health Information and
Management Society. In 2003, a cardiology domain was
initiated by the ACCF, American Society of Echocardiog-
raphy, American Society of Nuclear Cardiology, SCAI, and
European Society of Cardiology to focus on integration of
information within the cardiology department. IHE does
not create standards but rather provides integration profiles
from existing standards for specific clinical needs. Multiple
profiles can be developed creating a cardiac catheterization
laboratory workflow integrating ordering, scheduling, image
acquisition, storage, and viewing (121). This can be inte-
grated with echocardiography, electrocardiogram, and stress
testing to display reports as well incorporate workflow
through procedure/postobservational areas.
The transition from cine film to digital acquisition and
storage in the catheterization laboratory was made possible
with the creation of the Digital Image Communication in
Medicine (DICOM) Standard (122,123). The DICOM
Standard is a set of rules that allow medical images to be
exchanged among all medical imaging devices. In the
digitally enabled catheterization laboratory, digital images
are stored for short-term archival on the proprietary digital
storage unit of the specific imaging equipment or network
servers with only limited storage capacity for immediate
access.
Cine image storage in the digital imaging era is chal-
lenged by the pure volume of data (124). Various compres-
sion ratios have been employed in order to optimize storage
capacity requirements, but the latter in anything greater
than a 4:1 compression ratio frequently resulted in nondi-
agnostic images. Therefore, to preserve image quality, only
lossless compression is currently used. A diagnostic cardiac
catheterization with 5 to 10 cine runs of 6 to 7 seconds at a
frame rate of 30 fps contains approximately 2,000 images.
With minimum specifications of a 512  512 matrix and a
pixel depth of 1 to 1.5 bytes, a standard diagnostic study
results in 500 to 750 MB at 30 fps. At 15 fps, this is
approximately 350 MB/case. In a facility that performs
5,000 cases per year for 7 years, this requires a storage
capacity of 10.5 terabytes. This calculation does not con-
sider the improvement in spatial resolution with a matrix
size of 1,012 1,012 to 2.5 to 3.0 LP/mm (line pairs/mm).
The latter is the preferred imaging technology to properly
visualize stents in the right coronary artery in the right
anterior oblique projection (125).
Long-term archival technology of these massive files has
similarly progressed over time from stacked magnetic disks,
to digital archival tapes, to large optical disks (“jukebox”), to
current generation RAID 5 subsystems (119). Speed for
recovery from long-term archival has dramatically im-
proved. A picture archiving and communication system
(PACS) is integral to hospital image storage and access. The tinclusion of cardiac catheterization laboratory studies into
the traditional radiology PACS system was generally pre-
cluded due to the file size requirements. Modern PACS may
now comfortably accommodate catheterization laboratory
images (120).
Duration of storage has been based more upon tradition
than written policy. The “standard” cine film storage was 7
years. Currently, in the digital era, storage duration is based
upon storage capabilities. However, the potential usefulness
of adult cine storage 7 years is in question, although
pediatric image storage may well require lifetime access to
appreciate anatomy prior to interventions. The reality is that
most laboratories provide image storage for only 7 years,
even in the pediatric cardiac catheterization environment.
The progressively low cost of digital image storage is
making these minimum storage guidelines rather obsolete,
as indefinite storage is now readily available.
3.4.5. Equipment Maintenance and Management
Equipment maintenance and management remain crucial
issues from a catheterization laboratory QA/QI standpoint
and specific guidelines are, therefore, provided. Each aspect
of the radiographic system should be able to meet these
performance expectations (126). The same is true for the
physiological recorders and other specific devices used in the
laboratories.
The modern diagnostic and interventional catheterization
laboratory uses many sophisticated radiological, electronic,
and computer-based systems, each of which requires a
program of rigorous maintenance and troubleshooting. The
x-ray imaging system, a crucial component of every labora-
tory, must be carefully assessed at frequent intervals to
detect early signs of deterioration in performance. Unfortu-
nately, this aspect of quality control is the first to be
sacrificed in an era of cost constraints.
A program of periodic assessment of system performance
and image quality has been recommended by SCAI (127).
dditional programs, which address issues specific to digital
maging systems, are under evaluation (127). A representa-
ive outline of the performance characteristics needed to
ssess radiographic cardiac imaging systems is presented in
able 16.
Note that at present, the only federally mandated param-
ter for fluoroscopic systems is the maximum “table-top”
xposure rate (see Section 9). The concept of minimum
mage performance standards must await universal accep-
ance of a suitable test instrument for cardiac fluoroscopy.
urrently, there is considerable heterogeneity across labo-
atories in selective measurements of image quality
123,128). Such heterogeneity precludes specific recom-
endations with respect to what is considered “acceptable”
erformance. Current-generation imaging systems must be
apable, at minimum, of providing images of sufficient diag-
ostic quality to enable decision making with respect to
ntervention and provide sufficient spatial and contrast resolu-
ion for the conduct of contemporary coronary intervention.
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high information density. In the past, physiological
recorders were used only for the acquisition and recording
of analog signals. They are now required to serve as front
ends for the increasingly complex gathering of data.
These recorders have essentially been transformed into
desktop personal computers capable of acquiring, storing,
and transmitting data to other sites. Given the critical
importance of these data for numerous administrative
purposes (billing, QA, report generation), flawless trans-
mission without data loss must take place at all times
(117). Backup systems and low-cost storage media are
essential (125).
The need for patient safety-related precautions is
paramount (129). The operational efficiency of infrequently-
used equipment (e.g., defibrillators and external pace-
makers) must be assessed routinely, and the appropriate
logs must be kept. Electrical isolation and grounding
systems must be regularly assessed (122). The number of
ancillary devices used in coronary intervention (Doppler
and pressure-tipped sensor wires and ultrasound cathe-
ters) now requires that electrical safety precautions that
were adequate in the past need to be revisited at periodic
intervals (122).
3.5. Minimum Caseload Volumes
The cardiac catheterization laboratory previously referenced
was primarily an arena for the diagnosis and treatment of
coronary artery disease. However, in the last decade, there
has been not only an expansion of the anatomic indications
for PCIs, but also an expansion of percutaneous interven-
tions to most other vascular beds, as well as the development
of a new branch of interventional cardiology involving the
treatment of numerous forms of structural heart disease.
Determining who should perform procedures based on
volume remains controversial and difficult to adjudicate.
The goal is to have successful procedures done on appro-
priate patients. There are clinical, angiographic, operator,
and institutional characteristics that have been shown to
influence procedural success. Operator characteristics in-
Table 16. Performance Characteristics of Radiographic
Imaging Systems
Category Example
System measure Image quality
Dynamic range
Modulation transfer function
Component measures
(not inclusive)
Fluoroscopy and cine spatial resolution
Fluoroscopy field of view size accuracy
Collimator tracking and alignment
Low contrast resolution
Record fluoroscopic mode and automatic exposure
control under standard conditions and at
maximum output
Calibration of integrated radiation dose metersclude cognitive skills, technical skills, experience (includingthe latest total cases and lifetime total cases), and training
(including fellowship, cardiology and interventional board
certification, and CME).
Utilizing minimum case volumes for credentialing focuses
on only 1 of many factors that may play a role. Case volumes
are often used as a surrogate for quality on the presumption
that a high volume enhances the operator skills. It is
presumed that skill maintenance is also greater for both the
operator and the institution if procedural volumes are high.
The documented relationships between activity level and
outcome are statistical associations, but they may be of
limited clinical significance. The heterogeneity within hos-
pital volume groups found by Epstein et al. (143) suggests
that activity level is an incomplete surrogate for quality.
High-volume operators and institutions are not necessarily
of high quality, and low-volume operators and institutions
are not by definition poor-quality operators. There is
limited statistical power to judge the outcome results of low
volume operators. Establishing appropriate oversight and
QA programs is more important than volume measures
alone. All major complications in any laboratory should be
reviewed by the QA committee at least every 6 months, and
individual operator complication rates exceeding national
benchmarks for 2 contiguous 6-month periods should be
reviewed by the QA director (76). Ideally an ongoing subset
of cases performed by all operators should be reviewed
yearly. To help facilitate the knowledge transfer that is
important in continuous quality improvement, participation
in catheterization laboratory conferences and a minimum of
12 hours of CME per year should be a required component
for operators in the cardiac catheterization laboratory.
Simulation training offers an additional method of im-
proving cognitive and technical skills that is increasingly
being used to increase clinical competencies, including
endovascular procedures (144). Simulation training is a tool
that may be used for maintenance of certification in the
Interventional Cardiology Board prerequisite and may be
particularly useful for low-volume operators and for low-
volume procedures. Simulation training of rarely performed
and/or complex procedures and new protocols may be of
value.
3.5.1. Operator Volumes
3.5.1.1. OPERATORS PERFORMING DIAGNOSTIC PROCEDURES
Because of the low risk of diagnostic cardiac catheterization,
it is difficult to arrive at any consensus as to what would
constitute a minimum caseload. There are no data support-
ing the prior recommendation of at least 150 diagnostic
cases per year (1). Previously, this has been simply conven-
tion. The minimum laboratory diagnostic caseload may vary
widely depending on arbitrary requirements such as the
presence of the CON process or state department of health
regulations. It falls upon the director of the laboratory to
ensure that all cardiac catheterization studies are appropri-
ately indicated, performed, and interpreted (76). A maxi-
mum number of procedures that an operator should be
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essentially no data. This emphasizes the dependence on the
QA process to monitor physician and laboratory behavior
appropriately.
3.5.1.2. OPERATORS PERFORMING INTERVENTIONAL
CORONARY PROCEDURES
An annual interventional caseload of 75 procedures per year
has been used for a considerable time as a standard for
ensuring quality. Numerous analyses have addressed the
relationship between individual operator caseload and pro-
cedural complications. Many of these studies have found an
inverse relationship between volume and outcome
(78,145,146) whereas others have found no relationship
(147–149). Hospital volume affects the operator volume–
outcome relationship (150,151). Malenka et al. (152) sug-
gested that differences between high- and low-volume
operators are minimized at a high-volume hospital. Mos-
cucci et al. (153) examined the operator volume issue in the
stent era and found no relationship between operator
volume and in-hospital mortality, though the relationship
between volume and any MACCE as measured by major
cardiovascular event rates (death, CABG, cardiovascular
accident or transient ischemic attack, MI, and repeat in-
hospital PCI) was demonstrable. Although there does
appear to be a statistical relationship between annual oper-
ator volume and MACCE rates, analysis of a linear plot
examining these 2 variables reveals a scattergram, though
the trend toward higher complication rates at lower volumes
is observable (Fig. 3). In this figure, the majority of
operators with procedural volumes 75 cases per year
perform with excellent outcomes, whereas there are clearly
operators 75 cases per year that have higher MACCE
rates than expected. The value of using an annual threshold
of 75 cases per year is limited when considering each
individual operator.
In a report from the Cardiac Advisory Committee of
New York State (58), the case volume range was dramatic,
ranging from a very small number of cases (presumably only
done when the physician was on call) over a 3-year period all
the way up to a maximum of 3,722. No comment is made
Figure 3. Linear Plot of Standardized MACE Ratios (Observed/
There remains only a general, but statistically important relationship with higher maj
from Moscucci et al. (153).regarding any possible relationship between volumes and
adverse outcomes. The report provides individual volumes
for the 3-year period from 2004 through 2006, but the data
are presented for each laboratory. Those that perform
procedures at multiple laboratories are also noted. With
those caveats, obviously creating the potential for substantial
error, if it is assumed that 225 cases per 3 years should be the
minimum for each operator during the 3-year period, then
up to 57.9% of the listed physicians in the New York State
Report (Table 3 of their report) did not meet the minimum
criteria. In Table 4 of the report, 17.5% of operators
performing procedures at multiple hospitals did not perform
225 procedures over the 3-year period. Even if these
numbers are inaccurate by a wide margin, it does point out
that there are many competent operators who do not
perform the minimum of 75 PCI procedures per year.
SCAI has noted that the AHA report on the number of
PCIs has been revised downward by about half, due to
double counting. In the AHA Heart Disease and Stroke
Update published in December 2010, the number of inpa-
tient PCIs in 2007 is actually about 0.6 million rather than
the 1.3 million in their publication (154).
As outlined earlier, performance of all interventionalists
regardless of the volume of procedures performed should be
assessed by a standing QA committee. There should be in
place a review process to provide evidence to the appropriate
oversight committee (usually the credentials committee in
association with the director of the cardiac catheterization
laboratory) that operators with 75 PCI procedures per
year are having a random subset of their cases (at least 15%)
critically reviewed each year. This should be in addition to
the guidelines for the QA process for all operators as
outlined earlier. The QA committee is encouraged to
require within their bylaws that each operator obtain some
level of PCI education every 2 years. This additional
education should be mandatory for the lowest (75 PCI per
year) volume operators.
Volume requirements are of a magnitude of importance,
as well as controversy, that a document specifically address-
ing clinical competence for cardiac interventional proce-
icted Rates) Versus Annual Operator Volume
erse cardiovascular events (MACE) in operators doing fewer procedures. ReprintedPred
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is currently being revised. The results of that writing
committee are embargoed at the time of this document’s
publication. The “2011 ACCF/AHA/SCAI Guideline on
Percutaneous Coronary Intervention” also include the same
volume requirements as herein stated, and it favors the
observational evidence of a volume–outcome relationship in
PCI at both the institutional and operator level (155).
However, the guideline also acknowledges that the volume–
outcome relationship is complicated and may be inconsis-
tent across low-volume institutions or operators and that
new data in primary PCI suggest that operator experience
may modify the volume–outcome relationship at the insti-
tutional level (156,157). The ACCF/AHA/SCAI Writing
Committee to Update the 2007 Clinical Competence State-
ment on Cardiac Interventional Procedures will review
current data and environmental trends and recommend how
we can best assess competence for both individual operators
and institutions for PCI in the current era.
3.5.1.3. PRIMARY PCI OPERATORS
PCI for AMI (primary angioplasty) is the application of
PCI to, as a group, the sickest patient population undergo-
ing PCI. Additionally, the constraints of D2B time of 90
inutes confer additional pressures on the operator and
ystem. Current recommendations suggest that primary
CI be performed only by higher-volume operators experi-
nced in both elective PCI and primary PCI for STEMI.
he current guidelines recommend the operator perform
75 elective PCI procedures per year and about 1 primary
CI per month (11 per year) (6,158). The reality is that this
equirement is not being followed in many institutions,
ould likely eliminate a large number of primary PCI
perators, and is likely to prevent many institutions from
roviding 24/7 interventional calls due to a limited number
f qualifying physicians. The data concerning volume–
utcome relationship for primary PCI are particularly dif-
cult to categorize because of the relatively small volume of
TEMI patients per operator per year.
Vakili and Brown (159), analyzing primary PCI proce-
ures for STEMI, could find no relationship between
hysician total PCI volume and mortality. The authors also
eported an association between an operator’s primary PCI
ctivity level and the outcome of primary PCI for STEMI
hat was independent of the operator’s experience in elective
CI (160). Hannan et al. (150) analyzed the New York
tate angioplasty registry data, found an increased in-
ospital mortality at institutions with lower volumes of
rimary PCI, whereas Politi et al. (161) showed no rela-
ionship between operator volume and mortality or
ACCE at a high-volume PCI institution. Other studies
ave also shown no relationship between institutional vol-
me of primary PCI and in-hospital mortality. It is there-
ore recommended that all primary PCI procedures be
ubject to review by a designated QA committee, regardless
f the operator volume. Operators who wish to performrimary PCI must participate in these reviews if they wish
o continue to perform primary PCI. Each facility’s QA
rocess must determine whether the results are acceptable
or both the institution and the operators involved.
3.5.1.3.1. PCI OPERATORS IN THE FACILITY WITHOUT CARDIO-
ASCULAR SURGICAL SUPPORT. Data from the ACC-
CDR, the largest and most comprehensive assessment of
CI centers with and without onsite cardiovascular surgery,
eveal that there are more patients presenting to lower-
olume centers without cardiovascular surgery with ACS
han to full-service facilities (36). In comparison to sites
ith onsite cardiovascular surgical back-up, sites without
nsite cardiovascular surgery have similar rates of procedural
uccess, morbidity, need for emergency surgery, and risk-
djusted mortality for all patients. Centers without onsite
ardiovascular surgery have significantly shorter reperfusion
imes (2.1  5.1 versus 2.6  8.4 h). Seventy-nine percent
of these sites without cardiovascular surgery provide both
elective and primary PCI. Eighty-one percent of interven-
tional operators work at both offsite and onsite surgery
facilities; only 17% operate exclusively at offsite centers. No
differences have been reported in outcomes (36).
Compared with full-service PCI centers, offsite PCI
programs are predominantly located in nonurban areas, have
lower annual PCI volume, treat a higher percentage of
patients who present with subsets of AMI, and have better
door-to-reperfusion for primary PCI. These same sites
have, for the most part, similar observed procedural success
rates, morbidity, emergency cardiac surgery rates, and mor-
tality in cases that required emergency surgery as full-service
facilities. The risk-adjusted mortality rates in offsite PCI
facilities are comparable to those of PCI centers that had
cardiac surgery onsite, regardless of whether PCI is per-
formed as primary therapy for STEMI or in a nonprimary
setting. These issues have been previously addressed in this
document (see Section 2.4.3.).
An SCAI expert consensus document (14) emphasizes
that though offsite surgical backup can be performed with
acceptable outcomes and risks, the development of such
programs should be based on the health needs of a local
area, not on desires for personal or institutional financial
gain, prestige, market share, or other similar motives. They
recommend that operators performing PCI without onsite
surgery should perform 100 total PCIs per year, including
18 primary PCIs per year. They also recommend that
initial operators at a facility without onsite cardiovascular
surgical backup should not begin performing PCI in such
facilities until they have a lifetime experience of 500
PCIs as primary operator after completing fellowship.
Operators in such facilities must demonstrate complica-
tion rates and outcomes equivalent or superior to national
benchmarks and must evaluate their outcomes against
established benchmarks.
There are obviously many operators performing primary
PCI in facilities without cardiovascular surgical backup who
do not meet these stringent guidelines, and these sugges-
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onsite cardiovascular surgical backup continues to evolve as
a strategy for the delivery of care in patients with MI.
Systems of care within a community should generally direct
STEMI patients to facilities that are able to achieve a D2B
time of90 minutes and have a laboratory available on a 24
ours a day, 7 days a week basis. As pointed out earlier, the
ommittee cannot recommend elective PCI programs with-
ut cardiovascular surgical backup that only provide primary
CI coverage during daytime and weekday hours.
It is the consensus of this committee that operators able
o achieve successful primary PCI within the established
uidelines may perform these procedures if there is a
edically obvious advantage to the patient and the commu-
ity. The decision must not be based on financial or prestige
ain to the disadvantage of patient care. It should only be
ade available where there are written and enforceable
uidelines from a full-service facility willing to accept
atients should complications arise. Partnership with an
xperienced tertiary care hospital with a PCI program
upported by cardiovascular surgery is mandatory. The
rganization of a primary PCI program and the patients
ligible for primary PCI procedures in sites without onsite
ardiovascular surgery have been discussed earlier and the
ighlights are outlined in Tables 2, 3, 4, 5, 6, and 7.
.5.2. Institutional Minimum Caseloads
3.5.2.1. DIAGNOSTIC CATHETERIZATION INSTITUTIONAL VOLUME
The minimum diagnostic caseload for the entire laboratory
facility varies widely from state to state, often depending on
the presence of the CON process or other frequently
arbitrary requirements. It falls upon the director of the
laboratory to ensure that all studies in the cardiac catheter-
ization laboratory are of the highest quality. In general,
high-volume laboratories have consistently been shown to
have fewer complications than low-volume facilities, al-
though quality cannot be presumed by analysis of the total
laboratory volume alone. Minimum laboratory diagnostic
volumes are generally about 600 cases per year for
financial viability, and that figure is often used as a cutoff
minimum value with no strong data to support that it is
the minimum number for highest quality. In some states,
a minimum volume of 200 diagnostic cases per year has
been found acceptable. All of these minimum volume
numbers appear arbitrary to the writing committee, and
there is concern that very low-volume laboratories may be
poorly equipped or poorly maintained because of cost
constraints. Just as in PCI programs, facilities performing
only diagnostic cardiac catheterization must have an
ongoing QA program that functions to ensure that the
procedures being done are appropriate and that there are
no quality issues with the procedure, the reporting
system, or the decision making based on the procedural
results.3.5.2.2. INTERVENTIONAL CORONARY CATHETERIZATION
INSTITUTIONAL VOLUME
In many states, the State Board of Health or the CON
process will stipulate a minimum institutional PCI vol-
ume. McGrath et al. (145) examined institutional volume
and outcome relationships. They noted an increased
30-day mortality rate of 4.29% for low-volume PCI
programs performing 80 Medicare-reimbursed proce-
dures per year versus high-volume programs that per-
formed 160 Medicare procedures per year (3.15%). It
should be noted that higher-volume facilities generally
have the capacity to provide more extensive supplies and
specialized equipment for PCI procedures, an immeasur-
able advantage in complex interventions and during
unanticipated in-lab complications.
Kimmel et al. (78) using data from SCAI, found an
inverse relationship between the number of PCI procedures
a hospital performed and the rate of major complications.
These results were risk stratified and independent of the
patient-risk profile. There were significantly fewer compli-
cations in institutions that performed at least 400 PCIs
yearly.
Jollis et al. (146) similarly found that low-volume hospi-
tals were associated with higher rates of emergency coronary
artery bypass surgery and death after PCI. Improved out-
comes were identified at a threshold of 75 Medicare PCIs
per physician and 200 Medicare PCIs per hospital. Using a
50% ratio of Medicare patients, the threshold value was
estimated to be 150 to 200 PCIs per cardiologist and 400 to
600 PCIs per institution.
Epstein et al. (143), using an administrative dataset,
analyzed risk-adjusted mortality in 362,748 admissions to
1,000 U.S. hospitals between 1997 and 2000, during which
a PCI was performed. They found a consistent trend of
decreasing risk-adjusted mortality with increasing hospital
volume. The differences among groups were small, though.
There was considerable heterogeneity within groups, sug-
gesting that hospital volume was not the sole determinant of
outcome. There are other studies that support the rela-
tionship of complication rate to institutional procedural
volume (80,162,163). However, some investigators have
pointed out that despite data that low procedure volume
is poorly related to outcomes (164), many of these studies
are small in number and underpowered (165). The
National Health Service in the United Kingdom recently
published the MACCE for each U.K. facility with data
from 2007 and 2008 (Fig. 4) and found no linear
relationship between MACCE and institutional volume
(166), though improved outcomes were suggested when
the institutional volume was 400 cases per year. These
data form the basis for the recommendations of the Joint
Working Group of PCI of the British Cardiovascular
Society (167).
Based on data accumulated in the current stent era, a
general volume–outcome relationship appears to exist. For
example, Brown and coworkers (168) evaluated the out-
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Mortality and emergency CABG rates for PCI in which a
stent was used was 1.5% and 1.2%, respectively, in hospitals
performing 400 procedures per year compared with 1.1%
and 0.8% in hospitals performing 400 procedures per year
(110). Taken as a whole, an institution should be considered
low volume if 400 PCI procedures are performed each
year. The 2011 ACCF/AHA/SCAI guidelines consider a
low laboratory volume of PCIs to be from 200 to 400 per
year (158).
For both institutional and individual volume assessments,
ongoing 2-year volumes should be measured then averaged
to arrive at annual statistics. It is recommended that
lower-volume institutions (400 per year) must hold con-
ferences with a more experienced partnering institution,
with all staff expected to attend on a regular basis. Weekly
cardiac catheterization laboratory conferences should be a
mandatory aspect of the quality control and inspection
program. It is also recommended that any institution that
falls 2 standard deviations outside the risk-adjusted na-
tional benchmarks in mortality or emergency same-stay
CABG during 2 of 3 contiguous 6-month periods have an
external audit looking for opportunities to improve quality
of care. The appropriateness of continuing to perform PCI
procedures in an institution with low volume and unsatis-
factory outcomes should be directly addressed from a
Figure 4. Relationship Between MACCE and Institutional Volum
No clear relationship is observable in this assessment of data from a national audit
mation Centre for Health and Social Care (166). MACCE  major adverse cardiac and cardmedical standpoint and not from a financial or marketing
standpoint.
3.5.3. Training
The cardiac catheterization laboratory represents a platform
for training in invasive cardiovascular procedures. The goal
of training programs is to teach the cognitive knowledge as
well as the technical skills used in invasive cardiology. This
includes indications and contraindications for the proce-
dures, pre- and postprocedure care, management of com-
plications, and the analysis and interpretation of hemody-
namic and angiographic data. The trainee’s professional
goals determine the knowledge and skill set to be acquired
during their time in the catheterization laboratory (169).
The ACCF COCATS requirements differentiate among 3
levels of training based on distinct career goals (169). Level
1 training is designed for noninvasive cardiologists, whose
invasive activities will be confined to critical care unit
procedures. The goal of their catheterization laboratory
experience is to learn the indications for procedures as well
as how to interpret the data obtained in the laboratory.
Level 2 training is for invasive cardiologists who will
practice diagnostic, but not interventional, cardiac catheter-
ization. Level 3 training is for interventional cardiologists
who plan to perform both diagnostic and interventional
cardiac catheterization (169).
I procedures in the United Kingdom (2007 and 2008). Reprinted from NHS Infor-e
of PC
iovascular events.
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A minimum of 4 months experience with at least 100
diagnostic catheterizations is required for Level 1 training,
with 8 months experience and at least 200 additional cardiac
catheterizations required for Level 2 (Table 17).
In contrast to diagnostic cardiac catheterization, train-
ing in PCI requires enrollment in an additional fellow-
ship year in interventional cardiology in an Accreditation
Council for Graduate Medical Education (ACGME)-
accredited program (169). The trainee should participate
in a minimum of 250 coronary interventional procedures
during this year. In addition, the trainee should be
proficient with the use of associated PCI procedures, such
as IVUS and fractional flow reserve. Newer procedures,
such as optical coherence tomography, may also find a
role, and adequate training in such procedures should be
anticipated. Completion of such a program leads to
eligibility to sit for the American Board of Internal
Medicine interventional cardiology examination. The
goal should be that board certification is accomplished for
everyone completing an accredited training program who
wishes to actively participate in a coronary interventional
practice. During fellowship training, all diagnostic and
interventional cases should be performed under the direct
supervision of a faculty member. Details of the cognitive
knowledge and technical skills required for all 3 levels are
outlined in the ACCF COCATS 3 training statement.
Participation in cardiac catheterization conferences and
exposure to cardiac catheterization research must be part
of the training of all cardiology fellows.
3.5.3.2. PERIPHERAL VASCULAR PROCEDURES
At present, catheter-based peripheral vascular interven-
tions are performed by subspecialists with diverse formal
training including interventional radiology, interven-
tional cardiology, and vascular surgery. Although guide-
lines of each subspecialty society include endovascular
procedures within their training curricula, there is a lack
of uniformity regarding the amount of patient exposure
required and the precise mechanisms for evaluation of the
experience (101,170).
Specific knowledge required for safe and effective perfor-
mance of peripheral interventions includes the pathophysi-
ology, clinical manifestations, as well as the evaluation and
treatment of diseases for a variety of vascular territories. The
Table 17. Summary of Training Requirements in Diagnostic
and Interventional Cardiac Catheterization
Area
Level of
Training
Minimum
Number of
Procedures
Cumulative
Duration of
Training (Months)
iagnostic catheterization 1 100 4
2 200 (300 total) 8
Interventional catheterization 3 250 20
Modified from Jacobs et al. (169).training requires knowledge of peripheral arterial disease,renal artery stenosis, extracranial cerebrovascular disease,
vascular aneurysms and arterial dissections, mesenteric isch-
emia, and both arterial and venous thromboembolism (101).
he ACCF COCATS 3 training statement suggests that
or vascular medicine and peripheral catheter-based inter-
ention, training be a minimum of 12 months for both
evel 2 (vascular medicine specialist) and Level 3 (periph-
ral vascular intervention) competence (100). Level 3 pe-
ipheral vascular training may be undertaken concurrently
ith advanced training for coronary interventions, but it
ust include a minimum of 100 diagnostic peripheral
ngiograms and 50 noncardiac peripheral vascular interven-
ional cases evenly distributed among the different vascular
eds (100).
The fellowship training requirements for performing
eripheral vascular interventions are detailed in Table 18.
imulation training has been shown to improve perfor-
ance of carotid angiography (171). Lower–volume estab-
ished operators may also benefit from including simulation
raining as part of their CME.
The ACCF/ACP/SCAI/SVM/SVS Writing Committee
n Clinical Competence on Peripheral Vascular Disease
uggests that in order to achieve a balanced experience
equired for competence, the trainee’s experience should
nclude no fewer than 20 diagnostic and 10 interventional
Table 18. Formal Training to Achieve Competence in
Peripheral Vascular Catheter-Based Interventions
Training requirements for cardiovascular physicians
● Duration of training*—12 months
● Diagnostic coronary angiograms†—300 cases
(200 as the supervised primary operator)
● Diagnostic peripheral angiograms—100 cases
(50 as supervised primary operator)
● Peripheral interventional cases†—50 cases
(25 as supervised primary operator)
Training requirements for interventional radiologists
● Duration of training‡—12 months
● Diagnostic peripheral angiograms—100 cases
(50 as supervised primary operator)
● Peripheral interventional cases†—50 cases
(25 as supervised primary operator)
Training requirements for vascular surgeons
● Duration of training—12 months§
● Diagnostic peripheral angiograms—100 cases
(50 as supervised primary operator)
● Peripheral interventional cases¶—50 cases
(25 as supervised primary operator)
● Aortic aneurysm endografts—10 cases
(5 as supervised primary operator)
This table is consistent with current Residency Review Committee requirements. *After complet-
ing 24 months of core cardiovascular training and 8 months of cardiac catheterization. †Coronary
catheterization procedures should be completed prior to interventional training. ‡After completing
general radiology training. §In addition to 12 months of core vascular surgery training. In addition
to experience gained during open surgical procedures. ¶The case mix should be evenly
distributed among the different vascular beds. Supervised cases of thrombus management for
limb ischemia and venous thrombosis, utilizing percutaneous thrombolysis or thrombectomy,
should be included.
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territories, including aortoiliac and brachiocephalic, ab-
dominal visceral, renal, and infrainguinal (101). The
12-month training period is in addition to the 24 months
required for clinical core cardiology training and at least
8 months acquiring experience in diagnostic cardiac
catheterization in an ACGME-accredited fellowship
program. It is recommended that the trainee perform a
minimum of 300 diagnostic coronary procedures, includ-
ing 200 procedures with supervised primary responsibility
prior to beginning interventional training. The trainee
should also participate in a minimum of 100 diagnostic
peripheral angiograms and 50 noncardiac peripheral vas-
cular interventional cases during the interventional train-
ing period. At least 50 of the diagnostic angiograms and
25 of the interventional cases should be as supervised
primary operator. The case mix should be evenly distrib-
uted among the different vascular beds. Supervised cases
of thrombus management for limb ischemia and venous
thrombosis that utilizes percutaneous thrombolysis or
thrombectomy should be included.
3.5.3.3. STRUCTURAL HEART DISEASE
The inherent problems in setting threshold volumes in
structural intervention is that the procedures—as compared
to coronary artery interventions—are more diverse, of
higher complexity, of lower frequency, and often require a
multidisciplinary approach. Many of these procedures re-
quire multiple imaging modalities during the procedure
(fluoroscopy and echocardiographic imaging). In addition,
most of these procedures are in evolution in terms of
indications, procedural issues, devices, and outcomes (172).
The current guidelines on congenital heart disease do not
offer volume guidelines (173). SCAI is actively addressing
this issue and has recently published initial guidelines
regarding training (174) as well as a survey of physicians to
gain a better understanding of how best to establish com-
petence (175).
Percutaneous noncoronary cardiac interventions for
structural heart disease, including ASD and PFO closure,
alcohol septal ablation therapy, and valvuloplasty repre-
sent growing and important components of the field of
interventional cardiology. In addition, newer methods are
being investigated for percutaneously approaching clo-
sure of other congenital vascular defects and connections
as well as repairing or replacing cardiac valvular abnor-
malities. Although it is recommended that trainees in
interventional cardiology programs get exposure to these
procedures (169,176), at present, there are few official
guidelines for training in each of these interventions.
Guidelines for alcohol ablation for hypertrophic cardio-
myopathy suggest a minimum of 20 procedures is re-
quired for proficiency. The “ACCF/AHA/SCAI 2007
Update of the Clinical Competence Statement on Car-
diac Interventional Procedures” provides a review of the
additional knowledge skills and training that are neces-sary for gaining competence in structural heart interven-
tions (6). Due to the small number of these procedures
performed, and the specialized knowledge and skills
required, it is recommended that both training and
practice activity be concentrated among a limited number
of operators to allow for adequate expertise to be obtained
(169).
For PFO and ASD closure or for the use of alcohol septal
ablation in the treatment of the outflow tract gradient in
hypertrophic cardiomyopathy, a minimum of 10 procedures
each during training is recommended for trainees whose
goal is to perform these procedures independently. Alcohol
septal ablation should be offered only in those institutions
that can employ a multidisciplinary program for pre- and
postprocedural evaluation, careful case selection, and assess-
ment of clinical outcomes. If available, partnership with a
pediatric interventionalist should be considered when per-
forming septal closure with the available percutaneous
devices. In almost all situations the proper performance of
interventions in structural heart disease requires a multidis-
ciplinary team of cardiologists, cardiothoracic surgeons,
vascular specialists, noninvasive imaging specialists, and
radiologists.
Percutaneous aortic and mitral valvuloplasties are among
the most complex and challenging interventional proce-
dures. The importance of an operator learning curve has
been well described for both of these interventions (177–
179). Therefore, it has been recommended that 5 to 10 cases
be performed with an experienced colleague, before per-
forming balloon valvuloplasty independently (6). The sig-
nificance of a learning curve is even more applicable for
novel techniques such as percutaneous mitral valve repair,
the closure of prosthetic paravalvular regurgitation, or trans-
catheter valve replacement. At the time of this document,
most of these latter procedures remain primarily within
clinical trials (177). In order for laboratories to become
competent in the performance of structural heart proce-
dures, the supervising or performing operator should be
fully credentialed by the local facility in the procedure.
Initially, this may require offsite training, simulation train-
ing, a visiting proctor, or a combination of these approaches.
These procedures should only be done in a full-service
hospital facility (Table 2). The operator responsible for
the performance of the procedure in the catheterization
laboratory should educate and supervise the staff in
acquiring the necessary skills for the particular procedure.
Since these are essentially always lower-volume proce-
dures, there should be a small number of dedicated staff
members and operators trained to perform structural
heart procedures. For adult cardiologists performing
these studies, a close working relationship with pediatric
invasive cardiologists is also critical to ensure optimal
performance in addressing percutaneous approaches to
adults with congenital heart disease.
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Cardiac Catheterization Laboratory
4.1. Safety in Patients With
Communicable Diseases
Screening for blood-borne pathogens is not routinely per-
formed before referral to the cardiac catheterization labora-
tory. Therefore, it should be assumed that every patient has
the potential to transmit an infectious agent. This reinforces
the need to apply Universal Precautions in the cardiac
catheterization laboratory. However, some patients referred
for cardiac catheterization laboratory will be known to carry
the HIV or the hepatitis virus (180). Heightened protective
care should be taken in any case in which a communicable
disease such as hepatitis or HIV positivity is present. Every
cardiac catheterization laboratory should have an approved
additional sterile technique protocol for known highly
infectious cases. This protocol should include the use of
surgical caps and masks as well as eye protection. Double
gloving has been shown to reduce the chances of a puncture
and to better clean an inadvertent needle that has punctured
the gloves. In a study by Gerberding et al. (181), 17.5% of
gloves developed a perforation during surgery. Wearing 2
pairs of gloves reduced the chances of a puncture hole in the
inner glove by 60%. Though this practice has not proven to
prevent transmission of hepatitis or HIV, it seems prudent
to use this technique when the operator is working with
high-risk patients. In case of blood-borne pathogen expo-
sure to personnel, the catheterization laboratory should have
in place ready access to hospital occupational health re-
sources to rapidly address the risk of exposure to the staff
along with the appropriate treatment, if indicated. For
example, timely assessment and treatment of HIV-exposed
personnel can reduce the risk of HIV-seroconversion. In
addition to the usual surgical gown, disposable shoe covers
for the cardiologist and all technicians and nurses in the
room should be considered. Protective eyewear should be
worn by all in-room personnel to prevent accidental blood
exposure to the operator’s eyes. The careful disposal of all
needles, catheters, sheaths, tubing, and other instruments,
as well as fluids that come in contact with the infected
patient, is obviously important. Disposal of protective gear
and all contaminated equipment at the end of the procedure
as well as proper disinfection for nondisposable equipment
is also important, especially for blood-borne pathogens that
are communicable by contact (e.g., methicillin-resistant
Staphylococcus aureus).
Vaccination for hepatitis B virus should be strongly
considered, if not mandatory, for all operators and other
personnel who work in the cardiac catheterization labora-
tory (182).
4.2. Patient Preparation
Many laboratories use a checklist to ensure that all relevant
data are available prior to a procedure. Although this can beindividualized, the checklist should at least include the
patient name and hospital number, birth date, the procedure
being planned, the status of the consent form signing, the
core physical exam features, the indications for the proce-
dure, the American Society of Anesthesiologists classifica-
tion, the planned site of entry, medications and any aller-
gies, pertinent laboratory findings (including creatinine
clearance), and proposed contrast media limit.
Prior to any procedure, appropriate informed consent
must be obtained. Discussing the risks and benefits of the
procedure, as well as the alternatives to the procedure, must
be done. Each facility must have an approved consent form
that includes risks of the procedure in terms the patient can
understand. For most coronary procedures, the potential
need for ad hoc PCI should be included along with the
adherent additional risks reviewed. All elective PCI proce-
dures must mention the possible need for surgical interven-
tion. The written informed consent may be obtained by
trained secondary operators or physician extenders, but the
major concerns should be reiterated when the primary
operator discusses the procedure with the patient. Risks
of PCI should be explained at the same time as the
diagnostic catheterization risks, if the case has the pos-
sibility of requiring PCI immediately following the diag-
nostic procedure.
Educating each patient about the procedure and explain-
ing in detail what they should expect allays patients’ anxiety
and ensures patients are fully informed. Additional proce-
dures that the patient has not consented to must not be
performed unless a life-threatening emergency develops.
Written informed consent should be obtained in all elective
cases, and ideally in emergency cases. However, in cases that
are emergent, it is recognized that written informed consent
may not be feasible. In these cases, local standards for
documentation of necessity should apply, and documenta-
tion should be clearly written in the patient’s record.
Prior to the start of the procedure, calling a time-out
assures that the appropriate procedure is being performed
on the correct patient. This is now a Joint Commission on
Accreditation of Healthcare Organizations requirement.
The time-out period must occur before the patient is
sedated at the start of the procedure. The time-out partic-
ipants include the attending physician, any trainees or other
participating secondary operators, and the procedural staff.
The patient should participate if awake to confirm the
information. A member of the procedural staff or the
attending physician should initiate the time-out period.
The elements of the time-out must include, but are not
limited to the following: 1) correct patient name; 2) correct
procedure being performed; 3) consent signed; 4) confirma-
tion of any allergies; 5) any antibiotic administration; 6) correct
site and side is being used; 7) confirmation of pre-wash
performed, if indicated, and/or double prep, if necessary; and
8) availability of any special equipment and/or imaging studies
that will be used during the procedure.
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for the Procedure
Within 2 to 4 weeks prior to any cardiac catheterization
procedure, a hemoglobin, platelet count, electrolyte panel,
and creatinine should be obtained on all patients. If the
patient arrives and has had any significant clinical change or
recent contrast exposure since the laboratory tests were
obtained, the studies should be repeated on the day of the
procedure and prior to the catheterization.
Unless the patient has a known liver disease or a hema-
tologic condition that might affect hemostasis or is on
antithrombin therapy, the consensus of the committee is
that the routine acquisition of a protime/INR procedure is
optional and no longer necessary before the cardiac cathe-
terization in most cases.
In addition, the committee feels that the patient’s need
for overnight NPO is not always in the best interest of
patient hemodynamics, and only a minimum NPO period
of 3 hours is sufficient, unless conscious sedation will clearly
be required. If conscious sedation is required, the NPO
period is suggested to be at least 4 hours. The American
Society of Anesthesiologists last published NPO guidelines
in 1999, at which time they suggested 2 hours of fasting
after clear liquids and 6 hours after a light meal (183).
Adequate hydration remains an overlooked but is an im-
portant preparatory feature.
Women of child-bearing age should have a urine beta-
HCG level or a serum beta-HCG checked within 2 weeks
prior to the procedure to exclude pregnancy. During the
initial 2 weeks of gestation, the embryo has little risk from
ionizing radiation unless a large dose is received (100
mGy). At that exposure, there is a higher likelihood of fetal
death or failure of the blastocyst to implant. The uterus
provides considerable protection. Since only a few cells
make up the embryo during that period, embryo cells that
survive are progenitors of many other cells and exhibit no ill
effects from the radiation exposure (206a). The data thus
appear to justify the 2-week margin before any woman of
child-bearing age receives ionizing radiation.
The presence of a nickel allergy has also been a concern
for patients in whom a nickel-containing device may be
implanted. It is estimated that about 15% of the popu-
lation has a skin nickel allergy (184). Nitinol is a
nickel/titanium alloy used in self-expanding devices. One
report suggests nickel allergy may result in an increase in
migraine headaches after ASD or PFO closure with large
occluder devices made from nitinol (185). Another report
suggested the use of the Helex device rather than the
Amplatzer to prevent any nickel allergic reactions (186).
The Helex device minimizes the nitinol exposure as its
circumferential support is enclosed in an ePTFE mem-
brane. Coronary stents are made of stainless steel, which
is biologically inert but may contain as much as 5%
nickel. Although there are anecdotal data regarding early
stent closure in nickel-allergic patients, there are no datato support routine skin testing for nickel allergy before
the use of either occluder devices, or of coronary or
vascular stents at the present time.
4.2.2. Patients Receiving Antiplatelet and
Antithrombin Agents
Aspirin is not stopped or held prior to cardiac catheteriza-
tion, and if patients have not been taking aspirin, it should
be started prior to the procedure. Many patients are loaded
with or started on thienopyridines prior to cardiac catheter-
ization if there is a high likelihood of PCI and low
likelihood of CABG. Ticlopidine is generally no longer
used (except in the rare clopidogrel-allergic patient), and
newer antiplatelet agents are becoming increasingly avail-
able and may be substituted when medically indicated.
Patients taking warfarin should be instructed to stop
taking it at least 3 days prior to the catheterization, and their
INR should be checked prior to the procedure. An accept-
able INR to perform femoral artery cardiac catheterization
procedure is 1.8.; an INR of 2.2 is acceptable for radial
access. These thresholds are rather arbitrary and based on
scant data. Of note, a new study of fully anticoagulated
patients undergoing PCI from either the radial or femoral
access site suggests a major advantage to the use of radial
access regarding periprocedural bleeding (187). Overuse of
parenteral vitamin K may make it difficult to re-establish an
antithrombin effect following the procedure, therefore al-
lowing the patient’s INR to drift downward after stopping
the medication is preferred. In high-risk groups, especially
those with mechanical heart valves, a bridging protocol is
generally followed (188).
Patients receiving heparin, low-molecular-weight hepa-
rin, or glycoprotein IIb/IIIa inhibitors undergo cardiac
catheterization safely with only a minimum increase of
bleeding risk, particularly in the setting of an ACS. A longer
time to hemostasis may be required postprocedure, and the
combination of aspirin, heparin, and other antiplatelet
agents increases the risk of bleeding. Newer non-heparin
anticoagulants may require a change in practice regarding
the timing of performing cardiac catheterizations and sub-
sequent angioplasty procedures. Following activated clotting
times (ACTs) for patients on IV heparin has been the
standard for years. With newer low-molecular-weight hepa-
rins, factor Xa inhibitors, and direct thrombin inhibitors
(e.g., bivalirudin [Angiomax]), ACTs are often not appro-
priate. Knowledge of the time when the last dose of the
low-molecular-weight heparin or factor Xa inhibitor will
dictate further anticoagulant therapy during PCI proce-
dures, risk of bleeding, and the timing of sheath removal.
The half-life of bivalirudin is short, 25 minutes in patients
with normal renal function.
Dabigatran etexilate (188a) is a small nonpeptide mole-
cule that reversibly inhibits both free and clot-bound throm-
bin (factor IIa) and has been approved for stroke prevention
in patients with atrial fibrillation. At the time of this
writing, it is being actively investigated for other indica-
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for a routine dosing regimen without need for routine
coagulation monitoring. Peak effect occurs in 2 to 4 hours
after administration. Its estimated half-life is 15 hours with
normal renal function. Testing for its effect provides a
qualitative and not quantitative measure. It does not alter
the INR. The activated partial thromboplastin time
(aPTT), although not sensitive to the effects, can provide
negative predictive value; an aPTT30 seconds suggests no
effect, whereas the median peak aPTT level is about 2 times
control. The thrombin time for direct thrombin inhibition
is sensitive, though it is still most useful to exclude an
anticoagulant effect as other anticoagulant agents can affect
its value. The ecarin clotting time has a linear relationship
with dabigatran levels, but at present, it is not widely
available. Drug levels are affected by renal function. Based
on the pharmacokinetics, in patients with normal renal
function (eGFR 50 mL/min), discontinuation of 2 doses
results in a decrease in the plasma level to about 25% of
baseline, and discontinuation of 4 doses will decrease the
level to about 5% to 10%. Some reversal of the effects can be
achieved by the use of recombinant activated factor VII and
prothrombin complex concentrates. It can also be removed
with dialysis. About 60% is removed after 2 to 3 hours of
dialysis. From a practical standpoint, the drug should be
stopped 24 hours (2 doses) prior to cardiac catheterization if
the eGFR is 50 mL/min and for 48 hours if the eGFR is
0 mL/min to 50 mL/min. The drug should not be used in
atients with eGFR 30 mL/min. The anticoagulant effect
in patients with such chronic kidney disease (eGFR 30
mL/min) may persist for 2 to 5 days (189).
Rivaroxaban, a factor Xa inhibitor that is structurally
similar to the antibiotic linezolid, has now been approved by
the Food and Drug Administration (FDA) as a once-a-day
alternative to warfarin. Apixaban, a factor IIa inhibitor
similar to dabigatran, is likely to be available soon. A review
summarizes their potential advantages and uses (190).
4.2.3. Chronic Kidney Disease/Renal Insufficiency
Though there is some controversy regarding the classifica-
tion of patients with CKD, groups can be divided by
glomerular filtration rate (GFR) into 5 categories (based on
the Modification in Diet in Renal Disease [MDRD] GFR
calculation method). The stages are outlined in Table 19.
Table 19. Progressive Stages in Renal Dysfunction Utilizing
the GFR via the MDRD Method
Stage Severity GFR (mL/min/1.73 m2)
I Slight 90
II Mild 60 to 89
III Moderate 30 to 59
IV Severe 15 to 29
V Severe and established 15Reprinted with permission from Levey et al. (191).
GFR  glomerular filtration rate; and MDRD  Modification of Diet in Renal Disease.The occurrence of contrast-induced nephropathy (CIN)
correlates directly with the severity of chronic kidney dis-
ease, contrast volume, and the combination of chronic
kidney disease and diabetes mellitus. CIN carries a poor
prognosis, particularly if patients become dialysis depen-
dent; however, the occurrence of CIN varies widely depend-
ing on the definition used (192). Two definitions (an
incremental increase in creatinine 0.5 mg/dL and 25%
ise in serum creatinine) are now accepted as a measure of
IN occurrence (193). A multitude of studies have been
erformed using different iodinated contrast agents, gado-
inium, and various modalities to try and prevent contrast
ephropathy.
4.2.3.1. ATTEMPTS TO REDUCE THE RISK OF CONTRAST NEPHROPATHY
The cause of nephropathy following radiographic contrast is
unknown. There are data that suggest both renal vasocon-
striction and direct (possibly free-radical injury) play a role.
Some reduction of contrast nephropathy can be accom-
plished by minimizing contrast volume (194). Iso-osmolar
or low-osmolar contrast agents are preferred. One report
suggests the volume threshold can be estimated by using the
ratio of contrast volume to creatinine clearance. Nephrotox-
icity is more likely when the contrast volume/creatinine
clearance ratio exceeds 3.7:1 (195).
Biplane coronary angiography should be utilized to re-
duce the contrast load if the equipment is available. Avoid-
ing unnecessary “test” or “puff” injections, eliminating ven-
triculography and aortography, and taking the least number
of angiograms can limit contrast volume. Careful fluoros-
copy setup to reduce panning and use of a higher frame rate
may also reduce the volume of each contrast injection per
image acquisition. Performing ad hoc interventions and
combined coronary and peripheral procedures should be
carefully reviewed. There should be a low threshold to have
the patient return for a repeat procedure to avoid large
volumes of contrast during a single procedure. A discussion
of maximum contrast limits should be part of the initial
“time-out” before the procedure. N-acetylcysteine has been
extensively studied, but the latest randomized data from the
Acetylcysteine for Contrast-Induced Nephropathy trial
evaluated the effectiveness using large doses of acetylcysteine
in 2,308 patients before and after the use of contrast media,
and the authors found no evidence for prevention of CIN
(196). Its use is no longer recommended. Vitamin C has
also been used with some favorable effect to reduce free-
radical injury, as has sodium bicarbonate. None have been
consistently useful, though, and none proven in any large
randomized trial. Fenoldapam and theophylline, agents
used to reduce the vasoconstrictive component, have not
been found effective (192), and the use of gadolinium is not
recommended for coronary angiography but has been used
in renal and peripheral angiography (197).
Prehydration and posthydration with normal saline or
sodium bicarbonate has been the gold standard for reducing
the incidence of contrast nephropathy and the only modality
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is generally easy to accomplish in an inpatient setting;
however, it is more difficult in an outpatient setting. The use
of sodium bicarbonate infusion 1 hour prior to and 6 hours
after angiography has been shown to decrease contrast
nephropathy in some studies and might have an advantage
compared to normal saline hydration, though the advantage
is very modest (198).
Continuous veno-venous hemofiltration and hemodialy-
sis have been tested and the benefits remain unclear. It may
be considered in the very high-risk patients (199). There are
also data suggesting an advantage with the use of statins
(200) and the use of iso-osmolar contrast (201). However,
the latest data do not suggest an advantage of iso-osmolar
contrast over low-osmolar agents (202). Guidelines to
reduce contrast nephrotoxicity have been developed by
SCAI (203) and the Contrast Nephropathy Working
Group that met in 2006 (204). At this juncture, the only
recommendations the writing committee suggests are out-
lined in Table 20. These are consistent with the “2011
CCF/AHA/SCAI Guideline for Percutaneous Coronary
ntervention” as well (158).
.2.4. Other Contrast Media Reactions
dentifying patients at risk for a reaction to iodinated
ontrast remains a cornerstone of the preprocedure history.
esides the nephrotoxicity issues noted above, contrast
edia reactions include 1) acute hypersensitivity (anaphy-
actoid reactions—non-IgE mediated); 2) delayed hypersen-
itivity (IgE mediated and often resulting in rash or fever up
o 48 hours after the procedure); 3) acute hemodynamic or
lectrophysiological consequences during the procedure
now less common with low-osmolar and iso-osmolar con-
rast); 4) possible hypercoagulation (e.g., stressing the im-
ortance of minimizing the contrast media–blood interface
Table 20. Suggested Protocol to Reduce the Incidence of
Contrast-Associated Nephropathy Following Cardiac
Catheterization
1. Identify risks
a. Highest risk—eGFR 60 mL/min/1.73 m2
b. Diabetes
2. Manage medications
a. Hold nephrotoxic drugs (e.g., NSAIDS)
3. Manage intravascular volume
a. Hydrate with either normal saline or sodium bicarbonate
(either acceptable)
b. Hydrate with 1.0 to 1.5 mL/kg/min for 3 to 12 hours before
and 6 to 12 hours post
4. Radiographic contrast
a. Minimize contrast volume
b. Use either low-osmolar or iso-osmolar contrast
5. Follow-up data: obtain 48-hour creatinineeGFR  estimated glomerular filtration rate; NSAIDS  nonsteroidal anti-inflammatory drugs.in syringes); and 5) hyperthyroidism (the only real side effect
due to the iodine in the contrast media—seen usually in
elderly patients with history of thyroid nodules).
A previous anaphylactoid reaction and a history of atopic
conditions such as asthma are the most significant risk
factors for acute hypersensitivity reactions (205). It should
be recognized that contrast reactions can be idiosyncratic so
that a history of any past reaction (regardless of subsequent
reactions) should be treated. Patients with other food or
medication allergies, those of an advanced age, and women
are at higher risk. It has never been shown that patients with
a history of shellfish allergy have a higher risk of a reaction
to radiocontrast media and, in fact, the allergen is actually in
the tropomysin protein and appears unrelated to iodine.
Pre-medication is recommended for those with a strong
atopic history and for patients with a known prior allergy to
contrast. It appears that anaphylactoid reactions are much
more common when contrast is administered in the venous
rather than the arterial circulation, so these types of poten-
tially life-threatening reactions are much more common
with computed tomography (CT) angiography or IV py-
elography use than during cardiac angiography. Pre-
medication regimens with H2 blockers and steroids are
recommended for the highest-risk atopic patients, particu-
larly those with known prior reaction. Current options
include giving 50 mg oral prednisone 13 hours, 7 hours, and
1 hour prior to the procedure or 200 mg IV hydrocortisone
2 hours before the cardiac catheterization with or without
H2 blockers (205). Anaphylaxis results in profound vasodi-
lation, bronchospasm, and circulatory collapse. Treatment
not only includes epinephrine but requires circulatory sup-
port with large doses of IV fluids and other inotropic agents.
The importance of recognizing delayed hypersensitivity
due to contrast is important to avoid stopping appropriate
medications, such as clopidogrel, on the assumption the
transient fever and rash may be due to a new medication
started after the procedure rather than simply due to the
contrast media.
4.2.5. Diabetes Mellitus
Patients with diabetes mellitus require precautions to pre-
vent hypoglycemia. Insulin doses the night before are
generally cut in half, and in the morning oral hypoglycemic
and insulin are held. These patients should be scheduled
early in the morning to avoid prolonged fasting. Blood
glucose levels should be checked upon arrival in the prec-
atheterization staging area and treated accordingly. Patients
with normal renal function taking metformin are instructed
to not take the metformin the day of the procedure and not
to restart it for at least 48 hours afterwards and until an
assurance of no contrast-related nephropathy (206). The
danger of metformin and contrast media is the clinical
syndrome of severe and persistent lactic acidosis. This
syndrome invariably occurs in patients with renal insuffi-
ciency, and metformin should not be used in this group
anyway. Because diabetes mellitus itself is an independent
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dations are to stop the metformin the day of the procedure
and not resume (usually 48 hours) until a normal creatinine
level has been documented (see Table 20).
4.2.6. Sedatives and Relaxants
Conscious sedation is most commonly used for the
majority of procedures performed in the catheterization
laboratory. Appropriate sedation is imperative and en-
sures patient comfort. Pre-medication with oral diphen-
hydramine and diazepam is common. IV sedative hyp-
notics and analgesic regimens vary. A combination of
midazolam and fentanyl citrate is very popular. IV mor-
phine, diphenhydramine, and hydromorphone hydrochlo-
ride are also used. Conscious sedation protocols must be
strictly adhered to and excessive sedation should be avoided.
All patients should have baseline blood pressure (BP),
oxygen saturation, and heart rate and rhythm documented.
These vital signs must be monitored closely throughout the
procedure and in recovery. Reversal agents should be readily
accessible in the laboratory.
General anesthesia is often used if transesophageal echo-
cardiography is required for a procedure. Many patients
undergoing valvuloplasty, percutaneous aortic or mitral
valve procedures, and ASD and PFO closures are managed,
with the assistance of an anesthesiologist, under general
anesthesia.
4.2.7. Heparin-Induced Antibodies
Great precautions must be taken in patients with known
antibodies to heparin. Heparinized flush is not to be used in
the manifold system. Therefore, great care must be taken
between catheter exchanges with wiping wires thoroughly,
and extra attention to flushing the sheaths and catheters
must be performed. If patients require anticoagulation, then
direct thrombin inhibitors are used.
4.2.8. Pregnant Patients
Radiation exposure should be avoided as much as possible in
pregnant patients. The concept of ALARA (As Low As
Reasonably Achievable) in regard to radiation dose should
always be followed. Despite the fact that direct x-ray
targeting during the procedure mostly affects the upper
torso, Compton scattering within the body results in indi-
rect x-ray exposure to the developing fetus. Efforts to
minimize x-ray dose should also include using low fluoros-
copy settings or in-laboratory echocardiography rather than
cineangiography, limiting total exposure time, using re-
duced framing rates, using the minimum number of contrast
injections, and avoiding angulated or magnified views when
possible. A lead apron between the x-ray tube and abdomen
is recommended. The fetus is less vulnerable during the first
2 weeks of gestation but becomes especially vulnerable
during the duration of the first trimester (206a).4.3. Access Site (Femoral, Radial, Brachial)
The most common site for percutaneous arterial access for
both diagnostic and interventional cardiac procedures is the
common femoral artery. Localization of the appropriate
access insertion using the radiographic femoral head as a
marker has been popular and found helpful. The sheath
entry should be located within the femoral artery at the
medial third of the femoral head (207). The radial artery
approach is gaining more and more popularity, especially for
obese patients and outpatients. The use of the radial
approach in the United States remains much lower than
many other countries, despite fewer bleeding complications
using the radial approach compared with the femoral artery
approach in the elderly and those undergoing PCI for ACS
(208). Brachial access is rarely used. Brachial cut-downs are,
at this point, of historical interest only. Femoral cut-downs
for large abdominal aortic aneurysm stent grafts or for
percutaneous aortic valve replacement are still required at
times. In cases where greater wound exposure is necessary,
such as in pacemaker implantation or femoral cut-downs, a
full surgical sterile technique should be used. A vascular
sheath should be used to minimize vascular trauma, espe-
cially when multiple catheter changes are anticipated. Each
percutaneous vascular site (femoral, brachial, radial, subcla-
vian, or internal jugular) requires that the operator have
specialized training. Although some aspects of percutaneous
vascular access are similar for all sites, certain issues (e.g.,
compression and/or administration of heparin or intravas-
cular verapamil or nitroglycerin) are unique to each site. If
venous access is required, in most cases it should be
performed using the femoral vein or the internal jugular
vein. The use of ultrasound to localize and facilitate cannu-
lation, particularly of the internal jugular and subclavian
veins has become routine in many institutions. Multiple
venous catheters can be safely inserted in the same femoral
vein; multiple arterial catheters require separate arterial
access sites. In radial artery access cases, it is routine and
acceptable to obtain venous access via the femoral vein.
Strict sterile procedures should be followed at each site.
4.4. During the Procedure
4.4.1. Medications
Adequate hydration, appropriate for the patient’s underlying
condition, is important before the procedure. Drugs, such as
long-acting phosphodiesterase inhibitors (e.g., tadalafil)
should be held in case nitrates would be needed. Chlorhexa-
dine is now the preferred prep solution over the use of
betadine.
Multiple medications can be administered during the cath-
eterization procedure. These are related to sedation, procedural
performance, and BP or heart rate changes. Anticoagulants,
antiplatelet adjuncts, and emergency-related medications may
also be used. Vasoactive medications for either high or low BP
may be required depending on the clinical situation. The
selection of the appropriate agent should be based on the
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abnormal hemodynamic state. Hypertension is common, in
part because of the heightened adrenergic tone from anxiety,
as well as from the underlying condition. Treating high BP
during a procedure (after adequate sedation) can be accom-
plished with IV boluses of hydralazine, labetalol, nicardi-
pine, or metoprolol. Nitroprusside and nitroglycerin con-
tinuous infusions may also be of benefit. Caution should be
exercised in patients with certain conditions, such as severe
pulmonary hypertension or critical aortic stenosis. Hypo-
tension must be diagnosed and managed aggressively, and
management is critically dependent on the etiology. Vagal
episodes are characterized by an inappropriately low heart
rate in association with hypotension, whereas other causes
of hypotension are generally associated with a high com-
pensatory heart rate. IV fluid boluses with normal saline are
often first-line therapy for hypotension from any cause.
Patients are commonly dehydrated from having food and
drink withheld for many hours prior to the procedure. If
volume resuscitation is unsuccessful, dopamine, norepi-
nephrine, and phenylephrine infusions can be started to
maintain adequate BP. Specific conditions that need to be
considered and treated include vagal reaction, hemorrhage,
allergic reaction (anaphylaxis), cardiac tamponade, or car-
diogenic shock.
During both diagnostic angiography and percutaneous
coronary interventions, a variety of vasodilator agents may
be required. These agents include intracoronary nitroglyc-
erin, nitroprusside, verapamil, nicardapine, adenosine, and
other vasodilators. There is a significant variation regarding
the use of intracoronary vasodilators among hospitals. Car-
diac catheterization labs should have standard medication
doses and procedures regarding the use of these medications
so that all personnel are familiar with the most commonly
used and requested vasodilators in their region.
4.4.2. Sterile Techniques
Infection is rare after invasive cardiovascular procedures.
The Occupational Safety and Health Administration rec-
ommends that preparation of all patients include the re-
moval of hair from the site (electric clippers are preferred
over typical razor-blade shaving to avoid skin abrasion),
application of antiseptic to the skin, and the use of sterile
drapes. Sterile covers for the image intensifier and protective
operator shielding should be placed when these are used
over or next to the sterile field. Systemic antibiotics are not
required, although some operators use them with large-
vessel noncoronary stents or other devices that will be left in
the body. A generally sterile environment should be main-
tained during the procedure. Disposal of all materials should
also follow local safety and infection control guidelines.
Although the strict sterile techniques used in the operat-
ing room are not necessary for most cardiac catheterization
laboratory procedures, operators should use appropriate
hand washing and wear a sterile gown and gloves. Personnel
should wear hospital-based scrub attire. Occupational andHealth Safety Guidelines (180) and Usual Precaution
Guidelines suggest that masks, an eye shield, and protective
caps should be worn during cardiac catheterization. These
protect from accidental blood exposure to the operator as
well as help preserve the sterile access field. Strict adherence
to aseptic techniques are mandatory when devices are being
implanted, such as those used in the treatment of structural
heart disease.
4.4.3. Technical Issues
4.4.3.1. CORONARY ANGIOGRAPHY
The safe injection of a contrast agent into coronary arteries
is predicated on the coaxial placement of the coronary
catheter in the coronary ostium and the correct positioning
of the tip of the catheter in the coronary artery. Assurance
of an air-free connection between the contrast manifold port
or syringe and the catheter must be established. To avoid
red blood cell clumping and potential thrombus formation,
the syringes should be flushed clear of blood. Careful
replenishment of contrast in the injection syringe and the
maintenance of an air-free environment is the responsibility
of the operating cardiologist. Most invasive cardiologists
inject the coronary arteries manually themselves or use
support personnel to perform the injection. Specialized
mechanical injectors can be used with appropriate equip-
ment and training. Coronary injections should include a tiny
test dose of contrast once the catheter tip is in position. This
ensures that the catheter is not subintimal or under a plaque
that might result in an extensive coronary artery dissection if
a full injection of contrast were administered. Monitoring
catheter tip pressure is obligatory. A “flush” injection into
the respective coronary sinus may help define ostial coronary
disease.
It remains the responsibility of the individual invasive
cardiologist to ascertain whether nonphysician personnel or
power injectors are capable of administering contrast into
the coronary arteries. Physician extenders should never be
primary operators. They can be secondary operators but
should always be viewed as extensions of the primary
operator’s hands, with the responsibility for safety ultimately
residing with the invasive cardiologist.
In the majority of cases, the use of single-plane x-ray
imaging is satisfactory, recognizing that most laboratories
do not have biplane capabilities. It is desirable for labora-
tories contemplating angiographic evaluation of patients
with congenital heart disease, however, to have biplane
capabilities. A biplane option also is useful to keep contrast
volume at a minimum in patients with renal failure. In the
case of left ventriculography in patients with coronary artery
disease, an appropriate view should be selected to gain the
most information regarding LV function. This may include
a left anterior oblique view if left circumflex disease is
discovered, and there is interest in observing lateral ventric-
ular wall motion. The use of noninvasive modalities to
assess wall motion and ejection fraction prior to the cathe-
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LV angiography is now required.
The use of multiple orthogonal views of the coronary
arteries is of obvious importance, as coronary lesions are
defined by “worst view.” The invasive cardiologist must be
certain that appropriate information is obtained and re-
corded in order to make an accurate diagnosis and to
determine suitability for PCI or CABG. Each segment of
the coronary artery should be seen in at least 2 orthogonal
views. Although it may be helpful and expeditious to have
routine views performed on each coronary study, additional
views should be obtained if the anatomy is not clearly
presented or there are overlapping structures. The knowl-
edge and application of additional views is the hallmark of
excellence for angiographers.
In the case of right-heart and pulmonary angiography, it
is important that the appropriate views be obtained to
demonstrate the anatomy being interrogated. Because most
cardiac catheterization laboratories have only a maximal
9-inch image intensifier, multiple images of the lung are
usually required to interrogate the entire lung fields. If the
aorta is to be investigated, cine aortography can be per-
formed in the catheterization laboratory to ascertain the size
of the aorta (in cases of aortic stenosis with anticipated
aortic valve replacement) and to visualize the arch vessels. If
detailed examination of the lung and aorta and arch vessels
is required, it is often better to use a system with a
larger-size image intensifier field of view designed for that
purpose. It should be recognized that angiography in the
catheterization laboratory is limited by 2-dimensional im-
aging, hence complete evaluation of the aorta and pulmo-
nary arteries (PAs) may be difficult, and the potential use of
alternative imaging modalities (i.e., CT or magnetic reso-
nance imaging [MRI]) should be considered if clinically
important.
4.4.3.2. VENTRICULOGRAPHY AND VASCULAR ANGIOGRAPHY
Power injectors are recommended for optimal opacification
and visualization during ventriculography and large vessel
angiography, such as aortography. Hand injection can be
performed for selective subclavian, carotid, or renal angiog-
raphy. Using a pigtail catheter appropriately placed in the
mid–left ventricle usually avoids or minimizes inducing
premature ventricular contractions or ventricular tachycar-
dia. End-hole catheters should generally not be used for
ventriculography power injections because of the risk of
perforation or an intramyocardial contrast injection. At
times, visualization of the pulmonary veins can be obtained
by wedge angiograms (the injection of contrast into a
pulmonary wedged balloon catheter then release of the
balloon to observe the pulmonary veins during the washout
period).
4.4.3.3. PRESSURE MEASUREMENT
During a routine left heart and coronary arterial catheter-
ization, a preprocedural and postprocedural aortic pressure
tracing, as well as the recording of the LV systolic and aend-diastolic pressure should be obtained. Some laborato-
ries find it useful to repeat the LV pressure after the left
ventriculogram to report the LV end-diastolic pressure after
contrast, although the clinical value of this exercise is
questionable. During right-heart catheterization, the acqui-
sition of right atrial (RA), right ventricular (RV), PA, and
PA wedge tracings is routine, and sufficiently long strips of
phasic recordings should be obtained to account for respi-
ratory variation. Obtaining the end-expiratory pressure
helps reduce the respiratory variation, although some pa-
tients are unable to hold their breath without performing a
Valsalva maneuver, and thus the pressures are influenced by
the resultant high intrathoracic pressure generated. The
mean pressure in atrial and pulmonary chambers should be
obtained over 10 beats to allow for correction of respiratory
changes. A 10-beat average should also be reported in
patients having atrial fibrillation.
If pullback pressures are used to measure valvular gradi-
ents, the patient should be in as steady a state as possible to
diminish the likelihood of any respiratory variation between
pressure measurements from 1 chamber to another. Simul-
taneous pressures to gauge gradients across valvular lesions
are preferred to pullback pressures when feasible. Care
should be taken if the femoral artery pressure is used as a
substitute for aortic pressure in younger patients, as nor-
mally the femoral pressure is higher than the central aortic.
If femoral pressure is to be used as the aortic pressure
surrogate, documentation should be obtained that the pres-
sures between the 2 sites are similar. Newer dual lumen
catheters should generally be used for the measurement of
aortic or pulmonic gradients.
On occasion, the pulmonary capillary wedge pressure will
also not correspond well with the LA pressure (especially
after mitral valve replacement), and a transseptal puncture
with simultaneous measurement of the LA and LV pressure
may be required for an accurate transmitral gradient. With
the improvement in noninvasive assessment of valvular
gradients, it is not uncommon that cardiac catheterization
hemodynamics focus only on the pulmonary pressure, out-
puts and coronary anatomy and the valvular gradients are
not directly assessed. Pressure wires are of small enough
caliber that they can be used to cross even mechanical
prosthetic valves safely.
4.4.3.3.1. HEMODYNAMICS. The importance of high-quality
ressure measurements has unfortunately been de-
mphasized in most laboratory facilities. The availability of
umerous types of hemodynamic equipment precludes de-
ailed description here. Appropriate filtering of the pressure
ignal is important for adequate interpretation of individual
aveforms. Careful balancing and zeroing of the system at
he level of the mid-atria are necessary for each procedure.
ften, simultaneous pressures are important, and frequently
igher-speed recordings (100 mm/s) are needed to obtain
dequate data for waveform analysis. It is the responsibility
f the laboratory director to ensure that the equipment
vailable produces the information desired. Detailed knowl-
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be part of the orientation and a requirement for credential-
ing of invasive cardiologists in a particular catheterization
laboratory. It is each invasive cardiologist’s responsibility to
direct the acquisition of appropriate pressures so that key
hemodynamic data are obtained and not overlooked. Inva-
sive cardiologists using the laboratory should review the
quality of the pressure recordings obtained, and any defi-
ciency should be corrected.
Accurate hemodynamic measurements aid in sorting out
constrictive pericarditis from restrictive cardiomyopathy. In
either instance, it is important that simultaneous measures
of both LV and RV pressure during respiration are recorded
to assess for ventricular interdependence (209). In patients
with dyspnea, both a superior vena cava and PA oxygen
saturation may be useful to exclude an unanticipated left-
to-right shunt.
4.4.3.3.2. INTRACORONARY HEMODYNAMICS. Measuring the
pressure gradient across a lesion in a coronary vessel may
provide information regarding the hemodynamic signifi-
cance of that lesion (210). Multiple studies have confirmed
the use of pressure wires to assess pressure gradients across
an intermediate angiographic stenosis (211–213). This in-
formation can now be used to guide whether or not stents
should be placed (214,215). These studies have shown
excellent outcomes in patients who have had insignificant
gradients who did not have stents placed (216). The
fractional flow reserve (FFR) is measured after the pressure
sensor tip wire is placed distal to the lesion in question.
Adenosine is administered intravenously or intracoronary to
dilate the microvascular coronary circulation. An FFR
measurement of0.75 was initially used as the standard cut
off to defer stent placement. The latest studies suggest an
FFR 0.80 can be used with excellent long-term outcomes
(212,213).
4.4.3.4. CARDIAC OUTPUT AND VASCULAR RESISTANCE MEASUREMENTS
Cardiac output measurements commonly used in the car-
diac catheterization laboratory include the use of indicator
dilution methods (typically thermodilution), the Fick
method (use of pulmonary and arterial blood oxygen satu-
rations and oxygen consumption), angiographic methods,
and impedance estimates. Indocyanine green dye is no
longer used as the indicator. As a consequence, most cardiac
catheterization laboratories rely on either thermodilution
methods or the Fick method for determination of cardiac
outputs. Thermodilution methods use a thermistor on the
end of a right-heart catheter. As a proximally injected bolus
of saline traverses past the thermistor, the temperature
change results in a curve similar to that observed with dye
dilution methodology. Analysis of this curve allows deter-
mination of cardiac output by a variety of methods. Accu-
rate measurement requires a concentrated bolus of saline.
Thus, tricuspid or pulmonary insufficiency may significantly
alter the results obtained. Fick cardiac outputs require
measurement of oxygen saturation, hemoglobin, and oxygenconsumption. Oxygen consumption is the most difficult
variable to obtain. Most laboratories use an assumed value
from an established reference table or an established for-
mula. Direct measurement of oxygen consumption provides
a more accurate assessment using a variety of instruments,
but the unstable nature of some of these devices and the
expense and time involved have discouraged direct oxygen
consumption measurements in most catheterization labora-
tories. Angiographic cardiac output using area-length as-
sumptions or Simpson’s rule provides LV volumetric data
useful for estimating valvular stenosis severity in the pres-
ence of valvular regurgitation (assuming only 1 left-sided
valve demonstrates regurgitation). The regurgitant fraction
can also be derived. Angiographic methods suffer from
vagaries in the accuracy of shape assumptions and from the
determination of the requisite correction factors needed
because of x-ray divergence. Whatever method is used for
determining cardiac output should be well understood by all
personnel. Each cardiac output method has limitations and
errors that can be minimized with careful attention to the
inherent vagaries of each technique. Similar data are often
obtained now from noninvasive methods.
Vascular resistance calculations require knowledge of the
mean pressure before and after the resistance of interest and
a measure of the flow through the area. Thus, for pulmonary
vascular resistance, the pulmonary blood flow and the mean
PA and the mean pulmonary capillary wedge pressure (or
LA pressure if no pulmonary venous disease) must be
recorded.
4.4.3.5. SHUNT MEASUREMENT
Important information regarding physiology of congenital
heart disease is gathered from measurements of intracardiac
shunts. Both right-to-left and left-to-right shunts must be
able to be quantitated during the catheterization. Because of
the need to determine intracardiac shunting, oxygen satu-
ration samples are drawn from many sites rather than simply
from the PA for mixed venous oxygen level and from the
systemic artery for arterial oxygen level. The availability of
oxygen saturation measurements and arterial blood gas
determinations within the catheterization laboratory is use-
ful for the efficient performance of the typical congenital
cardiac catheterization. The availability of blood gas mea-
surements also allows for the inclusion of dissolved oxygen
in the determination of oxygen content.
4.4.4. Other Diagnostic and Therapeutic Procedures
in the Cardiac Catheterization Laboratory
4.4.4.1. PULMONARY VASODILATORS IN THE EVALUATION
OF PULMONARY HYPERTENSION
The World Health Organization classifies pulmonary hy-
pertension into 4 categories (217). Pulmonary arterial hy-
pertension, or “idiopathic” pulmonary hypertension, is as-
sociated with a normal pulmonary capillary wedge pressure
and elevated pulmonary vascular resistance. The normal
pulmonary pressure is generally considered to be 25/10 mm Hg
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Pulmonary hypertension is considered present when the mean PA
pressure is25 mm Hg at rest or 30 mm Hg with exercise.
he pathophysiology of pulmonary hypertension involves a
eduction of flow through the lungs due to pulmonary
ascular remodeling and vasoconstriction. Remodeling in-
olves endothelial, smooth muscle, and fibroblast cell types,
s well as inflammatory cells and platelets (218). Vaso-
pasm plays a greater role early in the disease, and its
resence can be assessed in the cardiac catheterization
aboratory using 100% oxygen, adenosine, and epopros-
enol and inhaled nitric oxide (usually 40 to 80 ppm). A
0 mm Hg fall in mean PA pressure and a final mean PA
ressure of 40 mm Hg is considered a positive vasodilator
esponse. Therapy for pulmonary arterial hypertension is
hen dependent upon the response to these vasoactive agents
219). In general, responders are treated with calcium
hannel blockers and phosphodiesterase inhibitors whereas
onresponders are considered candidates for endothelial-
eceptor blockers and prostacyclin analogs. The clinical
unctional class also plays a role in the aggressiveness of
herapy (219).
Response to vasodilators has also been used to decide on
urgical suitability for patients with congenital heart disease
r transplantation. In those instances, the change in the
esistance in the pulmonary circulation (Rp) over the sys-
emic resistance (Rs) is often used, with high risk associated
ith an Rp/Rs ratio 0.7. One study shows the achieve-
ent of an Rp/Rs ratio of 0.33 and a 20% decrease in the
atio with vasodilators allowed for safe surgical intervention
220).
Of note, in pediatric catheterization laboratories, the
ulmonary vascular resistance is calculated using the cardiac
ndex rather than the cardiac output alone. Despite this
orrection making sense, the practice has unfortunately
ever been adopted in the adult cardiac catheterization
aboratory.
4.4.4.2. VASODILATOR OR INOTROPIC STRESS TESTING IN AORTIC STENOSIS
Patients with aortic stenosis (AS) and depressed ejection
fraction may have low valvular gradients despite significant
AS by aortic valve area (1.0 cm2). Whether to replace the
ortic valve in this situation is often a difficult clinical
uestion. When data from noninvasive studies using dobut-
mine are not available or are equivocal, the use of either
obutamine or nitroprusside during cardiac catheterization
o assess the response of the aortic valve area, gradient, and
troke volume has been used to help decide whether the
tenosis is an actual or a pseudo-stenosis due to low output.
n increase in the aortic valve area and a little increase in
he aortic valve gradient suggest the primary problem is
yocardial and not valvular stenosis. Graded doses of
obutamine (5 mg/kg/min, 10 mg/kg/min, 20 mg/kg/min)
o test whether there is “contractile reserve”—a20% increase in
troke volume—have been used to separate those who are
andidates for surgical intervention from those who areelieved to be too high risk (221). Nitroprusside may be
sed to improve cardiac output in patients with atrial
brillation to help prevent the rapid ventricular response
ften seen with the administration of dobutamine. Patients
n atrial fibrillation with a wide variability in the ventricular
esponse are best studied with RV pacing greater than
aseline to control the heart rate before and after the
nfusion. There are data that suggest the use of brain
aturietic peptide (BNP) may influence whether the results
ruly separate the operable candidate out from the inoper-
ble candidate, with poor outcomes regardless of the result
n those with BNP levels 550 pg/mL (222). In addition,
sing contemporary surgical methods, some have demon-
trated excellent surgical results despite failure to demon-
trate any contractile reserve in this patient population
223). The threshold for therapy in these difficult patients
ay also be changing with the availability of the percuta-
eous aortic valve replacement procedure.
4.4.4.3. TRANSSEPTAL CATHETERIZATION
Transseptal catheterization is performed from the femoral
artery by placing a long, pointed, sheathed introducer with
a hollow Brockenbrough needle first into the superior vena
cava then rotating into the foramen ovale. The stiff system
is “locked” into the foramen ovale and pressure applied to
the foramen ovale. In about a third of cases, the system will
push open the septum primum in the foramen ovale. If the
system does not cross, then the needle is extended just past
the introducer tip and the interatrial septum is punctured. A
change in the waveform reflecting LA pressure should be
evident before advancing the catheter and sheath. Once LA
pressure is obtained, the needle is withdrawn and a guide-
wire inserted into the LA. The sheath and transducer are
advanced into the LA and once inside, the introducer is
withdrawn and the sheath remains. Catheters can then be
inserted through the sheath into the LA. Transseptal
catheterization to obtain LA pressures is primarily used in
the adult catheterization laboratory during the performance
of balloon mitral valvuloplasty or mitral repair using the
eValve mitral clip. It is required to perform stenting of
pulmonary vein stenosis or in the EP laboratory during
atrial fibrillation ablation. Hemodynamically, the LA/LV
pressure gradient may be different from the pulmonary
capillary wedge/LV pressure gradient, especially in patients
with mitral valve replacement, and it is useful to document
the difference. Entry into the LA allows entry into the LV
when crossing the aortic valve retrograde is not feasible or
desirable and LV pressure is necessary. Percutaneous aortic
valvuloplasty or valve replacement can be performed in this
manner. In congenital heart disease, at times the only access
to the pulmonary arterial pressure is retrograde through the
pulmonary veins and both hemodynamics and pulmonary
angiography can be performed via a reverse wedge in most
patients when this is the case. The procedure is also required
for the placement of an LA appendage occluder. Compli-
cations related to transseptal puncture include perforation of
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tamponade, pain perception by the patient while crossing
the septum, vagal stimulation, or inadvertent entry into the
ascending aorta. Care must be taken to avoid air entry into
the LA or thrombus formation. Recently, the addition of
intracardiac echocardiography/Doppler methods can be
used to help guide the transseptal procedure.
4.4.4.4. LV PUNCTURE
There is essentially no longer any indication for percutane-
ous LV puncture to assess the LV pressure. Echocardiog-
raphy/Doppler methods and MRI are adequate to evaluate
combined mitral disease and a mechanical aortic prosthesis.
Fine pressure wires have also been used to cross even
bileaflet mechanical aortic valves or the Starr-Edwards
aortic prosthesis with little risk. Surgical LV puncture may
be used for the placement of the percutaneous aortic valve
and to stabilize guidewires when attempting to plug para-
valvular leaks in a hybrid room situation.
4.5. Therapeutic Interventions for
Hemodynamic Compromise
4.5.1. Improving Cardiac Output
4.5.1.1. INTRA-AORTIC BALLOON PUMP
The intra-aortic balloon pump (IABP) improves cardiac
output, improves myocardial perfusion and reduces myocar-
dial demand by maintaining diastolic pressure and reducing
afterload. This is because maintaining diastolic pressure
improves coronary and systemic perfusion, whereas the
afterload reduction reduces myocardial demand. It is par-
ticularly useful in situations of hypotension due to low
cardiac output and in patients with refractory unstable
angina. The intra-aortic balloon pump is a thin synthetic
balloon positioned within the descending thoracic aortic
about 2 cm below the normal takeoff of the left subclavian
artery. It is inflated with helium during ventricular diastole
and deflated during ventricular systole. Cyclic obstruction of
the aorta in this manner increases diastolic aortic pressure
and helps maintain coronary perfusion (primarily an early
diastolic phenomenon, especially in the left coronary).
Systolic deflation of the balloon unobstructs the aorta, and
cardiac ejection occurs against a markedly lower aortic
impedance and peripheral vascular resistance, improving
stroke volume. The physiology is ineffective if significant
aortic regurgitation, excessive tachycardia or other arrhyth-
mias are present. The latest meta-analysis of the use of
IABP therapy in STEMI suggests, however, that there was
no impact on mortality (224) despite short-term hemody-
namic improvement.
Balloon placement is not feasible unless the aortoiliac
vessel lumens are large enough (7 mm) to accommodate
the device. Aortic dissection and extreme tortuosity may not
allow for the IABP placement. Because the device is placed
in the femoral artery and aorta, it could obstruct flow to the
limbs, and lead to limb ischemia and even a compartment
syndrome. Renal failure can occur if placed too low in theaorta over the ostia of the renal arteries. Other possible
complications include cerebral embolism during insertion,
infection, dissection, or perforation of the aorta or iliac
artery, and hemorrhage into the mediastinum. The balloon
may fail to deflate or may rupture, requiring surgical
removal. Showering of aortic atherosclerosis particles can
lead to leg ischemia from cholesterol embolization or from
thrombi originating on the balloon’s surface—this is espe-
cially a risk during balloon removal. Mechanical failure of
the balloon may require vascular surgery for removal.
4.5.1.2. OTHER CATHETER DEVICES TO IMPROVE CARDIAC OUTPUT
Several newer percutaneous devices have become available
to augment cardiac output during high-risk cardiac cathe-
terization. These include the Impella device (Abiomed, Inc.,
Danvers, MA) and the TandemHeart (Cardiac Assist,
Pittsburg, PA). Both have been used in a variety of
situations. The Impella device is a 12-F rotary micropump
catheter able to produce continuous flow up to 2.5 L/min. It
is placed across the aortic valve and augments LV output
directly into the aorta. The TandemHeart is placed into the
LA via a transseptal puncture using a 21-F venous catheter.
It pulls oxygenated blood from the LA and returns it to the
femoral artery via a 15-F catheter. It is capable of contin-
uous flows up to 5 L/min. Early studies comparing the
results with that of an IABP suggest that the acute hemo-
dynamics are superior, but there is no difference in early
survival (225). ECMO can also be used to provide both
cardiac and respiratory support via either veno-veno or
veno-arterial cannulation. The role of all these types of
devices to augment cardiac function during cardiac cathe-
terization remains to be further defined.
4.6. Pericardiocentesis
The performance of pericardiocentesis is a critical skill that
every invasive cardiologist should acquire. Although the
methods may vary, the importance of being able to remove
pericardial fluid in a patient who is experiencing tamponade
physiology is critical, especially when the fluid has resulted
from a complication of a catheterization procedure. All
invasive cardiologists should be able to recognize the hemo-
dynamics associated with cardiac tamponade, including
equalization of the end-diastolic RA, RV, and LV pressures,
and usually an associated paradoxical pulse (a fall in the
pulse pressure and systolic central BP with inspiration).
Emergency echocardiography is critical to define the effu-
sion and assess for RA collapse and RV diastolic collapse.
Most acute pericardial effusions are not large, and the use of
echo-guided aspiration is generally preferred. A defined sterile
pericardiocentesis package should be part of any cardiac cath-
eterization laboratory so that there is no scrambling for the
items required to perform an emergency tap of the pericar-
dium. The director of the cardiac catheterization laboratory
should define what equipment is in the package and ensure it
is available at all times within the laboratory area. All operators
should be familiar with the contents of this package for any
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equipment if the need arises.
4.7. Coronary Artery Catheter Imaging Devices
A variety of diagnostic and some therapeutic catheters are
now either available or are being tested for use within the
coronaries during cardiac catheterization. IVUS devices
have the longest track record, and a consensus document
from the ACCF still provides important information on the
proper use of these tools (226). Both mechanical and
phased-array catheters are available. IVUS studies have
provided information regarding the unreliability of angiog-
raphy to define lesion severity. IVUS studies also provide
valuable information at times on plaque composition and
remodeling, stenosis severity (especially in left main dis-
ease), the satisfactory deployment of intracoronary stents,
and in cardiac transplant vasculopathy. It has also been a
valuable tool to assess plaque burden over time in some
clinical trials, to identify thrombus, and to help assess
bifurcation lesions. The use of IVUS catheters in any
laboratory setting is undoubtedly dependent on the skills
and the enthusiasm of the operators for these procedures. Its
use is not without a small risk; an early European registry
found a 1.1% complication rate due to spasm, dissection, or
wire entrapment (227). Competence in using these devices
holds sway over any established guidelines, and all of these
devices have a learning curve, not only in their placement,
but more importantly in the interpretation of the images
and then appropriately altering therapy based on the results.
Newer coronary imaging devices are being investigated
including such devices as forward looking IVUS, plaque
imaging with virtual histology, and tissue ingrowth assess-
ment using optical coherence tomography, for instance. The
proper use of all of these novel devices requires the ongoing
QI program to be involved so that proper technique is
followed and all complications are reviewed and discussed.
If the device is still under investigation, it is vital that all
local policies regarding investigational devices be followed,
and appropriate oversight by the institutional review board
at the facility be established.
4.7.1. Intracardiac Ultrasound and Doppler
Intracardiac echo cardiography/Doppler is now being used
to visualize the atrial septum during transseptal catheteriza-
tion to facilitate left-sided EP ablation studies, mitral
valvuloplasty, appendage occluder implantations, and ASD
or PFO occlude positioning. The devices have also been
used in complex myocardial biopsy procedures. Doppler
methods help define flow and are of particular value in
balloon sizing of ASD defects to detect when total occlusion
has occurred. There are no data specifically addressing the
incidence of complications related to these devices, but the
complication rate is acknowledged to be low. Known
complications include cardiac tamponade from perforation,
thrombus formation in the sheath, and air emboli. In the
face of no established guideline, competence assessment isleft to the QI process with oversight by the director of the
cardiac catheterization laboratory. Similar to all the proce-
dural methods that are used in only a small number of
patients, there is a learning curve, and there needs to be a
careful review of any complications associated with the use
of intracardiac ultrasound.
5. Postprocedural Issues
5.1. Vascular Hemostasis
The most frequent complication of coronary angiography
and coronary interventions occurs at the vascular access site.
Although careful vascular entry is essential in reducing such
complications, vascular hemostasis obtained after the pro-
cedure is a crucial component of the procedure. Methods to
achieve hemostasis include manual compression, mechani-
cal compression, percutaneous vascular suture, and staples or
clips, vascular plugs, and topical hemostatic pads.
5.1.1. Routine
In cases of femoral puncture, where a vascular closure device
is not used, it should be routine to assess the ACT value
before access-site compression following interventional pro-
cedures whenever heparin has been used. Once the ACT
has returned to near normal (180 s), sheaths can be
removed and manual pressure or mechanical pressure
clamps applied. If lytic agents have been used, prolonged
vascular compression may be necessary. The size of the
sheath roughly determines the length most patients should
be confined to bed after manual compression. A minimum
of 1 to 2 hours after the procedure for 4- to 5-F sheaths,
whereas 2 to 4 hours for 6- to 8-F sheaths is common
practice. The use of the radial or brachial artery approach
obviates the need for prolonged bed rest, but hemostasis
must still be achieved by manual or device pressure. All
patients should have the puncture site auscultated before
discharge and, if a mass is palpated and/or a new bruit
audible, then a vascular ultrasound should be obtained to
exclude a vascular pseudoaneurysm or fistula that may need
repair. Most pseudoaneurysms are now closed with percu-
taneous thrombin.
5.1.2. Use of Vascular Closure Devices
The last decade has seen revolutionary changes in the
development of vascular closure devices. Local femoral
angiography is generally performed to assess puncture site,
size of common femoral artery, and extent of atherosclerosis
and calcification in order to properly place these devices.
Although they do not decrease all complications compared
with manual compression, they have become the standard of
care in many cardiac catheterization laboratories because of
the convenience and economic pressures to reduce length
of stay. Whether they are being placed by the invasive
cardiologist or a physician extender, adequate education and
hands-on training is necessary to become consistently pro-
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results and very low complication rates. A bleeding risk
model has been developed using data from the ACC-
NCDR database. The bleeding risk score assigns points to
a variety of variables including STEMI (10 points), cardio-
genic shock (8 points), age 85 (8 points), sex (6 points),
prior CHF (5 points), age 76 to 85 (5 points), no prior PCI
(4 points), NYHA (New York Heart Association) func-
tional class IV (4 points), NSTEMI (3 points), peripheral
vascular disease (2 points), and age 66 to 75 (2 points). The
risk of a postprocedural bleed was then 0.7% for those with
7 points, 1.8% for those with 8 to 17 points, and 5.1% for
those with 18 points (136). Using similar data from the
ACC-NCDR database to test the association between the
use of bleeding avoidance strategies and post-PCI bleeding,
Romaguera et al. found some advantage to the use of both
bivalirudin and vascular closure devies (213).
The failure of these devices does occur (228), however,
and not all reviews suggest a great advantage of the vascular
closure devices in low-risk patients (229). Because of the
expense of these devices, each laboratory should systemati-
cally review whether they are being used in a cost-effective
method. In many cases, the radial approach appears to
reduce the vascular risk compared with the standard femoral
approach, and this may be an appropriate alternative (72).
An AHA Scientific Statement on the use of vascular
closure devices has been published (230). This committee
reviewed those recommendations and endorse the sug-
gestions outlined.
5.2. Medications Postprocedure
5.2.1. Pain Control and Sedation
Patients should not require substantial pain control or
sedation postprocedure. If patients have access site discom-
fort, fentanyl hydromorphone hydrochloride, or morphine
can be used. If sheath removal will require prolonged
manual or mechanical compression pain management will
be necessary. Patients who appear to be oversedated or are
not regaining appropriate level of consciousness should be
given naloxone and/or flumazenil to reverse the effects of
any narcotics or benzodiazepines they received during the
procedure.
5.2.2. Hypertension
Severe postprocedural hypertension can cause increased
vascular site bleeding complications, myocardial ischemia,
and with associated diastolic dysfunction, pulmonary
edema. Postprocedural hypertension should be managed
relatively aggressively. Patients can be given doses of their
outpatient medications and/or can be given IV doses of
antihypertensives. Hydralazine, labetalol, nicardipine, or
metoprolol are commonly used as IV push medications;
nitroglycerin infusions can be used as well. In general, the
goal BP should be 140/80 mm Hg. More aggressive
reduction in BP is not necessary. Hypertension could be asign of an overdistended bladder; therefore, placement of a
temporary Foley catheter if the patient is unable to void may
resolve the hypertension. The use of bedside bladder ultra-
sound devices may be confirmatory.
5.2.3. Vagal Complications and Hypotension
Vagal responses occur most commonly after sheath removal.
The pain, from manual or mechanical compression, gener-
ally triggers this response. Pre-medication of patients with
subcutaneous lidocaine or the use of fentanyl or morphine
prior to sheath removal may diminish vagal reactions. The
hypotension and bradycardia must be recognized promptly.
Rarely, severe vagal complications result in asystole and the
need for CPR. Treatment with boluses of normal saline
followed by a saline infusion plus the use of atropine 1 mg
IV help counteract this complication, since vagal reactions
usually include both vasodilatory and a cardiodepressor
component. Nurses who care for post-cardiac catheteriza-
tion patients must be trained to recognize this and treat it
promptly and aggressively. Vagal responses can also occur
with loss of hemostasis and abrupt hematoma and pseudo-
aneurysm formation as well as pseudoaneurysm rupture. A
retroperitoneal bleed can often be confused with a vagal
reaction and must be considered, particularly if patients are
complaining of flank pain and are not responding rapidly to
treatments. A mass may be perceived, and usually the heart
rate is increased (unless the pain has resulted in a vagal
component). In many situations, the most rapid and appro-
priate diagnostic procedure is to return to the cardiac
catheterization laboratory for contralateral access and iden-
tification of any bleeding site angiographically. Balloon
occlusion may then prevent further bleeding until a more
definitive procedure can be carried out. Abdominal noncon-
trast CT is usually definitive in assessing the presence of a
retroperitoneal bleed when there is no sense of urgency or
hemodynamic compromise.
6. Personnel Issues
6.1. Personnel
A cardiac catheterization laboratory requires a critical mass
of interdisciplinary personnel to allow safe and optimal
performance of catheterization-based procedures, including
minimum key personnel. Most of the technical staff should
be certified by the appropriate certifying body. The labora-
tory staff should meet ongoing continuing education re-
quirements for current registration and institutional em-
ployment. The following is an outline of pertinent personnel
requirements, roles, and obligations.
6.1.1. Attending Physician
The attending physician is the physician in charge of the
procedure. The attending physician is considered the pri-
mary operator for the procedure. He or she must hold a
valid medical license and be credentialed by the institution.
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performance of the procedure, including procedural indica-
tions or contraindications, preprocedural and postproce-
dural evaluation and care of the patient, and the manage-
ment of periprocedural complications. If 2 attending
physicians participate in the procedure, only 1 may be the
attending of record for the purpose of billing. Adjunct
attending physicians may be responsible for specific aspects
of the procedure, such as the performance of transesopha-
geal echocardiography or general anesthesia, and they may
bill appropriately for the additional services provided, if
these services are required for the proper performance of the
catheterization procedure.
6.1.2. Teaching Attending Physician
A teaching attending physician meets the requirements of
an attending physician in a program instructing graduate
physicians in the performance of the procedure and trans-
mission of information to the trainee physician(s). A teach-
ing attending physician must be present for all critical
aspects of the cardiac catheterization procedure, and should
be board certified or eligible. Attending physicians directly
supervising fellows in the performance of interventional
procedures should perform a minimum of 75 interventions
per year at the primary training institution and meet all
other hospital credentialing requirements for the perfor-
mance of the procedure.
6.1.3. Secondary Operators
Secondary operators are additional “attending” physicians,
physician extenders, or cardiovascular trainees who assist the
primary attending physician. These physicians may fulfill
the some of the requirements for an attending physician, but
they are not in charge of the procedure at hand and are not
considered the primary operator. Cardiology fellows are
secondary operators but may be considered supervised pri-
mary operators for the purpose of the ACGME require-
ments. Secondary operators should not take credit for the
case for the purpose of fulfilling minimum performance
volume physician requirements or for billing.
6.1.4. Laboratory Director
The laboratory director should be a physician with the
experience and leadership qualities needed to monitor and
control the laboratory environment. The director is charged
with the responsibility for policy development, quality
control, and fiscal administration. Depending on the type of
laboratory and type of patients studied, the director may be
either an adult cardiologist or a pediatric cardiologist and
may have special interests such as in interventional cardiol-
ogy or electrophysiology. The director should be an attend-
ing physician who is board certified and thoroughly trained
in cardiac radiographic imaging and radiation protection.
The director must be proficient in performing procedures
specific to the laboratory and supportive to the needs of the
operating physicians. Ideally, the director should be knowl-edgeable of all the major procedures being performed in the
catheterization laboratory; however, with emerging technol-
ogies and the evolution of subspecialty areas (e.g., labs that
offer a large range of interventional, peripheral, and EP
services), the director may necessarily collaborate with other
attending physicians for management regarding specialized
procedures. He or she must have the necessary skills to
address emergent complications.
It is the director’s responsibility to ensure the laboratory
has the equipment necessary to competently perform the
catheterization or interventional procedures, as well as the
tools and personnel required to address complications
should they occur. The director’s qualifications should
include at least 5 years of cardiac catheterization experience
and possess recognized skill in the laboratory. He or she
should be board certified in interventional cardiology if
interventional procedures are performed in the laboratory,
though exceptions may occur in special instances with
approval of the facility leadership and the credentials com-
mittee at the specific institution. Directors that have not had
time to accumulate 500 PCI cases should have a QA system
in place, as noted previously, wherein a random number of
cases are reviewed by a large-volume PCI center. This
should be on a continuing basis until the minimum 500 PCI
cases have been satisfactorily achieved and competence
established.
For centers with cardiovascular, interventional, or EP
fellowship training programs, the catheterization laboratory
director must work in collaboration with the training
program director (if different) to assure the proper training
and supervision of the trainees. The interventional program
director must also be board certified in interventional
cardiology. This assures that the laboratory provides an
environment conducive to teaching the requisite knowledge
and skill sets, and that teaching attending physicians meet
the volume and professional standards necessary to qualify
them as educators.
The director is responsible for a wide range of personnel
management. The director shall set criteria for granting
privileges to physicians and then review and make recom-
mendations about applications for those privileges. The
director must periodically review physicians’ performance,
make recommendations for renewal of laboratory privileges,
review performance of trainees and nonprofessional staff,
and provide necessary training to personnel. The director
shall establish and monitor quality control, including mor-
bidity and mortality, and program and policy development,
including incorporation of guidelines and defining monitor-
ing plans for guideline compliance. He or she must be an
active proponent of a CQI and QA program for the
laboratory, as established earlier in this document.
In addition, the director should have the responsibility of
advocating and ensuring adequate healthcare resources (de-
vices, equipment, and supportive personnel) for the cathe-
terization laboratory. Necessary emergency equipment must
be available in the lab. Other important equipment might
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tion technology resources, integrated imaging resources,
nurse or technical specialists, diagnostic technology, point
of care testing, patient transport resources, or other health-
care resources.
The director must work in collaboration with the insti-
tution (including occupational and radiation safety) and
with a qualified medical or health physicist to ensure
personnel safety and compliance regarding the use of x-ray–
generating equipment, including compliance with local
regulations and laws. This includes advocating for adequate
radiation safety training and protective equipment for cath-
eterization laboratory personnel, patient and personnel
monitoring for radiation exposure, and a system to address
occupational exposures and injury.
The duties and responsibilities of the director are thus
multiple and wide-ranging and demand strong management
skills. The role should be appropriately compensated by the
hospital, group, or health system in charge of the laboratory
as these responsibilities are always in addition to other
clinical duties. Adequate time should be provided along
with adequate financial compensation.
Other responsibilities include oversight of patient sched-
uling, referral services, postprocedure reporting and tracking
of quality measures (including complications), establishing
quality improvement programs, procurement and mainte-
nance of equipment and supplies, budget preparation and
monitoring, organization of regular conferences for labora-
tory personnel, and regular reports on laboratory activity.
The director shall maintain communication and coopera-
tion among laboratory staff, clinicians, and the hospital
administration to ensure that the patient is best served. The
director must designate a substitute who will act in his or
her absence.
6.1.5. Operating Physicians
All physicians credentialed to operate in the catheterization
laboratory must have proper training and meet all creden-
tialing requirements for the facility. This includes those
classified as the attending physician and those functioning
as teaching attending or secondary operators. This training
may be in adult or pediatric cardiology. Clinical training in
any of these fields should fulfill requirements for that
specialty board and preferably from an ACGME-certified
program. The physician should be deemed competent to
perform the procedures by the program director of his or her
training institution. A laboratory physician should be a fully
accredited member of the hospital staff and ideally be
specialty certified or have completed formal training in the
area he or she practices. An operating physician who
provides only laboratory service without being a full member
of the hospital staff should not be the attending of record.
The physician must also be trained in general emergency
and critical care, which includes a minimum of current
advanced cardiac life support certification. This should also
include training and competence in emergency scenariosthat commonly occur in the specific procedural setting
(diagnostic or interventional). Operating physicians must
also be trained in patient and staff radiation safety, and meet
the institutional standards for the operation of fluoroscopic/
x-ray equipment that pertains to the procedures performed.
Finally, the physician should meet the institutional require-
ments for the administration of conscious sedation. Oper-
ating physicians must participate in the laboratory’s QA
program, including peer review. Physicians performing
electrophysiological procedures should have completed
formal training or be certified in electrophysiology. The
performance of complex electrophysiological procedures,
such as atrial fibrillation ablation, requires additional
training and experience, and the credentials committee
must certify anyone contemplating these procedures is
adequately trained.
6.1.5.1. CARDIOVASCULAR TRAINEE (FELLOW)
The primary role of the cardiovascular trainee is to obtain
the cognitive knowledge and technical skills necessary to
competently perform cardiac catheterization procedures.
This includes the indications, contraindications, and limi-
tations of the procedures; pre- and postprocedure patient
care; analysis, interpretation, and reporting of hemodynamic
and angiographic data; and management of complications
related to procedure performance (111). Combined with the
core training that occurs within a cardiovascular training
program, trainees obtain the critical skills necessary to
become qualified attending physicians. Trainees may per-
form all functions of the procedure as the primary operator
would, but only under the direct supervision of a creden-
tialed attending physician who assumes responsibility for
the procedure. In this capacity, the use of house staff not
directly engaged in a formal cardiovascular training program
is inappropriate. Outlines for current volume recommenda-
tions for the various levels of training are addressed in
Tables 17 and 18.
6.1.6. Use of Physician Extenders
(Physician’s Assistants and Nurse Practitioners)
Increasingly, “physician extenders” (e.g., physician’s assis-
tants and nurse practitioners) are being used clinically as
patient care assistants in the provision of medical services
within the field of cardiology. In regard to cardiac catheter-
ization and intervention, trained and credentialed physician
extenders may perform preprocedural evaluation and post-
procedural follow-up of cardiac catheterization patients. In
some medical centers, specially trained and qualified physi-
cian extenders may have an expanded role to assist the
physician with the invasive or interventional procedure itself
(231).
It should be recognized that extenders can never be
primary operators and should work only under the direction
of an attending cardiologist. The physician extender should
be proficient in both the technical and cognitive aspects of
cardiac catheterization, including 1) preprocedural evalua-
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ology; 4) emergency cardiac care; 5) radiation safety; and
6) application of diagnostic catheterization data regarding
the procedure.
The primary operating physician must be in the cathe-
terization suite during the procedure when secondary oper-
ators are performing the procedure and direct the physician
extender as well as provide all clinical decision making.
Specially trained nurses/nurse practitioners may assist at-
tending physicians in much the same role as physician’s
assistants in the performance of procedures. They may be
able to assist in place of cardiovascular trainees, but they
require even greater supervision during all aspects of the
procedure.
6.1.7. Nursing Personnel
The type and number of nursing personnel required in the
catheterization laboratory depend on the laboratory caseload
and types of procedures performed. This support group may
include nurse practitioners, registered nurses, licensed voca-
tional or practical nurses, or nursing assistants. In most
laboratories, the laboratory supervisor is a registered
nurse. This nurse must be familiar with the overall
function of the laboratory, have strong management
skills, help set the tone of patient surroundings, and
influence the efficiency and safety of procedures. The
nurse supervisor may also directly participate in observa-
tion and nursing care of the patient during catheteriza-
tion and should be ready to respond to any emergency.
The nursing supervisor should be in charge of the
preprocedure and postprocedure holding areas. Although
variation exists among institutions, in general, the nurse
supervisor should ensure that institutional guidelines for
patient monitoring, drug administration, and protocols for
patient care (including protocols for handling potential
complications) are established, and that all catheterization
laboratory nurses are properly trained) for the level of
patient care that they deliver. The nurse manager, in
collaboration with the hospital pharmacy and other clinical
managers, should work to ensure appropriate medications
are immediately available for administration in the cathe-
terization laboratory, particularly those needed in emer-
gency situations. In laboratories in which nursing personnel
administer conscious sedation (under physician direction
but in the absence of an anesthesiologist), the training,
qualifications, and safety of conscious sedation should be in
accordance with hospital policy, with compliance monitor-
ing by the nurse supervisor.
The background of a catheterization laboratory nurse
preferably includes critical-care experience, knowledge of
cardiovascular medications, the ability to start an IV infu-
sion and administer drugs, and experience in sterile tech-
niques. Ideally, there should be some formal training,
though certification programs have yet to be a prerequisite.
The committee would endorse a movement toward such
certification measures. Experience with vascular catheterinstrumentation, especially with identification, cleaning,
sterilization, and storage, is helpful and should be part of
training. Knowledge of vascular catheter materials and the
proper catheter size, appropriate guidewire, and adapters is
also valuable. Some familiarity with the manipulation of
manifolds, injection of contrast, and changing of guidewires
and catheters is important. The catheterization laboratory
nurse must have a thorough understanding of the flushing of
catheters and syringes to prevent clots or air emboli. The
nurse in the catheterization laboratory must also have
essential skills to monitor the patient’s vital status, including
BP, heart rate, oxygenation, general neurological function,
and pain. For nurses administering conscious sedation,
institutional training and guidelines for patient monitoring
and drug administration protocols must be followed. A
nurse with the primary responsibility of the patient should
be able to assist in acute cardiac care, including resuscitation
and related therapeutic efforts.
A licensed practical nurse with the proper background
and experience may have duties similar to those of the
registered nurse. However, a licensed practical nurse should
not supervise laboratory nursing. In some laboratories, an
appropriately trained nursing assistant may be responsible
for some duties. The nursing assistant may be a cardiopul-
monary technician who is familiar with procedures in
associated disciplines and is thereby able to function in the
dual capacity of cardiopulmonary technician and nursing
assistant.
Nursing personnel (registered nurse or licensed practical
nurse), when properly trained, can manage blood samples,
perform point-of-care testing (such as ACTs), and perform
blood gas measurements and saturations. In addition, team
training on simulators, especially for rarely done or more
complex procedures, may help ensure an understanding of
the optimal techniques and management issues.
6.1.8. Non-Nursing Personnel
Several kinds of technical knowledge are required in the
cardiac catheterization laboratory, and a single person may
not possess all the different types of technical expertise. At
least 1 technologist, preferably a certified radiological tech-
nologist, should be skilled in radiographic and angiographic
imaging principles and techniques. This technologist should
be experienced in the proper performance of x-ray genera-
tors, cine pulse systems, image intensification, pressure
injection systems, video systems, cine and digital imaging
and storage, and radiation safety principles. He or she, in
cooperation with electronic and radiological service engi-
neers, should be responsible for routine care and mainte-
nance of the radiological equipment. A basic ability to
troubleshoot this equipment is advantageous. This technol-
ogist, in cooperation with a qualified medical physicist,
should monitor radiation safety techniques for both patients
and laboratory personnel. Immediate availability of a radio-
logical engineer in the event of equipment failure is highly
desirable. The technologist, with the service engineers and
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quality while limiting radiation exposure to staff and pa-
tients. This technologist may also assist with the data
storage and report generation system.
Each laboratory should also be reviewed and managed by
a qualified medical physicist in order to provide appropriate
teaching, to ensure optimal monitoring equipment is being
used and to assist with the actual monitoring of radiation
exposure to patients and laboratory personnel. A program of
radiation safety should be in place in every cardiac cathe-
terization laboratory.
Laboratory technologists should be skilled in managing
blood samples, and performing blood gas measurements and
calculations. They should be qualified to monitor and record
electrocardiographic and hemodynamic data and have
enough skill and experience in interpreting these data to
report significant changes immediately to the physician
responsible for the patient. During any single procedure, the
monitoring technician or nurse must have no responsi-
bility other than monitoring and observing patient status.
It is encouraged that during each procedure at least 1
technologist (and/or physician) should be skilled in
radiographic and angiographic imaging techniques. In
facilities performing interventions, other equipment re-
lated to imaging, diagnosis, and treatment is generally
available. This ancillary equipment necessitates at least 1
available technologist within the laboratory to be profi-
cient in the equipment use, maintenance, and general
troubleshooting. These technologies may include the use
of digital subtraction angiography, intracoronary ultra-
sound, FFR or Doppler coronary velocity, intracardiac
echocardiography, optical coherence tomography, atherec-
tomy, rotational atherectomy, angioscopy, intra-aortic bal-
loon counterpulsation, and percutaneous mechanical cardio-
pulmonary support devices. In addition, an increasing
number of laboratories, particularly those performing EP
procedures, are integrating noninvasive imaging directly
into the catheterization lab suite for use during the invasive
procedure. The technologist should be familiar with these
multimodality integrative technologies so as to be able to
help troubleshoot when issues arise.
For technologists participating directly in patient care,
skills are necessary in patient preparation and for assistance
in acute cardiac care, including resuscitation and related
therapeutic efforts. Technologists at diagnostic and inter-
ventional labs should be trained in the sterile techniques as
well as emergency procedure (basic and preferably advanced
cardiac life support) and in the use of onsite equipment,
such as intra-aortic balloon counterpulsation and temporary
transvenous pacemakers, defibrillators, and mechanical car-
diopulmonary resuscitative vests if these are available. Tech-
nologists often directly assist the primary operator with the
procedure.
A technician with expert computer skills is a very valuable
addition to the team to assist with the handling of image
transfer methods and archival storage devices, image com-pression, and to maintain the digital libraries. Because of the
complexity of digital archival storage and database manage-
ment many catheterization laboratories will also require
dedicated information technology support.
On occasion, additional administrative personnel may
assist in the optimal functioning of the cardiac catheteriza-
tion laboratory. Such personnel may include a dedicated
case manager, scheduler, inventory manager and related
staff, compliance monitor, and database or administrative
staff for CQI and QA. In addition, some laboratories have
dedicated employees that apply groin compression devices
and report follow-up groin and other complications.
6.2. Staffing Patterns
A credentialed attending cardiovascular physician must
be present in the laboratory during each procedure and
must be responsible for the outcome as the primary
operator. To maintain effective and safe laboratory oper-
ation, each basic support function should be performed
by adequately trained personnel who constantly maintain
their skills and credentials. There should be adequate
cross-training among laboratory staff so that personnel
can rotate responsibilities and provide 24-hour coverage
of essential team functions.
Complex studies, especially those of children and acutely
unstable patients, require personnel with special training. In
complex cases and procedures, the presence of a second
physician may be needed for optimal care. The requirements
for a full-service facility are listed in Table 2.
6.3. Cardiopulmonary Resuscitation
All members of the catheterization team (physicians, nurses,
and technologists) should complete a basic course in CPR.
Certification in advance cardiac life support is also strongly
urged, especially for all members that are part of the actual
procedure. Recertification is to be expected every 2 years.
7. The Hybrid Cardiac
Catheterization Laboratory
7.1. Overview and Patient Selection
The hybrid cardiac catheterization/operating room repre-
sents an integrated procedural suite that combines the tools
and equipment available in a catheterization suite with
anesthesia facilities and sterility of a fully equipped operat-
ing room. A key feature is that the suite meets all the
standards of an operating room as well as all the standards
of a catheterization laboratory. Although the hybrid suite is
designed to meet the needs of an increasingly complex
patient population, it also serves as a platform for collabor-
ative work between subspecialists. In some hybrid suites,
operators can perform cardiovascular procedures ranging
from the most straightforward PCI to aortic arch recon-
struction. As a result, different teams across different sub-
specialties can benefit from the hybrid suite.
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ing equipment that has greater resolution and better
image storage capacity compared with mobile C-arms
previously used in some operating rooms. Higher-quality
imaging is required for many new techniques such as
hybrid coronary stenting and CABG and percutaneous
aortic valve placement.
Hybrid suites must also meet the strict environmental
standards of state-of-the-art open operation rooms to re-
duce the risk of wound infection associated with surgical
cut-down for vascular access, large prosthetic devices (e.g.,
valves and stent grafts), and open cardiac surgical proce-
dures. These standards include a closed environment, traffic
control specifications, specific HVAC requirements, the
availability of vacuum equipment, and structural designs to
promote a sterile environment. Because many will be placed
in the traditional cardiac catheterization suites, special
attention to converting a portion or all of the catheterization
area into a sterile environment is often required.
Procedures best suited for the hybrid laboratory include
those where surgical vascular access is required for large
endovascular devices that are deployed using high resolution
imaging (e.g., percutaneous aortic valves or aortic stent
grafts), where conversion to open surgery may be required if
endovascular procedures are unsuccessful (e.g., aortic stent
grafts), or for hybrid treatments such as PCI with minimally
invasive valve or CABG (Table 21).
Table 21. Examples of Procedures for a
Hybrid Catheterization Laboratory
Surgical vascular access required for large endovascular devices
Percutaneous aortic valves
Thoracic and abdominal aortic stent grafts
Large-bore percutaneous ventricular assist devices
Conversion to an open surgical operation may be required
Percutaneous aortic valves (apical approach or bailout)
Thoracic and abdominal aortic stent grafts
Percutaneous ventricular septal defect closure
Hybrid treatments
Combined percutaneous coronary intervention and minimally invasive or
open coronary bypass grafting
Combined percutaneous coronary intervention and minimally invasive
cardiac valve surgery
Combined iliac stenting and distal bypass grafting
Endomyocardial/epicardial atrial fibrillation ablation
Apical access to assist in percutaneous closure of paravalvular leaks
Electrophysiology device placement
Implantable defibrillators
Temporary rhythm recorders (e.g., loop recorders)
Removal of pacemaker leads
Emergency procedures
Extracorporeal membrane oxygenation
Emergent thoracotomyModified with permission from Hirsch (232).7.2. Special Considerations
7.2.1. Staffing
The hybrid laboratory must serve as both a surgical suite and
cardiac catheterization laboratory facility. The operation can
only be done properly if there is a team approach, with each
team member contributing differing expertise. As a gener-
ality, a specific team of nurses, technicians, and clinical staff
familiar with the room and the goals of the procedure being
performed is necessary for optimal care. These staff should
be selected and trained for use in this room rather than
rotating individuals unfamiliar with the stringent sterile
requirements and diverse nature of the procedures to be
performed. As each institution will use the hybrid room for
different procedures, a definitive staffing pattern is facility-
and procedure-dependent. Laboratory staff must understand
there can be no compromising either the surgical procedure
or the cardiac catheterization if the laboratory is to be used
safely and effectively.
7.2.2. Location
The location of the hybrid suite is related to the availability
of space and to the training and experience of those who will
primarily use the facility. Some are located in the cardiac
catheterization (232) or interventional suites, while others
are upgraded operating rooms (233,234). Ideally, the hybrid
suite would be located in a single cardiovascular procedural
area, where standard catheterization laboratories are in the
same general area as open heart surgical suites, so that the
people (cardiologists, surgeons, catheterization technicians,
operating room technicians, perfusionists) and equipment
(catheters, stents, cardiopulmonary bypass, perfusionist
equipment, surgical equipment) are readily available for all
conventional catheterization laboratories, operating rooms,
or hybrid suites.
Hybrid suites are designed to maximize sterility and
conform to operating room guidelines that may differ state
to state. These include laboratories located off a clean core
or semirestricted corridor where staff are required to wear
scrubs, hats, and masks. Scrub alcoves are located outside
the hybrid laboratory with a window into the laboratory to
observe patient and staff movement. A separate control
room with wide windows permits technicians to observe the
procedure and assist running the x-ray equipment without
jeopardizing the sterility of the hybrid room. Alternatively,
a monitor station can be used within the hybrid suite. Audio
and video monitoring assists communication between op-
erators and other staff (see Section 7.2.8).
Although design standards for hybrid catheterization
laboratories are evolving, operating room standards serve as
a guide for hybrid suites. Veterans Affairs standards suggest
cardiac surgical operating rooms be a minimum of 65 m2
(700 ft2), with an upper limit for special purpose operating
ooms being 75 m2 (800 ft2) (235). Given the extra space
requirements for x-ray imaging, anesthesia equipment,
the additional staff and equipment compared with con-
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ing rooms, 70 m2 (750 ft2) may be a reasonable minimum
guideline for the hybrid suite. We believe that 90 m2
(1,000 ft2) will provide the needed space for safe perfor-
ance of hybrid procedures.
.2.3. Room and Floor Design
alls and flooring should generally follow seamless designs
revalent in operating rooms to avoid joins and cracks that
ay trap blood and other body fluids that can form a nidus
or bacterial growth.
The hybrid laboratory requires x-ray shielding on walls
nd doors and a structure that is able to support the weight
f the x-ray equipment. Floor trenching is required to run
quipment infrastructure such as cable and conduit from the
ontrol room and the table to the C-arm.
Power outlets should include a range of high-voltage
utputs (e.g., for laser catheters and cardiopulmonary by-
ass), regular-voltage outputs, and emergency (backup)
ower outlets. These should be distributed on the walls,
rom pull-down columns, and under the table (235).
Each room should have wall-mounted video monitors
onnected to the appropriate PACS server to call up CT,
RI, and other x-ray reference images. Because hybrid
rocedures usually require constant reference to multiple
maging modalities (e.g., angiography, ultrasound, FFR) as
ell as hemodynamic monitoring (e.g., indirect and direct
rterial pressure, heart rate, electrocardiogram, oxygen sat-
rations), these should be displayed simultaneously on
ultiple monitors or a large flat screen mounted on a
ovable ceiling-mounted boom adjacent to the table.
.2.4. Ceiling Lighting and Design
n general, dim lighting is used in catheterization proce-
ures to help view the images on the monitors. However,
urgical operations use bright lighting that includes fixed
eiling fluorescent lights and movable ceiling mounted
urgical lights. Therefore, the hybrid room needs a range of
exible lighting options to accommodate the needs of x-ray
uidance and the operative stages of a procedure.
Many new hybrid suites use a ceiling-mounted (rather
han floor-mounted) C-arm gantry. Ceiling mounted
-arms can be moved further away from the table during
urgical procedures and are arguably easier to clean as they
re less likely to have crevices where blood or bacteria can
ccumulate. However, ceiling mounted C-arms have tracks
hat protrude over the table, and track placement must not
nterfere with lighting or with laminar airflow. The C-arm
eeds to move in and out of the operating field and allow
ngulations (cranial–caudal and oblique angles) without
nterfering with anesthesia needs. Some operators prefer
oor-mounted C-arms despite these issues.
In general, the mounts for the surgical lights are not
irectly over the table as this zone is preserved for the supply
ir outlet. However, these need to avoid the ceiling track of
he C-arm and not interfere with angulations of the C-arm. sifty percent of fluorescent lighting should be on emergency
ower with battery backup (235). Dimmable recessed light-
ng is distributed around the ceiling over the table for the
-ray procedure.
.2.5. Anesthesia Requirements
eneral anesthesia requires greater space at the head of the
able for staff and equipment compared with conventional
ardiac catheterization laboratories. This area should have
edicated medical gas supplies (vacuum, medical air, nitro-
en, nitrous oxide, oxygen, and waste gas lines)... similar to
n operating room, and space for the transesophageal
chocardiography. Inventive solutions include incorporating
hese equipment into movable ceiling booms so that they
ay be moved in and out of place as needed (232).
onitoring cables and other equipment should be radiolu-
ent if at all possible.
.2.6. HVAC Standards
VAC should meet operating room standards for the
umber of air exchanges per hour, laminar air flow over the
perating table, positive air pressure, and optimal tem-
erature and humidity (235). The hybrid laboratory
hould have thermostat and humidistats for recording
emperature and humidity.
.2.7. Table Requirements
he surgical table needs to meet the individual require-
ents of interventional cardiologists, surgeons, and their
eams. Surgeons need a fully motorized table and table-
op. In special circumstances (such as performing an
ortic valve replacement), often the best position is to
ave the patient “sitting up,” in reverse Trendelenburg,
ith the head up to 30° from the horizontal. The
nterventional cardiologist requires a radiolucent table
ith a full range of motion and a floating tabletop to
llow fast movements during angiography. Both require-
ents are satisfied by a nonmetallic, carbon-fiber surgical
able, with floating table-top and lateral and vertical tilt
234). Most tables designed for hybrid suites include in
heir specifications adequate weight tolerance (e.g., over
50 lb), longitudinal and lateral displacement, height
isplacement (e.g., 28 to 48 inches [685 to 1180 cm]),
ateral tilt (e.g., 20° or more), and Trendelenburg and
everse Trendelenburg tilt (20° or more). The table can be
ositioned horizontal or diagonal in the room, depending
n the size of the hybrid suite and the location of
ncillary equipment.
.2.8. Audio Video Inputs and Outputs
s procedures in a hybrid laboratory may involve many
perators, audio and video monitoring may help to orientate
nesthesia staff, staff in an adjacent control room, or those
utside the sterile field. It may also provide an opportunity
o educate staff and students without them entering the
terile zone around the table. Multiple video cameras that
2279JACC Vol. 59, No. 24, 2012 Bashore et al.
June 12, 2012:2221–305 Cardiac Catheterization Laboratory Standardsare remotely operated with zoom function may be mounted
on a wall, the x-ray monitors, or the surgical light handle.
Key operators may choose to wear microphones and head-
sets to request equipment or to inform or receive requests
from other team members (232).
7.3. Representative Procedures Suitable to the
Hybrid Room Environment
Table 21 outlines some of the types of procedures that may
benefit from the use of a hybrid cardiac catheterization
laboratory.
8. Ethical Concerns
A physician’s primary obligation is to act in the best interest
of his or her patient. Associated with this is the obligation
to “do not harm,” and respect patient autonomy (236–238).
The respect for autonomy mandates that patients be given
appropriate and uncoerced choices about their health and
potential medical care and requires that physicians provide
accurate and unbiased information about the patient’s med-
ical condition, and disclose all potential avenues of care. The
physician is responsible for obtaining satisfactory informed
consent, and delineating the potential risks, benefits, and
alternatives of the agreed-upon diagnostic and/or therapeu-
tic strategy (236). The physician is responsible for docu-
mentation of the indication for the procedure and to
document review of appropriate data (e.g., noninvasive
tests). In addition, the physician must be transparent con-
cerning any and all potential ethical or financial conflicts
concerning therapies or devices employed in the patient’s
care.
Changing practice patterns in medicine, including the
increased pressure for productivity from practice and hos-
pitals due to declining reimbursement, and other non-
monetary factors (academic promotion, etc.) have altered
the relationships among physicians, patients, and payers,
creating potential conflict of interest in maintaining the
patient’s best interest (237,239,240).
Physicians may now serve simultaneously as physician,
inventor, and investigator of new therapies for vascular
intervention. Similar issues exist with respect to the conduct
of clinical research, in which the patient may be encour-
aged to participate in clinical protocols that may lead to
little personal benefit (and potential risks), by physicians
who may have a direct or indirect financial interest in
their participation (112,239,241). This practice cannot be
condoned.
8.1. Operator Assistant’s Fees, Sharing of Fees,
Fee Splitting, and Fee Fixing
There has been close scrutiny by third party payers and
the federal government of the ethical (and financial)
relationships between the referring physicians and the
interventional cardiologist. Although some procedures may
be optimal with the participation of 2 operators (e.g.,percutaneous mitral repair, percutaneous aortic valve re-
placement, complex coronary procedures, or pediatric inter-
vention), it is only ethical and legal for a cardiologist to
charge an operator assistant’s fee when he or she has directly
participated in the procedure and was necessary for the
performance of the procedure. Only 1 may be the primary
attending physician as noted earlier. Furthermore, offering
or providing a shared fee with another physician for the
performance of cardiac catheterization is unethical and
illegal.
It is also not ethical for a cardiologist to receive an
admission fee, referral fee, or other “kickback” or commis-
sion for admitting or referring a patient to a hospital or
cardiac catheterization facility (242). This principle applies
not only to fees, commissions, and compensation received
from other physicians and hospitals, but also to those
received from manufacturers of catheters, medications, in-
struments, devices, or supplies that may be used in the
catheterization laboratory. Great care must be exerted to
avoid procedural incentives, as more and more cardiologists
become employees of healthcare systems and hospitals, and
incentives for increased productivity may be construed as
violating the principles behind the Stark laws. Furthermore,
such collusion may be illegal when such arrangements
involve Medicare funds and are construed as inducement for
referral. Collusion with other cardiologists in an attempt to
fix fees for catheterization services may also violate antitrust
laws.
8.2. Unnecessary Services
Duplication of services with additional charges or perfor-
mance of unnecessary procedures or add-on procedures
(right-heart catheterization, temporary pacemaker inser-
tion) without specific indications and documentation of
those indications is unethical and potentially illegal. A
charge to over-read data by a physician who has not
performed the procedure is also an unnecessary duplication
of services and fees (241).
The overuse of tests as a means to protect providers from
medical malpractice is an issue that needs further examina-
tion. Any unnecessary testing is discouraged and may place
the patient at unnecessary risk as well as incurring unnec-
essary cost.
8.3. Self-Referral, Self-Ownership,
and Self-Reporting
Physician self-referral is the practice of a physician referring
a patient to medical facility in which the physician or an
immediate family member has a financial interest. That
interest may be in the form of ownership, investment, or like
compensation (237,239,243–246). In response to the sug-
gestion that self-referral unnecessarily increases the cost of
medicine by overutilization of services, the Stark Laws were
introduced. Stark I was introduced into law in 1989 (Om-
nibus Budget Reconciliation Act of 1989) (246a) and
prohibited self-referrals of services of Medicare beneficiaries
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expanded to include Medicaid beneficiaries in 1993 and
extended in 2007 (246b).
Critics of physician-owned facilities, whether hospital or
laboratory, consider them a source for overutilization and
unnecessary increase in the cost of medicine, whereas
backers of physician-owned facilities point out that individ-
ual procedures are cheaper, and there is a significant
convenience for the patient.
A provision in the recently enacted health reform law
(Patient Protection and Affordable Care Act of 2010) now
places major limits on physician ownership of hospitals
(246c). New doctor-owned facilities that are not certified as
Medicare participants by December 31, 2010, no longer will
be allowed into the program. Existing physician-owned
facilities are currently being reconsidered and debated and
may face restrictions on expansion.
8.4. Informed Consent
Informed consent is a legal procedure to ensure that a
patient knows all of the benefits and risks involved in a
treatment. The elements of informed consent include in-
forming the client of the nature of the treatment, possible
alternative treatments, and the potential risks and benefits of
the treatment. The patient should be informed of the
experience of the primary operator responsible for the
procedure. In order for informed consent to be considered
valid, the patient must be competent and the consent should
be given voluntarily. In the absence of a patient’s ability to
understand or give informed consent, a person holding
power of attorney may act as a surrogate.
Patient autonomy mandates that informed consent be
obtained before performance of any invasive diagnostic or
therapeutic cardiovascular procedure. Informed consent is
an “ongoing process,” and the education can be presented by
any of the personnel involved in the procedure and may
involve the use of written or video material, as well as
traditional oral explanation. Although, there may be multi-
ple people involved in obtaining informed consent, the
physician is responsible for presenting him/herself to the
patient and family and for the consent process. Informed
consent must include an accurate description of the proce-
dures, benefits, risks, and potential complications. Although
not every eventuality can be predicted, it is adequate to
present the common and usual risk and complications. The
risks and complications must be presented accurately and
must not be understated. They must be presented at a
communication level that the patient and family can under-
stand. If a physician extender (e.g., physician’s assistant or
nurse practitioner) or cardiology trainee is to perform any
part of a procedure, this should be stated. If an “ad hoc” PCI
procedure is anticipated immediately after a diagnostic
procedure, then consent for this should be done prior to any
sedation for the diagnostic procedure.
Informed consent must be obtained in a nonpressured
environment when possible, but in situations (such asprimary PCI for AMI) it is recognized that the environment
may not allow a leisurely description, but nonetheless must
be complete. Written informed consent should be obtained
and documented in the medical record before the procedure.
Frequently, interventional procedures are performed as ad
hoc procedures where the intervention immediately follows
the diagnostic procedure. Ad hoc angioplasty has several
inherent advantages; it expedites patient care, avoids a
second invasive procedure with its associated risks and
recognized morbidity, and reduces total x-ray exposure and
therefore cost. However, it is associated with a larger
volume of procedural contrast and ideally requires interven-
tional pretreatment. A staged procedure allows ample time
to review the angiogram; plan the procedural strategy;
discuss the risks, benefits, and alternatives with the patient
and family; and give informed consent based on the anat-
omy. Previous documents (110) have endorsed the recom-
mendations from the SCAI (247) that ad hoc PCI be
individualized and not be the standard or required strategy
for all patients. Whenever there is a medical advantage to
staging the procedures, this should be strongly considered.
The convenience and cost advantage of ad hoc procedures,
however, has made this practice commonplace and perfectly
appropriate for most situations. The European Society of
Cardiology has emphasized the importance of engaging the
patient in any decision regarding an interventional proce-
dure and making sure the patient has the final decision
when there are several therapeutic options with no clear
evidence for a particular strategy over another (248).
8.5. Ethics of “Teaching”
Although teaching hospitals have been essential to medical
training for decades, patients admitted to a “teaching”
hospital have a right to be aware of the level of training of
the various physicians and related personnel involved in
their care. It is ethical for the cardiologist to delegate the
performance of certain aspects of the procedures to assis-
tants, such as physician’s assistants or fellows, providing that
this is done transparently with the patient’s consent and
under the attending physician’s supervision. Fellows or
physician’s assistants, if qualified, can also perform certain
components of the invasive procedures, provided that they
are supervised at all times by the attending cardiologist. It is
not ethical to delegate the entire responsibility of invasive
procedures to anyone not appropriately experienced and
properly trained in the performance of the procedure. The
attending physician must be responsible for all major deci-
sion making and must physically be present during all the
critical points in the procedure.
8.6. Clinical Research Studies During Diagnostic
and Interventional Cardiac Catheterization
An increasing number of teaching and community hospitals
participate in clinical research protocols. Local institutional
review boards now require a higher standard of disclosure
for research studies than that required for clinical practice.
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to participate in clinical research to ensure that all questions
have been addressed. Research studies should not increase
the risk of major complications disproportionally to the
possible benefit when combined with diagnostic catheter-
ization and interventional procedures. The investigative
procedure should be performed after the essential informa-
tion has been obtained if possible, but only if the patient’s
condition is stable and the diagnostic procedure has been
performed in a timely fashion. Research procedures per-
formed during the catheterization must be reviewed and
approved by an institutional review committee.
Safeguards for ensuring that patients are appropriately
enrolled in clinical research trials are as follows: that the
clinical investigator has thoroughly reviewed the protocol
for its scientific validity; the patient has met all the inclusion
criteria and none of the exclusion criteria; the patient has
been fully informed about the risks, benefits, and alternative
therapies; and the clinical investigator follows the clinical
protocol without unjustified deviation. In fact, most clinical
investigators are ethical individuals whose motivations are to
further scientific knowledge. Strict adherence to the clinical
protocol is the best assurance that conflicts of interest will be
minimized.
Although many challenges face cardiologists today, high
ethical standards, including maintenance of proficiency,
avoidance of real or perceived financial conflict of interest,
disclosure of potential conflicts, and, most important, main-
taining the patient’s best interest as primary, remain of
paramount importance. Only with attention to these issues
will our profession continue to be viewed by the public (and
our patients) as trustworthy and deserving of their respect.
8.7. Physician– and Physician Group–Industry
Relations
Physicians and industry have a common interest in advanc-
ing medical knowledge. Nonetheless, the primary goal of
the physician is to promote the patient’s best interests,
whereas promotion of profitability is a goal of industry.
Although partnerships between physicians and industry can
result in impressive medical advances, they also create
opportunities for bias and can result in unfavorable public
perceptions even if unintended. Accepting industry hospi-
tality and gifts, even drug samples, can compromise judg-
ment about medical information and subsequent decisions
about patient care. It is unacceptable for physicians to
receive gifts from industry. Physician–industry conflicts of
interest can arise from other financial ties between physi-
cians and industry, whether to outside companies or self-
owned businesses. Such ties include honorariums for speak-
ing or writing about a company’s product, payment for
participating in clinic-based research, and referrals to med-
ical resources. All of these relationships have the potential to
influence a physician’s attitudes and practices (249). Exces-
sive fees for speaking on behalf of industry or for participa-
tion in advisory boards are to be avoided. Most institutionshave in place well-defined conflict of interest statements
where gifts and income of even a modest amount from
outside the respective institution are reported, and then
reviewed by disinterested parties (usually a conflict of
interest committee). These can then be judged whether
appropriate. It is the responsibility of each physician to
honestly and completely report such gratuities, honoraria, or
income to these governing bodies.
Similarly, providers of medical education to interested
groups of medical personnel have a duty to present objective
and balanced information and should not accept any funds
that are tied to industry-shaped programming. Medical
educators have the sole responsibility to evaluate and control
the planning, content, and delivery of education. They
should disclose industry sponsorship to medical education
participants and should adopt explicit organizational poli-
cies about acceptable and unacceptable interactions with
industry (250).
8.8. Hospital Employment of Physicians
With wholesale changes in the U.S. healthcare system
occurring currently, many cardiologists are being targeted to
become employees in an effort to control costs. Physicians
should never compromise patient care nor perform unnec-
essary procedures to satisfy a corporate or hospital “expec-
tation.” All decisions regarding the delivery of care should
be focused on providing better patient results and not
corporate profits.
9. X-Ray Imaging
Significant qualitative and quantitative changes in x-ray
systems have transpired since the previous ACCF/SCAI
consensus document on Catheterization Laboratory Stan-
dards published in 2001 (2). The qualitative changes reflect
the migration to digital image acquisition, processing, and
archiving, whereas the quantitative changes reflect the
extent of market “penetration” of these digital systems.
Consequently, the following discussion will be limited to
significant advances in the field since the 2001 publication.
Details of analog and digital imaging chains can be found in
previous ACCF/AHA documents (1,251), past proceedings
of the SCAI Melvin P. Judkins Imaging Symposia, NCRP
Report 168 (252), as well as classic textbooks on the subject
(253,254).
Continuing improvements in gantry design, ergonomics,
and room layout belie the fundamental use of this equipment
in the contemporary cardiac catheterization laboratory—the
performance of potentially high-dose, fluoroscopically
guided interventions. In 2000, the International Electro-
technical Commission published an interventional stan-
dards document in which a number of key technical and
performance criteria were delineated (255). These standards
were updated in 2010 (255). These standards are the basis of
many of the FDA legally enforceable regulations (256).
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date, and designated for the purpose of high-dose, fluoro-
scopically guided interventions, must demonstrate compli-
ance with these criteria. Additional criteria were added by
the FDA in 2005 for all such units manufactured after that
date (257). A number of these criteria are discussed below,
but it is important to point out that some portions of these
standards are not applicable to simple mobile gantry sys-
tems. Any x-ray unit used for high-dose, fluoroscopically
guided cardiovascular interventions should be compliant
with the IEC interventional standard.
9.1. Equipment and the “Imaging Chain”
9.1.1. Image Formation
The advent of digital x-ray systems has fundamentally
transformed the process of image formation and, conse-
quently, image quality (Table 22). Although “analog” and
“digital” systems share a common means for generating
x-rays using high-output, micro circuitry-driven generators
and similar x-ray tube technologies, it is the “detector” that
has fundamentally changed the way in which images are
formed and processed. “Flat-panel” detectors (and their
inherent charge-coupled device technology) have not only
physically replaced the image intensifier and television
camera in traditional analog imaging chains, but have
improved the overall efficiency of the process of image
formation. Although a detailed description of the physical
design and electronic configuration of these detectors is
beyond the scope of this document, the translation of
information contained within the pattern of x-rays exiting
the subject to that contained within an electrical (digital)
video signal created by the flat panel detector is a major
improvement over the sequential conversions (and conse-
quent loss of information) of x-ray energy to light energy
(image intensifier) and light to electrical/video signals (TV
“pick-up” tubes, video scanners). Such improved process
performance with flat-panel systems is measurable and
expressed as greater detective quantum efficiency, or DQE
(258). Flat panel detectors have enhanced image uniformity,
uniform brightness, and dynamic range when compared
with the image intensifier. However, there are scant objec-
tive, comparative data on other measurable parameters of
digital fluoroscopic “image quality” (e.g., high-contrast
spatial resolution and low-dose, low-contrast resolution)
Table 22. Summary of Major Changes in the Contemporary Cat
X-ray generator: electronic control/high-frequency/high-output; automatic dose
of “stations” corresponding to different procedure types, as well as multiple d
-ray tube: high-heat capacity tubes with more efficient anode cooling mechani
(“beam hardening”); use of wedge filters.
lat panel detector: improved “dynamic range”; improved uniformity of image/
mage processing: recursive filtering; edge enhancement/“smoothing” algorithm
mage display: in-room liquid crystal display flat panel monitors; improved dyna
ose monitoring: dose-area product monitoring/display/reporting (suggested); i
(FDA mandated since 2006).
ose management: virtual collimation permitting collimator settings without flubetween flat panel systems and traditional image inten-
sifier– based systems (259). The use of the National
Electrical Manufacturers Association fluoroscopic phan-
tom (260), although developed for image-intensifier–
based technology, is a significant advance in this area and
may allow for such cross-system comparisons. Impor-
tantly, despite initial aspirations to the contrary, the
consequences of these improved performance character-
istics have not been consistently shown to result in
reduced x-ray dose (258).
Just as an understanding of the generation of x-rays is
fundamental to the process of image formation, so is an
understanding of the control of the dose-rate (strength) of
the x-ray beam. The importance of dose-rate control for
both image quality and patient and staff safety is discussed
elsewhere in this document. However, an understanding of
the characteristics of the x-ray beam, and its modification, is
critical from a catheterization laboratory standards view-
point. Although none of these factors is uniquely different in
flat panel systems, they may be overlooked owing to the
other (perhaps forgiving) features of flat panel detectors
(e.g., greater dynamic range and improved contrast). In
addition, in most flat panel systems, image, or quantum,
noise may be reduced with special recursive filtering and
image processing algorithms, resulting in a more attractive
visual image display.
The main “beam factors” that affect image formation, and
patient dose, are beam penetrating power (hardness), scat-
ter, and signal-to-noise ratio. The current generation of
x-ray tubes and generators are designed for the high-
performance, high-power requirements of interventional
cardiology. High heat load capacity x-ray tubes in combi-
nation with the filtering of “soft” (low-frequency) x-rays
from the beam prior to patient entrance enhance the
“hardness” of the beam in order to reduce patient dose and
improve overall image quality. The amount of scattered
radiation—the result of Compton interactions within the
patient—is directly related to the primary dose. Scattered
radiation not only degrades image quality and reduces
contrast, but is the main source of staff exposure as well as
patient exposure outside of the primary field. It is difficult to
overheat state-of-the-art x-ray tubes.
In traditional “analog” catheterization laboratories with a
classic image intensifier, the level of light intensity at the
rization Laboratory Imaging Chain Over the Last Decade
l; pulse and continuous modes of operation with a large selection
xposure settings for each procedure.
ore effective collimation (automatic); more effective spectral filtration
ness; improved contrast; improved detective quantum efficiency.
nge.
ntional reference point cumulative dose monitoring/display
py, fluoroscopic last-image-hold; retrospective storage of fluoroscopy data.hete
contro
ose/e
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maintain a preset, calibrated level of intensity on the
phosphor (automatic brightness control, or ABC). In “dig-
ital” catheterization laboratories with flat panel detectors,
the flat panel–produced digital video signal is fed back to the
generator in order to maintain the preset, calibrated voltage
output from the detector (automatic dose-rate/exposure
control, or ADC). Variability in patient body habitus or
angled gantry configurations will be sensed by the genera-
tor/x ray tube unit as conditions requiring greater beam
penetrating power (increasing kVp and/or increasing mA)
and subsequently increased dose-rate.
Unavoidable variability in the construction of the
detector itself may result in an inherently “noisier” image,
particularly at the lower dose rates employed during
fluoroscopy, thereby necessitating a higher dose- rate of
x-ray. While the higher dose-rate may result in an
“improved image,” the need for total dose monitoring
under such conditions should be obvious. Thus, U.S.
federal and international standards for dose monitoring
and dose limits are important additions to catheterization
laboratory safety and performance standards. Operators
need to be aware of the dose-monitoring capabilities of
newer x-ray systems as this information can be used to
minimize patient radiation exposure.
9.1.2. Digital Storage and Display
The increase in information content and flux that occurs
with digital imaging requires a commensurate increase in
storage capacity and system “bandwidth” to facilitate “on-
line” and postacquisition review and archiving of studies.
“In-room” central processing units with storage capacity in
the terabyte range are not unusual nor are archiving systems
with multiterabyte capacity. The fundamental requirement
for online, immediate review of portions of a coronary interven-
tional procedure mandate fast Ethernet-transmission speeds for
the acquired images at mega-pixel resolution that are then
“processed,” “filtered,” and presented for review. The im-
portance of high-resolution, in-room, table-side monitors
cannot be overstated. Although the latter are often incor-
porated into the entire “package” of a newly purchased x-ray
system, “retrofitting,” “upgrading,” and “refurbishing” of
extant in-room monitors are still frequently encountered
and may be primarily responsible for less-than-expected
improvement in fluoroscopic image quality. Careful atten-
tion must be paid to the calibration, resolution (contrast and
spatial), and dynamic range of these monitors, including
those installed as part of a new system.
9.1.3. Quantitative Measures
Although multicapability “software” packages and modules
are now universally available with the purchase of a new
x-ray system, the full extent of use of such capabilities is
unknown. In contrast to the near-universal use of adminis-
trative and logistical (scheduling, billing, coding, etc.) soft-
ware modules—all provided in one form or another with thepurchase of a new catheterization laboratory—the quality-
assured, routine use of quantitative ventriculographic, he-
modynamic, and/or coronary angiographic software is less
widespread. Even less frequent is onsite validation of the
information provided by such user-interfaced software.
This is particularly important in instances of “lesions of
borderline significance” and likely contributes to the still
widespread practice of ad hoc PCI (99). Similar issues
abound with incorrectly obtained hemodynamic informa-
tion “processed” with such software, the consequences of
which may lead to erroneous conclusions regarding con-
dition severity (261). The importance of “acceptance
testing” or onsite validation of such software cannot be
overemphasized, and physician diligence and clinical
judgment is always critical for the proper interpretation
of these data.
9.2. Radiation
9.2.1. Biological Risks
The biological risks of x-radiation have been discussed in
great detail in The NCRP Report 168 and in standard texts
(262) in addition to recently updated reports and expert
consensus documents (251,263–267). X-rays produce cellu-
lar injury primarily by causing fractures in the DNA
backbone. X-ray radiation risks can be broadly categorized
as 1) deterministic—that for which a “dose–injury” relation-
ship exists and for which a threshold dose has been
determined and 2) stochastic—that for which the probabil-
ity of injury is related to dose and for which no threshold
dose has been defined (“linear–no-threshold” hypothesis).
The former relates most importantly to the risk of skin
injury and possibly cataract formation whereas the latter
relates to the long-term risks of radiation-related cancer.
When enough cells of a particular organ (such as the skin)
are injured so that its function is impaired, that defines a
deterministic risk, and the dose when that occurs is the
threshold dose. In contrast, a stochastic injury occurs when
there is injury to the DNA backbone that does not properly
heal itself, and the result is not cell death but a mutation
leading to either a cancer or a genetic abnormality. A single
x-ray photon may cause this change and is not directly dose
related, though the risk of acquiring such injury increases
with dose. Risks to the germ plasm, and offspring of the
x-radiated subject are stochastic in nature albeit substantially
lower than the risk of cancer development to the subject.
Although the clinical manifestation of deterministic injury
is seen in characteristic skin lesions (268–270), there is, at
present, no validated or reliable “biomarker” for stochastic
risk. Risks to the irradiated fetus can be considered deter-
ministic (a defined threshold dose), although periods of
highest vulnerability to radiation-related effects are time
dependent and confined to the first trimester. Doses to the
fetus of 100 mGy may result in mortality or failure to
implant during the first couple weeks, but it is unlikely a
fetus would receive this amount from cardiac catheteriza-
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have few lasting effects due to the fact that the embryo is
composed of only a few cells that will eventually differentiate
into multiple organs (206a). The stochastic risk of cancer
induction in a fetus is considered similar to that of a
newborn.
9.2.2. Measuring Radiation Exposure
and Radiation Dosimetry
Monitoring of personnel in the cardiac catheterization
laboratory is important to detect potentially unsafe working
practices and to remediate them whenever possible. It is the
individual’s legal and ethical responsibility to wear radiation
badges to monitor their exposure to ionizing radiation. If
specific individual records reveal unusual dose exposure, a
review of the individual practice is warranted (252) and
corrective action should be undertaken.
The International Commission on Radiation Protection
recommends 2 monitoring badges, 1 under the radiation
protection garment (between the waist and chest) and 1 on
the collar (271). The NCRP accepts a single outside collar
monitor, though prefers the 2 monitor suggestion (272).
The SCAI suggests a single monitoring device worn on the
collar is acceptable. If a worker declares she is pregnant, a
fetal monitor under the lead apron is required at waist level
(273).
Table 23 provides the standard terminology and defini-
tions for catheterization laboratory–based considerations of
radiation exposure.
Further, and more detailed, explications of the terminol-
ogy employed can be found in authoritative review articles
on the subject (271). Importantly, although “exposure” to
x-radiation can be directly measured, the dose to internal
organs cannot be directly measured and must be estimated.
Thus, the measure of risk is imprecise, subject- and
procedure-dependent, and ultimately, obtained from epide-
miologically derived associations of such estimated absorbed
doses with long-term, clinically manifest disease. A detailed
discussion of this subject is beyond the scope of this
document, but the interested reader is referred to the latest
publication of the BEIR VII report (264).
Table 23. Relevant Nomenclature for Radiation Exposure and D
Term What Is Being Measured
xposure Ionization produced in air by x-rays
Air kerma The sum of the initial kinetic
energies of all the charged
particles liberated by uncharged
particles
Absorbed dose The energy imparted to matter by
ionizing radiation per unit mass
of irradiated material at the
point of interest
Effective dose Estimated total body doseOf most relevance to the catheterization laboratory envi-
ronment is the derivation, and meaning of, the effective dose
(ED), as it is the latter that encompasses the stochastic risk
associated with ionizing radiation. ED, a quantity derived
from the weighted sum of Monte Carlo–derived estimates
of individual organ doses, should more properly be viewed
as a metric of radiation safety and used for interprocedural
comparisons rather than a unique “dose” of radiation to a
given individual (275). Given the above-noted complex-
ity in the assessment of ED, an approximation of the
stochastic risk associated a given x-ray procedure can be
estimated by multiplying the DAP—the product of the
air kerma at any point along the center axis of the x-ray
beam and the beam cross-sectional area at that point—
and an anatomically based and empirically derived con-
version factor reflecting the conversion from DAP (Gy-
cm2) to ED (Sv) (276). The DAP is derived from a
ransmission chamber fitted to the output of the x-ray
ube. It represents total x-ray energy directed toward the
atient. The accumulated reference point air kerma when
ombined with gantry position and patient geometry
rovides a rough idea about how much x-ray dose the
atient’s skin received. The association between the risk
f radiation-related cancer mortality and exposure is
erived mainly from the atomic bomb survivor experience
here exposure was whole-body (in contrast to localized,
s in invasive procedures), averaged over a population of
arying ages and gender (hence the need to specify age-
nd sex-specific risks of cancer mortality) and cancer-
elated deaths in individuals with exposures below 100
Gy. However, this latter dose is well above the reported
ange for EDs associated with most but not all fluoro-
copically guided interventional procedures. Further-
ore, the risk of radiation-related cancer development
nd mortality must be placed in perspective with respect
o the overall lifetime risk of cancer mortality (25%
verall). Currently, the overall lifetime incremental risk
f cancer-related mortality attributable to radiation ex-
osure is estimated at 4% to 5% per Sv (264,277). A
ose–response relationship between occupational expo-
ure and posterior lens changes in the eyes has also been
uggested recently (278).
etry
Unit of Measure Conversion
ntgen, R, or coulomb/kg air 1 R2.58 104 coulomb/kg air
, or gray (Gy) 100 Rad1 Gy
, or gray (Gy) 100 Rad1 Gy
or sievert (Sv) 1 Rad10 mGyosim
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There is an extensive literature on patient exposure during
coronary angiographic procedures. The majority of this
literature was generated in the “pre-flat panel” era, but
remains applicable. Overall, estimated patient ED for diag-
nostic coronary angiographic procedures ranges from 2.3 to
22.7 mSv with a mean of 7 mSv (279,280), whereas EDs for
simple coronary interventional procedures range 50% to
100% higher than those for diagnostic studies and, on
average, are approximately 15 mSv (281). To put this into
some kind of perspective, the average nonmedical back-
ground radiation dose in the United States is about 3.0 mSv
per year, and the average dose from a routine chest x-ray is
about 0.02 to 0.10 mSv. Manufacturer-originated claims
have suggested reduced patient exposure with flat panel
systems, although these claims are likely confounded by
secular trends in enhanced awareness of radiation safety and
improved operator technique. The need for vendor-
independent, geographically disperse data in this regard is
significant.
The increased complexity of interventional procedures—
coronary as well as peripheral vascular, valvular, and con-
genital heart disease—is of increasing relevance in any
contemporary consideration of patient exposure. A median
ED in the pediatric diagnostic catheterization experience
has been reported at 4.6 mSv and that for therapeutic
procedures at 6.0 mSv (282). Similarly, estimated EDs for
complex electrophysiological procedures have been reported
to average 50 mSv in men and 32 mSv in women (283).
Limited data in the setting of complex structural heart
disease interventions in adults suggest that, on average, ED
exceeds that for coronary intervention by 25% to 50% (284).
A more immediate concern with increasingly complex
and lengthy high-dose fluoroscopically guided interven-
tional procedures is that of radiation-related skin injury
(269,270,285). The awareness and likelihood of skin injury
with increasing dose has focused attention on its recognition
and prevention. The skin dose metric that is believed to best
capture this deterministic risk is the peak skin dose. How-
ever, such a determination requires the placement of nu-
merous dosimeters over, or adjacent to, the irradiated
area—a cumbersome and infrequently performed routine.
Analogous to the use of the DAP as an estimate of
stochastic risk, the cumulative dose at the IRP—15 cm
below isocenter—has been suggested as an alternative
measure of deterministic risk (255). The 15 cm distance
from the patient’s isocenter is about the distance one would
expect the skin to be located. Note that the displayed
cumulative value of air kerma is not skin dose. It does
provide a starting point for calculating skin dose. Other
factors, including beam motion during the procedure, pa-
tient–gantry geometry, and backscatter from the patient,
affect the amount of radiation received by the skin as well.
A clinically useful simplification is to regard cumulative
reference point values above 5,000 mGy as the threshold of
a substantial dose (252,255). This is an amount that would lbe quite rarely received during cardiac catheterization but is
not uncommon in complex interventions. Tissue skin reac-
tion for various parts of the body is outlined in Table 24.
Ideally an estimate of the patient radiation dose should be a
part of every clinical report, and if a substantial dose has
been delivered, the patient should be appropriately informed
prior to discharge.
9.2.2.2. OCCUPATIONAL EXPOSURE
The major source of exposure to catheterization laboratory
personnel is scattered radiation from the patient, with the
latter strongly dependent on procedural length and com-
plexity, operator technique, and gantry configuration
(263,286). The extent of scatter radiation is closely associ-
ated with the DAP. In a review of the literature on
occupational exposures in cardiac catheterization laborato-
ries over the past 30 years, the authors identified primary
operator EDs ranging from 0.02 to 38.0 Sv and 0.17 to
31.2 Sv, for diagnostic and interventional procedures,
espectively (287). Exposure of support personnel working
n catheterization laboratories, but not in immediate prox-
mity to the tableside or image detector, receive the lowest
xposures (272).
.2.3. Minimizing Radiation Exposure
rofessional societal guidelines directed towards radiation
afety and the minimization of patient and personnel
xposure have been available for 25 years (263,288,289) and
ave been recently summarized and updated (251). The
echanics of reducing patient exposure require proper use
f the equipment itself (e.g., gantry positioning, degree of
agnification, detector input dose, x-ray tube output dose
ate, collimation and beam filtration; recognition of
atient-specific factors; procedure-related factors, length
nd complexity of procedure, and proper use of control
echanisms).
The mitigation of patient exposure translates directly to
itigating the exposure of operator and staff because scatter
adiation increases (decreases) as beam intensity increases
decreases). The driving principle behind reducing occupa-
ional exposure is the ALARA principle (290). Attention to
time” (beam on-time or the period in which x-rays are
mitted from the x-ray tube), “shielding” (the use of lead-or
ts equivalent-lined aprons for the torso and waist, as well as
hyroid collar and protective eyewear), and “distance” (es-
ablishing a safe working distance from the patient as well as
mage detector, utilizing the “inverse square law”) are the
ost effective means of reducing occupational exposure.
ables 25 and 26 highlight the major means of reducing
xposure to patients and staff, respectively.
.2.4. Quality Management and Measurement of
adiation Exposure in the Cardiac Catheterization
aboratory
n effective QA/QI program in the cardiac catheterization
aboratory must be centered on patient and staff safety.
(
e
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published a monograph in 1999 in which seminal and
relevant publications addressing the many dimensions of
catheterization laboratory standards for the assessment of
quality and safety can be found (291). A broader discussion
of the assessment of procedural quality and outcomes is
found elsewhere in this document. The ongoing assessment
of quality and outcomes in the catheterization laboratory, a
fundamental aspect of any continuous quality improvement
process (292), must include dose monitoring for both
patients and personnel. Although personnel exposure always
needs to be monitored in the catheterization laboratory
(293), there are surprisingly fewer sets of guidance data for
patient exposure. Maximum allowable exposure limits for
medical radiation workers exposed to various sources of
ionizing radiation are explicitly described in Table 27
(272,288).
The FDA has set an upper limit to “tabletop” fluoro-
scopic exposure rate of 10R/min for systems with automatic
exposure control (256); however, there are no regulatory
limits on cine exposure rates. The fluoroscopic guideline,
however, serves more as an indicator of x-ray generator and
overall imaging chain function (294) than a direct measure
of skin dose (and, therefore, deterministic risk). As noted
earlier, differences exist between the FDA-specified air
Table 24. Tissue Reactions From Single-Delivery Radiation Dos
Band
Single-Site Acute
Skin-Dose Range (Gy)*
NCI Skin
Reaction Grade† Prompt
A1 0–2 NA No observable effects
expected
A2 2–5 1 Transient erythema
B 5–10 1–2 Transient erythema
C 10–15 2–3 Transient erythema
D 15 3–4 Transient erythema;
after very high
doses, edema and
acute ulceration;
long-term surgical
intervention likely
to be required
Note: Applicable to normal range of patient radio-sensitivities in absence of mitigating or aggrav
not rigid boundaries. Signs and symptoms are expected to appear earlier as skin dose increases
refers to actual skin dose (including backscatter). This quantity is not the reference point air ker
255). Skin dosimetry is unlikely to be more accurate than 50%. †Refers to radiation-induced te
arlier. Reprinted with permission from Balter et al. (285).
NA  not applicable; NCI  National Cancer Institute.kerma determination 30 cm in front of the detector versusthe IEC-recommended (cumulative) air kerma determina-
tion at the IRP 15 cm from middle of the patient to the
source along the isocenter line (assuming that equates to
where the skin lies). Unfortunately, neither measurement is
an accurate indicator of stochastic (earlier) or deterministic
(later) risk. However, all catheterization laboratory x-ray
systems manufactured after 2005 and sold in the United
States are now required to provide real-time information
regarding total radiation exposure time (fluoroscopic and
acquisition mode) and reference point air kerma; many
systems also measure and display DAP. These data provide
patients and physicians more meaningful estimates of risk.
This information should be included in the procedural
report. A summary of these records should be incorporated
into the catheterization laboratory’s performance improve-
ment process logs. All of this information should be
reviewed for internal consistency within the lab and in
comparison to published external guidance data (252).
The measurement and management of radiation exposure
in the catheterization laboratory environment cannot be
divorced from the issues of competence, credentialing, and
proficiency. Accordingly, physicians (and staff) must be
knowledgeable in matters of radiation physics, radiation
biology, and technological developments in x-ray imaging
systems and x-ray dose management (251). A rigorous
Skin of the Neck, Torso, Pelvis, Buttocks, or Arms
Approximate Time of Onset of Effects
Early Midterm Long Term
servable effects
ected
No observable effects
expected
No observable effects
expected
ion Recovery from hair loss No observable results
expected
ma, epilation Recover; at higher doses,
prolonged erythema,
permanent partial
epilation
Recovery; at higher
doses, dermal
atrophy or
induration
ma, epilation;
sible dry or moist
quamation; recovery
m desquamation
Prolonged erythema;
permanent epilation
Telangiectasia; dermal
atrophy or
induration; skin
likely to be weak
ma; epilation;
ist desquamation
Dermal atrophy; secondary
ulceration due to failure
of moist desquamation
to heal; surgical
intervention likely to be
required; at higher
doses, dermal necrosis,
surgical intervention
likely to be required
Telangiectasia†;
dermal atrophy or
induration;
possible late skin
breakdown;
woundmight be
persistent and
progress into
deeper lesion;
surgical intervention
likely to be required
hysical or clinical factors. Data do not apply to the skin of the scalp. Dose and time bands are
t is 2 weeks; early, 2 to 8 weeks; midterm, 6 to 52 weeks; long term, 40 weeks. *Skin dose
cribed by the Food and Drug Administration (256) or International Electrotechnical Commission
tasia associated with area of initial moist desquamation or healing or ulceration may be presente to
No ob
exp
Epilat
Erythe
Erythe
pos
des
fro
Erythe
mo
ating p
. Promp
ma des
langieccurriculum for the latter should be an integral part of every
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tant segment of the certifying examination. The increasingly
complex clinical conditions seen in catheterization labora-
tories today require a more sophisticated understanding of,
and approach to, the technical, pharmacological, and radio-
logic aspects of interventional cardiology. Rigorous training
and ongoing assessment of each of these 3 “pillars” is,
ultimately, the responsibility of each practitioner. Numerous
excellent training and “refresher” curricula are currently
available from authoritative sources (295,296) and are rec-
ommended readings.
10. Special Concerns for the Pediatric
Cardiac Catheterization Laboratory
Routine cardiac catheterization of children is performed in
most of the 120 children’s hospitals in the United States. In
general, these hospitals also provide the infrastructure for
comprehensive pediatric cardiovascular centers, which sup-
port pediatric open-heart surgery, pediatric ECMO, ad-
vanced pediatric and neonatal intensive care, as well as
noninvasive pediatric cardiology diagnostic services. Basi-
cally all facilities that perform cardiac catheterization on
children must be full-service facilities as defined earlier.
Table 25. Reducing Exposure to Patients
Minimize beam “on-time”
Minimize framing rates
Minimize total fluoroscopy time
Use pulse fluoroscopy whenever possible with frame rates 15 fps
Minimize use of “high dose” rate fluoroscopy
Minimize number of acquisition runs
Minimize use of geometric/electronic “magnification” modes
Keep tube current (mA) low
Keep tube potential (kVp) as high as possible without washing out image
Use collimation to irradiate only the area of interest
Use copper and other filters at the x-ray tube output to reduce unnecessary
x-ray photons
Appropriate use of gantry configuration
Optimize the source-to-skin distance
Minimize the source-to-detector distance (“air gap”) (source-to-image distance)
Minimize extreme compound angulations to reduce the x-ray beam path in the
patient
Use multiple rotational and axial skew configurations
Do not work in 1 view exclusively to vary radiation distribution on the skin
(if so, minimize need for extreme compound angulation (e.g., left anterior
oblique projection)
Limit cineangiography acquisition and save fluoroscopic image data in its
place when possible.
Table 26. Reducing Occupational Exposure
Control dose to patient (see Table 27)
Implementation of time/shielding/distance
Correct positioning of staff relative to gantry
Staff education and trainingPediatric catheterizations are performed either in dedi-
cated pediatric cardiac catheterization laboratories (PCCLs)
or in catheterization laboratories used for both children and
adults. Dedicated pediatric laboratories are most often
components of free-standing children’s hospitals. Joint-use
laboratories are most often located in general hospitals that
have either a large inpatient pediatric service or a closely
affiliated neighboring children’s hospital that shares core
infrastructure with the general hospital.
Whether children have catheterizations in dedicated or in
joint-use laboratories, it is appropriate for both catheteriza-
tion laboratory environments to adhere to applicable guide-
lines of all catheterization laboratories outlined earlier in
this Statement. Furthermore, additional PCCL guidelines
and best practices designed to address the unique challenges
and issues related to pediatric patients and to congenital
heart disease should be instituted. These additional PCCL
guidelines and best practices are the focus this section of the
document.
10.1. Differences in Goals
The PCCL should function as one of the critical elements
within a pediatric cardiovascular center. The goals of the
PCCL within a center should be to provide the diagnostic
information needed to support medical, interventional,
hybrid, and surgical treatments, as well as to provide the full
range of interventional and hybrid treatments needed to
achieve high-quality outcomes in pediatric patients with
congenital and acquired heart diseases (297). Diagnostic
catheterizations in children and adults with congenital heart
disease are distinct from typical adult catheterizations,
because, by definition, they are designed to evaluate struc-
turally abnormal hearts. Catheterizations usually include
right (and left) heart catheterization, quantification of car-
diac index, multichamber oximetry assessments, calculations
of left-to-right and right-to-left shunts, and pulmonary and
systemic vascular resistance. Cardiac index may be measured
by thermodilution, but because of the presence of shunts,
the Fick principle is more commonly employed, and oxygen
consumption is usually assumed. Because of dramatic
growth-related changes in pediatric body surface area and
the need for comparative hemodynamic data, flow and
Table 27. Maximum Allowable Radiation Limits for
Medical Workers
Whole body 5 REM/y (50 mSv/y)
Skin 50 rad/y (500 mGy/y)
Lens of eye 2 rad/y (20 mGy/y)
Fetus (for pregnant worker) 0.5 rad (5 mGy) for the total pregnancy or
0.05 rad/month (0.5 mGy/month)
(estimated by abdominal badge under
lead apron
Cumulative exposure (lifetime) 1 REM  age (10 mSv  age)
In the context of the catheterization laboratory: National and international general recommenda-
tions have been reformatted to better distinguish between local dose (measured in rad or mGy)
and effective dose (measured in REM or mSv).resistance values are usually indexed for body surface area.
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coronary arteries, pediatric angiographic studies are usually
intended to define and display complex intracardiac anat-
omy as well as pulmonary and systemic vessels. These
imaging data may supplement or complement other com-
mon imaging modalities such as echocardiography, CT
angiography, and MRI. A wide variety of congenital and
acquired heart and great-vessel defects and abnormalities are
investigated in the PCCL.
Interventional procedures are the primary or a secondary
objective in up to three fourths of all catheterizations
performed in the PCCL. A substantial number of unique
interventional procedures are performed. Most of the indi-
vidual procedures are performed in relatively small numbers.
These procedures include atrial septostomy, valvuloplasty,
angioplasty, stent implantation in large vessels, vascular
closure (patent ductus arteriosus, other anomalous vessels,
and fistulae), device closure of atrial communications and
ventricular septal defects, transcatheter valve implantation,
endomyocardial biopsy, foreign-body retrieval, pericardio-
centesis, and a range of electrophysiological procedures
(298,299). Expertise in these procedures is acquired during
pediatric cardiology fellowship training and in pediatric
cardiology post-fellowship training in the interventional
cardiac catheterization laboratory (often during an addi-
tional training year) (300).
Hybrid procedures are an important activity in many
PCCLs. These procedures are performed jointly or cooper-
atively by an interventional cardiologist and a cardiac
surgeon. They are often performed in infants who have a
thoracotomy exposing the surface of the heart. Interven-
tional catheterization procedures are performed with access
provided directly through the anterior wall of the right
ventricle or the main PA. The most common interventions
are Stage I palliation of hypoplastic left heart syndrome
(stenting of the patent ductus arteriosus), angioplasty and/or
stenting of PAs, and closure of muscular ventricular septal
defects (301,302).
10.2. Who Should Perform Catheterizations
in the Pediatric Cardiac Catheterization Laboratory?
PCCLs, whether dedicated or shared with adult cardiolo-
gists, should have a pediatric director. The director should
be board certified in pediatric cardiology and should have
additional training in pediatric cardiac catheterization and
intervention (or qualifying experience). The director should
be responsible for all aspects of the administration and
function of the PCCL (including backup of other pediatric
operators with less training or experience). In addition, QA
and QI activities related to pediatric studies should be under
the director’s guidance.
Other attending physicians who perform cardiac cathe-
terization in children are generally board eligible or board
certified by the American Board of Pediatrics, Subspecialty
Board of Cardiology. There may be exceptional cases in
which a competent physician has gained extensive experi-ence without formal board certification, but these physicians
usually have been allowed privileges by a “grandparent”
clause. Whether privileges for non–board-eligible physi-
cians may be granted is left to the discretion of the
individuals involved and the hospital credentialing process.
The pediatric age range is usually considered to be from
birth through 18 (or 21) years of age. It is recommended
that pediatric cardiologists perform catheterization on pa-
tients under the age of 18 years who require cardiac
catheterization for congenital cardiac problems. Adult pa-
tients with previously diagnosed (repaired or unrepaired)
congenital heart disease or with native congenital heart
problems requiring cardiac catheterization should have the
procedure performed 1) by a pediatric cardiologist; 2) by an
adult cardiologist and a pediatric cardiologist collaborating
during the procedure; or 3) by an adult cardiologist with an
established special interest and expertise in adult congenital
heart disease.
10.3. Quality Assurance Issues in the
Pediatric Cardiac Catheterization Laboratory
New methodologies have recently been developed and
applied to assessing adverse events occurring in the PCCLs
(303). Contemporary complication rates for pediatric car-
diac catheterizations have been defined in a large, well-
structured, and controlled prospective multicenter catheter-
ization laboratory registry study utilizing these methods
(304). The median rate of overall adverse events is 16%:
10% for diagnostic cases and 19% for interventional cases—
considerably higher than adult laboratories due to the
marked difference in the patient population. Moderate
severities to catastrophic adverse events are less common,
occurring in 1% of endomyocardial biopsies, 5% of diagnos-
tic cases, and 9% of interventional cases. Death occurred in
0.3% of cases. Previous studies reporting adverse events in
the PCCL had been uncontrolled, retrospective, single-
center studies, and/or reflected practice patterns and tech-
nologies from the 1980s and 1990s (305–307). These
studies report lower rates of adverse events and are not so
reflective of the contemporary era. Further prospective
adverse events data in the PCCL are being collected by the
IMPACT Registry.
The Bergersen et al. study (304) suggests that cata-
strophic complications (those resulting in death, rescue
ECMO, or emergency surgery) should occur in well under
1% of all cases and in under 1% of interventional cases in a
PCCL. Major complications (those requiring admission to
the intensive care unit, emergent readmission to the hospi-
tal, a major nonsurgical intervention) should occur in 2%
of all cases and in 4% of interventional cases. Informed
consent for PCCL procedures is usually obtained from the
patient’s parents or guardians. This consent includes the
physician’s (or his or her designees, such as the cardiovas-
cular fellows) explanation of the risks, benefits, and alter-
natives related to the procedure, with documentation of the
explanation and of the parent/guardian understanding
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when a transferred patient requires emergency balloon
septostomy and the parents are in transit, consent may be
obtained by telephone or even assumed and the procedure
performed. The committee recognizes that there are con-
sent and assent procedures and guidelines that vary by
jurisdiction (hospital, state, county) and defers to those
where applicable. Age or other circumstances that afford
competence to the patient vary as well. These will determine
whether it is acceptable to obtain the patient’s “assent” or
whether formal consent is required.
10.4. Inpatient Versus Outpatient Setting
for Procedures
Although outpatient procedures have become common in
the PCCL, there is less uniformity in patient and parent
suitability for hospital discharge shortly after catheterization
than in adult patients. Infants and young children cannot be
instructed or expected to remain still without moving their
legs for a period after a procedure. Any volume of blood lost
into the subcutaneous tissue or retroperitoneum or onto the
bandage or bedclothes will have more significance if the
patient is smaller. Given the small number of PCCLs,
pediatric patients and their families often have to travel
farther for treatment than adult catheterization laboratory
patients. The pediatric patient may also be farther from
appropriate medical attention after returning home. Despite
the smaller size of the patient, the sheath sizes used in
pediatric cases may be nearly the same size (5-F to 8-F) as
those used in adults. For these reasons, it is suggested that
overnight observation be anticipated and allowed whenever
there is any concern about patient safety. Nonetheless, a set
of written criteria should be established for same-day
catheterization and discharge by each PCCL. These criteria
would account for differences in procedure type, patient age
and expected compliance, parent or guardian reliability, travel
distance, procedure duration and time-of-day completion, and
the cardiac physiology in determining which patients are
eligible for discharge on the day of catheterization. These
guidelines should establish discharge criteria such as absence of
bleeding, presence and adequacy of pulses and perfusion, access
to medical evaluation and care after discharge, and parental
understanding and ability to observe overnight.
10.5. Operator and Laboratory Volumes
Although the committee recognizes that access to services is
important, there is also the valid impression that an ade-
quate and maintained level of experience is required for the
cardiologist and staff to obtain and preserve proficiency. In
its 2002 “Guidelines for Pediatric Cardiovascular Centers,”
the American Academy of Pediatrics elected to specify
outcome benchmarks rather than to recommend minimum
operator or PCCL volume (297). However, previous
ACCF/SCAI statements have recommended that individ-
ual operator minimum annual caseloads to be in the range of
50 to 100 cases per year (1). The committee continues tobelieve that an individual cardiologist performing catheter-
ization in the PCCL should have a minimum annual case
number 50 per year. Furthermore, if a PCCL routinely
performs 100 cardiac catheterizations per year, consider-
ation should be given to whether the volume justifies the
program. In addition, because the level of skill and expertise
required and the complication rates are related to the type of
intervention and to patient characteristics, credentialing for
therapeutic cardiac catheterization should be procedure
specific (308).
A number of considerations must be taken into account
when a decision is made regarding the minimum operator or
PCCL volumes and credentialing of operators for specific
interventional procedures. Although there are ample data
regarding adult interventional procedures, there are no data
relating number of pediatric procedures to skill or outcomes. It
is important that institutional, local, and personal factors be
weighed.
Importantly, QA plans must be in effect in all PCCLs to
monitor outcomes of pediatric cardiac catheterization.
There are some similarities and differences between the
strategies required for QA in the PCCL versus the adult
cardiac catheterization laboratory. For example, there is not
a prior acceptable rate of normal cardiac catheterizations. In
patients undergoing cardiac catheterization for hemody-
namic reasons or possible intervention, the rate of normal
should be zero. Any number of patients may have electro-
physiological abnormalities or acquired disease with struc-
turally normal hearts but abnormal physiology, and these
would not be considered to be in the “normal” group. The
effort to operate within benchmark adverse event rates is the
same in all laboratories, although the types and rates of
complications in the PCCL are different from those in
the adult laboratory. Although intervention procedures
are usually planned well in advance, ad hoc procedures
might well be required. Such procedures as coil occlusion
or vascular plugging of a ductus arteriosus or an aorto-
pulmonary collateral or balloon dilation with or without
stent placement may be needed even when not previously
planned. Diagnostic quality and accuracy of catheteriza-
tions and procedural outcomes should be examined, with
each PCCL responsible for earmarking certain indicators
and examining them with plans for improvement if
warranted by the data.
10.6. Procedural Performance Differences
Compared With Adult Cardiac Catheterization
10.6.1. Pre-Medication and Baseline Laboratory Data
In many pediatric laboratories, if the patient is in
otherwise good health and on no medication, no prelim-
inary laboratory tests are obtained prior to the cardiac
catheterization procedure.
The choice, dose, timing, route, and overall use of
pre-medication vary widely with age, size, and condition of
patient and the experience and training of the operator.
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diphenhydramine, and diazepam are frequently given orally
for sedation. Intravenously, midazolam, morphine, fentanyl,
hydromorphone hydrochloride, and other medicines can be
used with good effect. The advantages of midazolam are
that it can be given by continuous infusion and it can be
reversed if necessary. Reversal of midazolam with flumazenil
(Romazicon) does not usually precipitate the severe discom-
fort and agitation seen with naloxone (Narcan) narcotic
antagonism. Ketamine may be used in small intramuscular
or IV bolus doses for rapid-onset anesthesia. This may help
during precise intervention when patient movement might
be detrimental to procedure success. Meperidine (Demerol)
alone or in combination with promethazine is sometimes
used intravenously or by the intramuscular route for anal-
gesia and sedation. Chlorpromazine is used less often than
previously, because of the availability of and experience with
other medicines.
10.6.1.1. VASCULAR ACCESS ISSUES
Techniques for venous and arterial access are similar for
children and adults. Most catheterizations are performed
using the femoral vein and femoral artery. However, in a
significant number of cases the left heart and aorta may be
accessed through the venous approach, and retrograde
arterial catheterization may not be required. Furthermore,
transseptal procedures are commonly performed during
diagnostic and/or interventional procedures in patients of a
variety of ages (including infants). Properly performed, this
approach does not add significantly to the incidence of
complications. In general, newborn catheterization should
be performed through the umbilical vessels when possible in
order to preserve femoral vessels. In addition, because of the
frequency of venous catheterizations and indwelling femoral
venous lines in neonates and infants, limited or absent
venous access from the femoral veins is not uncommon.
Therefore, venous access from the internal jugular, subcla-
vian, basilica, and transhepatic approaches are frequent.
Alternative arterial approaches are also required in some
children because of occluded femoral arteries. In young
infants, a hybrid approach with carotid artery cut-down may
be used to access the aorta in order to perform balloon
valvuloplasty in critical aortic stenosis or for stenting of the
patent ductus arteriosus in cyanotic infants. In addition,
percutaneous brachial artery access or axillary artery cut-
down may be used as alternative approaches in some
children if femoral arteries are occluded.
The use of heparin in the flush solutions is routine, but
the additional use of bolus-dose heparin depends on the
patient’s preprocedural ACT, procedure type, and vascular
approach. It is common practice, for example, to avoid use
of bolus heparin for right heart catheterization or prograde
right and left heart catheterization, but heparin bolus is
commonly used in retrograde left heart catheterization. At
the end of a procedure, an ACT may be checked, and if
necessary, the heparin effect reversed with administration ofprotamine sulfate in much the same manner as for adults.
Some laboratories no longer use heparin during the cardiac
catheterization procedure. Hemostasis is usually achieved by
direct manual pressure followed by placement of an adhesive
or elastic tape over a gauze pad on the percutaneous access
site. However, percutaneous suture closure of suitable arte-
rial and venous sites has become relatively common among
suitable patients in the PCCL.
10.6.1.2. SEDATION AND ANESTHESIA FOR PROCEDURES
Medications used during the procedures in the PCCL are
essentially the same as those noted earlier for pre-
medication. Repeated bolus doses of sedatives may be used,
and/or a continuous infusion of midazolam or other drug
may be instituted. It is necessary that a nurse or physician
assess and document the patient’s condition after each bolus
dose of sedative according to the institution’s conscious-
sedation guidelines. Systemic arterial oxygen saturation
should be continuously monitored by pulse oximetry. Gen-
eral anesthesia is performed by an anesthesiologist or nurse
anesthetist under supervision for all or most patients in
many PCCLs. Indications for anesthesia include patient
considerations and procedure characteristics. For example, a
developmentally delayed teenager who is fearful may be
unable to be sedated without general anesthesia. Patients
who are critically ill or in pain will benefit from anesthesia.
Prolonged procedures such as those that require trans-
esophageal echocardiography may be greatly facilitated
with general anesthesia. Certain interventional proce-
dures such as aortic or mitral valve dilation, ASD
occlusion, and others may be made significantly easier,
safer, and more effective when performed with general
anesthesia. The use of anesthesia is a judgment made by
the attending cardiologist in consultation with the anes-
thesiologist, just as it is in surgery.
In the current era, the PCCL has become the site for
more invasive percutaneous interventions as well as hybrid
procedures. The opportunity for catastrophic or critical
events is thereby heightened. Therefore the committee
believes that the PCCL should have plans for and access to
rescue ECMO, in addition to standard resuscitation meth-
ods and technologies, in order to provide definitive resus-
citation of patients having such events in the laboratory
(308).
10.6.2. Single-Plane Versus Biplane Angiography
The standard equipment in a PCCL includes biplane
radiographic equipment. In general, pediatric and congen-
ital cardiac catheterizations are performed using biplane
fluoroscopy and angiography. This is important both for
localizing the catheter in space within the heart and great
vessels and for reduction in contrast dosage administration.
Certain procedures can be routinely performed with single-
plane fluoroscopy, including (in many laboratories) electro-
physiological study and radiofrequency ablation, some types
of ASD occlusion, and others. ASD occlusion is often
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using transesophageal or intracardiac echocardiography as
well as fluoroscopy. Coronary arteriography in children
may be performed with single-plane use, especially if it is
assisted or performed by an adult cardiologist for whom
performance of single-plane fluoroscopy/angiography
might be standard.
10.6.3. Hemodynamics
As noted, right and left heart catheterizations are performed
in combination in many pediatric and congenital heart
catheterization procedures. In addition to the LV systolic
and end-diastolic pressures and aortic or arterial pressures
normally obtained in the adult cardiac laboratory, right-
heart pressures are standard. Pressure waveforms and deter-
minations of oxygen saturations are generally obtained from
each chamber of the heart entered and from the PAs or
veins, aorta, or systemic veins as indicated during any
particular procedure. The routine pressure measurements
and recordings necessary are difficult to specify, because they
vary widely depending on the anatomy and physiology
involved. For example, in a patient with pulmonary valve
stenosis, an LV pressure may not be obtained at all, whereas
an RV systolic and diastolic pressure recording is manda-
tory. On the other hand, PA pressure, routinely obtained in
a right-heart catheterization, may be ill advised in a patient
with severe tetralogy of Fallot. Even an invasive arterial or
aortic pressure might not be obtained in the setting of a
cardiac transplant repeat biopsy or other limited right-heart
procedure. Pressures should be able to be recorded with
excellent and reliable fidelity on scales, which range from
a full scale of 10 mm Hg to 400 mm Hg. Rapid
availability of oxygen saturations and blood gas determi-
nation is essential for interpretation of shunt physiology
and for patient safety.
10.6.4. Angiographic Acquisition Differences
Angiograms are routinely performed with framing rates
ranging from 7.5 to 30 fps (60 fps are rarely needed). The
frame rate depends on the patient’s heart rate and the types
of images to be acquired. For example, during balloon
dilation, images may be acquired at 15 (or 7.5) fps, whereas
a ventriculogram in an infant with a high heart rate may
require imaging at 30 fps. A wide variety of catheters,
appropriate contrast materials, and injection techniques and
parameters are available. Contrast is often injected at a faster
rate in the PCCL compared with the adult laboratory,
because fine details of the anatomy are sought rather than
global function or regional wall motion abnormalities. In
selected patients, 30 to 40 mL of contrast may be injected
over 1 to 2 seconds, for instance. In addition, in most
cases, premature ventricular beats or even ventricular
tachycardia are better tolerated in younger patients with
no ischemic heart disease. Angiograms should be avail-
able for immediate review after acquisition with instant-
replay digital playback. Short- and long-term archival ofdigital data or cineangiograms does not differ from that
described in prior sections.
10.6.5. Radiation Protection and Pregnant
(or Potentially Pregnant) Patients
The same principles of radiation protection applied in the
adult cardiac catheterization laboratory apply in the PCCL.
In addition, girls and young women of child-bearing age
should undergo beta-HCG testing to ensure that they are
not pregnant before having a cardiac catheterization. This
might be based on history in some cases (e.g., if a patient has
an implanted chronic chemical contraceptive or if she has
had a bilateral tubal ligation or hysterectomy), but it should
otherwise include a serum or urine HCG level obtained
within 2 weeks of the procedure. If a pregnant patient must
be studied, the abdominal and groin areas should be
shielded to help reduce any direct x-ray exposure, acknowl-
edging that most of the fetal exposure is from scatter
radiation. Efforts to minimize exposure should include using
fluoroscopy or in-laboratory echocardiography rather than
cineangiography and include all of the suggestions noted in
Tables 25 and 26.
10.6.6. Shunt Measurements
Important information regarding physiology of congenital
heart disease is gathered from measurements of intracardiac
shunts. Both right-to-left and left-to-right shunts must be
able to be quantitated during the catheterization. Because of
the need to determine intracardiac shunting, oxygen satu-
ration samples are drawn from many sites rather than simply
from the PA for mixed venous oxygen level and from the
systemic artery for arterial oxygen level. Therefore, the
availability of oxygen saturation measurements and arterial
blood gas determinations is essential for the efficient per-
formance of the typical congenital cardiac catheterization.
The availability of blood gas measurements also allows for
the inclusion of dissolved oxygen in the determination of
oxygen content.
10.7. Laboratory Personnel Issues
The laboratory staff in the PCCL should be specifically
trained and experienced in the care of sick infants and
children during performance of cardiac catheterization.
The responsibilities within the laboratory may necessitate
the services of 1 or more registered pediatric-trained
nurses, a radiography technician, a certified catheteriza-
tion technician, or others. It is the responsibility of the
director and supervisor of the PCCL to ensure adequate
staffing on a case-by-case basis. On-call cases must be
considered, and a call schedule available in order to
provide adequate staffing and anesthesia support in the
PCCL for emergent and urgent pediatric catheterizations
at all times. Timeliness of cases must also be part of the
on-call planning.
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